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Abstract 
Macrophages play key roles following nerve injury releasing cytokines and chemokines 
thought to be involved in the development and maintenance of neuropathic pain. ATP is a 
transporter of chemical energy, but can also act as an extracellular signalling molecule that 
signals through purinergic receptors. ATP, probably released from damaged neurons, can 
promote the migration of macrophages and microglia to the site of injury, and can be 
responsible for the onset of neuropathic pain. Purinergic signalling via ATP and other 
nucleotides is now well established and increasing evidence suggests that ATP could play 
important roles in pathophysiology. 
The neuroprotective neurotrophin brain derived neurotrophic factor (BDNF) inhibited 
ATP-induced invasion of macrophages though an extracellular matrix.  The well-
characterised Sigma-1 Receptor chaperone, previously implicated in BDNF function, was 
shown to be an important overall regulator of macrophage invasion, and to be potentially 
implicated in BDNF suppression of ATP-induced invasion. BDNF may thus have a 
neuroprotective role to inhibit further macrophage recruitment to the site of injury. 
Matrix metalloproteinases (MMPs) are capable of remodelling the extracellular matrix and 
the activation of inflammatory mediators. Exploration of MMP responses to extracellular 
ATP stimulation in a macrophage cell line revealed that MMPs -8, -12, and-13 as well as 
TIMP-2 steady state mRNA levels were significantly up-regulated ATP, ATP can alter matrix 
remodelling.   
Macrophage recruitment is a significant player in atherosclerosis and may be modulated 
by Apolipoprotein E genotype. N3-polyunsaturated fatty acids (obtained from dietary fish 
oils) have been implicated in cardiovascular protection. Using a high fat diet model the 
effects of dietary fish oil supplementation and Apolipoprotein E subtype were explored in 
ex vivo primary macrophages.  Unexpectedly, a fish oil supplemented diet led increased 
macrophage migration speed and reduced TIMP-2 mRNA levels, suggesting that fish oil 
supplements play complex roles  in atherosclerotic-related scenarios.  
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1.1. The Nervous System 
The nervous system in the body is made up of two interconnected sections, the Central 
Nervous System (CNS) comprising the brain and the spinal cord and the Peripheral Nervous 
System (PNS) which comprises all other nerves. 
 
The PNS consists of two major types of neurons to help communicate what is happening 
in the body to the CNS and to respond to signals from the CNS: sensory neurons and motor 
neurons. Sensory neurons detect stimuli such as touch, taste, light, heat, cold and pain. 
Motor neurons stimulate muscles in the body to respond to certain stimuli resulting in 
muscle contraction and subsequent movement. Both sensory neurons and motor neurons 
are essential for all complex organisms. 
 
The PNS is more readily exposed to chemical and environmental stimuli whereas in a 
healthy individual the CNS is protected by the blood brain barrier, the skull and the spine.  
However, the general structure of individual neurons is rather similar throughout the body, 
and do not vary greatly until they are observed at a molecular level – where the types of 
receptors expressed, neurotransmitters and other properties can be seen. All neurons 
have certain features, such as the cell body, the axon, and dendrites (Figure 1.1). 
 
The axon, along which the action potential is transmitted, extends from the neuronal cell 
body towards the axon terminal or nerve ending. The axon can vary greatly in length, (up 
to a metre in the sciatic nerve), and axon thickness can vary between only 0.2µm to 20µm 
in diameter. To aid speed of transmission of the action potential, some axons have 
insulation in the form of a myelin sheath, comprising the Schwann cell plasma membrane 
which wraps around the axon in the PNS (with the oligodendrocyte performing a similar 
function in the CNS). However, the entire axon is not wrapped in Schwann cells and there 
are points at which the axon is unmyelinated and where the action potential has to be 
regenerated – these points are called the nodes of Ranvier. At the end of the axon, the 
neuron branches out into dendrites and a synapse is formed with other neurons or muscle. 
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Figure 1.1. This diagram shows a myelinated nerve cell. The action potential is generated in the soma at the axon 
hillock (where the axon starts) and travels along the axon resulting in a synapse at the axon terminal dendrites. The 
arrow stipulates in which direction the action potential flows. Image adapted from Lodish et al., 2000. 
 
At this point, the neuron may make connections with many other neurons (eg in the brain) 
and the synapse will cause the generation of an action potential in those neurons, so a 
single action potential can, if necessary, trigger action potentials in 100 neurons. Dendrites 
are found at the terminal of the neuron, so the axon is able to receive and send as many 
signals as possible. (Kandel, 2000). 
 
 Neurons are segregated spatially, for example sensory neuron cell bodies are located in 
the dorsal root ganglia, whereas the autonomic ganglion contains autonomic neurons, and 
the ventral horn of the spinal cord or the brain stem contain the cell bodies of motor 
neurons (Topp and Boyd, 2006). 
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PNS nerves have a very complex structure to allow insulation from other axons and to 
provide some protection to each axon. This is primarily one by organization of the 
peripheral nerves and association with 3 different layers of connective tissues. The three 
layers of connective tissue are called the endoneurium, the perineurium, and the 
epineurium, and each surround the axon to form a nerve (Topp and Boyd, 2006). 
  
In more detail, the endoneurium is where the axon is associated with Schwann cells, where 
the myelin insulation is caused by the plasma membrane or the Schwann cell, when 
wrapped several times around the axon. An unmyelinated axon is still associated with a 
Schwann cell, but the Schwann cell does not wrap around the cell tightly, and does not 
provide the axon with several layers of myelin plasma membrane. The Schwann cell is then 
surrounded by extracellular matrix components including type IV collagen, laminin, 
heparan sulphate proteoglycan and fibronectin – which form the basal lamina. The axons 
are separated by types I and II collagen fibrils, macrophages and mast cells, with fibroblasts 
and endoneurial fluid (Topp and Boyd, 2006). 
 
Several of these endoneurium-axon complexes are then bundled together by the 
perineurium, which is a dense connective tissue. The perineurium consists of around 15 
layers of perineurial cells, with types I and II collagen fibres and elastic fibres, which 
provide the perineurium with mechanical strength. Perineurial cells are linked together by 
tight junctions, with the most inner of the perineurial cells forming a blood-nerve barrier 
by forming a diffusion barrier – thus controlling the endoneurial environment and forming 
a peripheral version of the blood brain barrier. The perineurium forms a nerve 
fascicle(Topp and Boyd, 2006). 
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Several nerve fascicles are then joined and held together by the epineurium to form a 
nerve. The epineurium can be divided into inter-and epi-fascicular regions, the 
epifascicular region is involved with Wallerian degeneration (the process by which neurons 
degenerate) of axons after injury, whereas the interfascicular region is attached to the 
perineurium, but loosely, as to allow for the sliding of each individual fascicle 
independently (Topp and Boyd, 2006). 
  
1.1.1. Nociception 
Nociception, the process whereby pain is perceived involves the detection of a noxious 
stimulus, such as intense heat, by primary sensory neurons. Even though pain is unpleasant 
and can be distressing, it is an essential process which is used as a mechanism to avoid 
harmful stimuli which could cause harm to the organism. We detect pain using a specific 
type of primary sensory neuron called a nociceptor (Julius and Basbaum, 2001). 
Nociceptors have certain characteristics which distinguish them from other neurons, such 
as the fact that they can only be activated by certain stimuli – intense heat, physical 
pressure, but that they are not activated by other normal stimuli such as light pressure, or 
Figure 1.2. A diagram to show the structure of a nerve, adapted from Topp and Boyd, 2006. Axons are surrounded by 
the endoneurium, which are bundled together and thus several are then bound by the perineurium. These 
perineurial fascicles are then bound together by the epineurium to form a nerve. 
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mild temperature changes. Nociceptors are also considered to be polymodal, and are 
either of the Aδ or C class of sensory afferent fibre. 
 
Sensory afferent fibres are grouped into 4 classes according to their myelination and 
diameter: Aα, Aβ, Aδ or C. However, it is acknowledged that Aδ and C fibres are mainly 
used for nociceptive purposes. There are three main classes of nociception and pain, 
thermal nociception – fibres are activated by extreme temperatures – above 45°C or below 
5°C. In thermal nociception, it is the thinly myelinated, small diameter Aδ fibres which 
detect the stimulus. Mechanical nociception is a measure of intense pressure, and is also 
detected by the Aδ fibres, which conduct quickly at 5-30 m/s. Polymodal nociceptors are 
activated by intense temperature – both hot and cold, and by chemical (such as acid or 
capsaicin) and mechanical stimuli. These nociceptors have C fibres, which are of small 
diameter but are unmyelinated, conducting slowly, usually less than 1 m/s (See Table 1.1 
for summary) (Kandel, 2000, Lee, 2005)  
 
The different fibres are said to be responsible for the perception of “first” and “second” 
pain, with “first” pain being the sharp fast pain at the beginning of an injury, such as 
stubbing your toe, whereas “second” pain would be the burning sensation afterwards. This 
is explained by the conduction speeds of the different nociceptor fibres, so the “first” pain 
would be caused by Aδ fibres as they conduct the quickest, and “second” pain would be 
caused by C fibres (Kandel, 2000, Julius and Basbaum, 2001).  
 
Many nociceptor receptors have been identified and classified. For example, it has been 
found that there are at least 2 sub-classes of C-fibre – those which express the peptide 
neurotransmitter substance P, and expresses TrkA (tyrosine kinase receptor which binds 
to nerve growth factor (NGF)), and those which do not express these proteins, but can be 
labelled with α-D-galactosyl-binding lectin IB4, and express P2X3 receptor, which is a 
specific type of ATP gated ion channel. (Julius and Basbaum, 2001). 
 
It is thought that epigenetic modification makes a significant contribution to pain 
variability – rat models have been bred to show high autonomy and low autonomy – they 
share a common genetic background but have been bred to have high and low sensitivity 
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to pain. This is expressed in both spontaneous pain behaviour and the neuroma model of 
neuropathic pain. Pain is normally mediated by Aδ and C fibres, with Aβ fibres signalling 
touch. It is thought that after nerve injury, Aβ fibres could also signal pain. Aβ afferents 
could be accountable for heritable differences in pain behaviour (Nitzan-Luques et al., 
2011). 
 
 
FIBRE TYPE STRUCTURAL PROPERTIES FUNCTION 
AΑ AND AΒ Large diameter 
Myelinated 
Conduction: 5-30 m/s 
Proprioception (non 
nociception, i.e. light touch) 
AΔ Medium diameter 
Lightly myelinated 
Conduction: 5-30 m/s 
Nociception - mechanical, 
thermal and chemical. Type 
I fibres have a 53°C 
temperature threshold, 
Type II have a 43°C 
threshold. 
C Small diameter 
Unmyelinated 
Conduction: less than 1 m/s 
Nociception – mechanical, 
thermal and chemical, has a 
temperature threshold of 
43°C but detects both hot 
and cold temperatures, also 
innocuous temperatures 
Table 1.1. This table shows the basic properties of the neuron fibre and their specialities. Adapted from Kandel et al 
2000, and Julius & Basbaum, 2001 
 
Transient receptor potential (TRP) ion channels are expressed in many cell types and are 
important in sensation because they can act as molecular sensors, and they are implicated 
in nociception and pain, in particular, the vanilloid receptor related TRPs (TRPVs). For 
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example, it has been found that TRPV1 is activated by capsaicin (an ingredient of chilli 
peppers which causes pain and irritation), stimulating primary sensory afferents 
(nociceptors). TRPV1 was found to be highly expressed in small sensory neurons and is 
considered to be poly modal since it is activated not only by capsaicin, but also by noxious 
heat at temperatures higher than 43°C, and by acid, endogenous lipids and lipoxygenase 
products (Lee, 2005). 
 
TRPV1 is also implicated in inflammation, as inflammatory agents such as bradykinin (a 
pain causing substance in the body) and histamine can either sensitize or activate the 
receptor, and it is thought that TRPV1 plays an important role in inflammatory pain 
(Endres-Becker et al., 2007). Bradykinin is able to activate sensory neurons via the PLA2 
and lipoxygenase pathway, and it also sensitizes neurons to heat, or in the case of TRPV1, 
heat and capsaicin (Lee, 2005).   
 
TRPV2 is a homolog of TRPV1, which has structural similarity with TRPV1, but it is not 
sensitive to acid or capsaicin, which was unsuspected, TRPV2 does retain the ability to 
respond to heat over 52°C. And it is also expressed in other cells than sensory neurons. It 
has also been shown to be sensitive to membrane stretch and shock, so a role as a 
mechanic nociceptor could also be considered. Other homologs of TRPV1 – TRPV3 and 4 
are also sensors for heat, although the threshold for activation is much lower (31°C for 
TRPV3 and 24°C for TRPV4), which would suggest that these are not nociceptors (Lee, 
2005). 
 
TRPA1 is a cold channel, and therefore activated by cold stimuli at less than 17°C, and is 
expressed in small sensory neurons, it is also co-localised with TRPV1 (which was explored 
earlier, is activated by heat) – this can explain why noxious cold can be detected as heat, 
and the experience is called “paradoxical heat”. TRPA1 is also activated by many other 
substances such as cinnamaldehyde, gingerol and mustard oil (Lee, 2005, Bautista et al., 
2006). It has also been found that stimulation of phospholipid C activates TRPA1, as well 
as stimulation of G-protein coupled receptors.  TRPA1 was also found to be highly 
expressed within sensory hair bundles in the inner ear – this, along with the fact that 
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siRNAs can silence TRPA1 and reduce hair cell mechanotransduction currents suggests that 
the receptor may also play a role in mechanotransduction. 
 
ASIC or acid sensing ion channel is activated by extracellular acid, and is distributed widely 
in sensory neurons. It also has a role in nociception, in inflammatory pain as extracellular 
acid is one of the major noxious stimuli, ASIC expression can be mediated by non-steroidal 
anti-inflammatory drugs (NSAIDs), which further implicates the role of the receptor in 
nociception (Lee, 2005). 
 
By looking at different receptors which are expressed by different sensory neurons, it is 
possible to observe why different sensory neurons have different functions. For example, 
type I and type II Aδ fibres have different thresholds to temperature, this could merely be 
because type I fibres express TRPV1 as a heat receptor, and type II fibres express TRPV2, 
which has a higher temperature threshold. 
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1.2. Neuropathic Pain 
1.2.1. Neuropathic Pain 
Neuropathic Pain is a pathology of pain and can be described as “pain resulting from 
disease or damage of the peripheral or central nervous system” (Scadding, 2004). 
Neuropathic pain serves no useful purpose. There are many causes of neuropathic pain – 
such as trauma and tumours, but conditions including diabetes, multiple sclerosis, HIV and 
vitamin B12 deficiency can contribute to a higher risk factor for developing the condition 
(Scadding, 2004). 
Neuropathic pain can be characterised by two conditions; hyperalgesia and allodynia. 
Hyperalgesia is a condition where there is an increased intensity of pain produced by a 
noxious stimulus and can lead to a delayed perception of pain and painful after-sensations. 
Allodynia is when an individual experiences low intensity mechanical stimuli can cause pain 
(so a low intensity stimulus such as someone brushing the skin can cause pain). Allodynia 
is a prominent marker of nerve-injury evoked pain syndromes (Chaplan et al., 1997, 
Scadding, 2004, Sandkuhler, 2009). 
 Individuals suffering from neuropathic pain may suffer from the delayed onset of pain, 
and an example of this would be central post-stroke pain, where a patient has suffers from 
pain several months and possibly years after the initial stroke. The pain felt by a sufferer 
of neuropathic pain is different from normal nociceptive pain (as are the mechanisms by 
which it is produced). Neuropathic pain is usually a burning, raw and stabbing sensation 
and can also be affected by fatigue and emotion, and there can be sensory impairment 
(Scadding, 2004, Baron et al., 2010). 
A basic pathophysiology of neuropathic pain is as follows; novel ectopic impulse 
generators develop at several points in the PNS as a result of damage, and inflammatory 
cells such as macrophages and leukocytes release a variety of chemicals including 
noradrenalin, bradykinin, ATP, BDNF, histamines and serotonin which work to sensitize 
nociceptors to increase nerve activity. As a result of these changes the threshold to 
activate nociceptors is lowered causing peripheral sensitization. Connections are formed 
between injured and uninjured nerve fibres leading to cross-excitation – meaning that 
non-painful stimuli can induce pain. Synaptic plasticity can occur in the spinal cord, which 
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can lead to possibly irreversible abnormal neuron connectivity (Scadding, 2004, Pasero, 
2004). 
Ectopic nerve activity causes the sensation of ongoing spontaneous pain and shooting 
pain, however, there is no stimulus that causes this and the pain felt is of no use. The 
activation of Aδ and C-fibres have high activation thresholds, because they indicate tissue 
damage, however, in neuropathic pain states this is dramatically changed in both injured 
and surrounding uninjured neurons. This could be due to increased expression of voltage 
gated sodium channels, observed as increased mRNA transcripts correlating with ectopic 
nerve activity and neuropathic pain (Hains et al., 2004, Baron et al., 2010). Further 
evidence in support of this view is provided by the chronic pain states experienced by 
people with paroxysmal extreme pain disorder and erythromelalgia – both of these 
disorders are hereditary and are caused by mutations of SCN9A – a gene which encodes 
the Nav1.7 voltage gated sodium channel (Hains et al., 2004, Baron et al., 2010). 
It is also possible that K+ channels such as Nav1.8 and Nav1.9 are involved in neuropathic 
pain by contributing to changes that are seen in membrane excitability of nociceptive 
nerves. The potassium channel is highlighted as a possible therapeutic target for 
neuropathic pain because it is involved in pain modulation and can suppress nociceptive 
neurons by hyperpolarisation (Lee, 2005, Baron et al., 2010, Zhao et al., 2010).  
Several different receptors are dysregulated in neuropathic pain, such as TRPV1 – which is 
down-regulated on injured neurons, and as activation thresholds of such receptors can be 
altered, if the threshold was lowered to below 38°C, then affected receptors would 
produce ectopic action potentials constantly. In addition, abnormal function or expression 
of the cold receptors such as TMRM8 could lead to cold allodynia (Baron et al., 2010). 
Other cell types also undergo changes – for example it is thought that microglial expression 
of receptors such as P2X4 increase in chronic pain conditions (Horvath and DeLeo, 2009) 
(see later). 
Central sensitisation is thought not to be caused by damage to the CNS itself, but is a 
consequence of repeated ectopic nerve activity and related to neurotrophic factors such 
as BDNF. Central sensitisation is often associated with reduced activation thresholds in 
dorsal horn neurons in response to noxious stimuli and also increased receptive field of 
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DRG neurons, thus inducing a secondary hyperalgesia and allodynia (Coderre and Melzack, 
1992, Jin et al., 2003, Baron et al., 2010, Biggs et al., 2010). 
CNS involvement can occur when excitatory amino acids and neuropeptides are released 
from peripheral afferent fibres; this can lead to post synaptic changes in 2nd order sensory 
neurons (those in the dorsal grey column or sensory nuclei) which can include the 
increased expression of sodium channels and phosphorylation of neurotransmitters such 
as NMDA and AMPA. Such changes act to lower the activation thresholds so that both Aδ 
and Aβ fibres can activate second order neurons. This neuronal hypersensitivity leads to 
increased pain from non-noxious stimuli such as light touch (Coderre and Melzack, 1992, 
Jin et al., 2003, Baron et al., 2010). 
Several mechanisms can contribute to ectopic nerve activity and central sensitization, 
which is one of the reasons why it is so difficult to treat neuropathic pain in patients. For 
example, after peripheral nerve injury or lesion, inflammatory processes will occur, thus 
causing activated macrophages to migrate into the afflicted area and release pro-
inflammatory cytokines including tumour necrosis factor α (TNFα). In the CNS microglia 
can release immune modulators which can maintain neuropathic pain, thus contributing 
to peripheral sensitisation (Baron et al., 2010). There is also a loss of inhibitory GABAergic 
neurons (neurons which produce GABA), which can contribute to neuropathic pain, 
through disinhibition mechanisms after a Cl- shift – GABA is excitatory and depolarizing 
when chloride ions flow out of the cell (Zhou et al., 2011). 
The mechanisms by which neuropathic pain is initiated are multifaceted and complex and 
as such there are several different areas to explore in research. Some proposed 
mechanisms include increased nociceptor excitability through increased glutamate input 
to sensory neurons (Baron et al., 2010), decreased GABA inhibition in dorsal horn neurons 
(Zhou et al., 2011), and phosphorylation of NMDA (Woolf and Mannion, 1999) amongst 
others.  
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1.2.2. Animal Models of Neuropathic Pain 
 
There are several animal models that are commonly used to study neuropathic pain, and 
these methods can themselves be grouped into various categories. These include central 
pain models – where pain is the result of CNS pathology; peripheral nerve injury models –
where nerve injury results in hyperalgesia and allodynia and disease-induced models of 
neuropathic pain (Honoré et al., 2010). An overview of the most commonly used animal 
models of neuropathic pain of relevance to studies on macrophages in this thesis is 
outlined in this section.  
Spinal Cord Injury (SCI) is a central pain model of neuropathic pain, which often causes 
spontaneous and evoked pain. SCI is usually induced by contusion in which a compression 
of the spinal cord takes place at T8. Weight dropping is another common method of 
producing SCI – in which a weight is allowed to drop on the exposed spinal cord at T12-
T13. SCI results in hypersensitivity to light mechanical stimuli and allodynia within 1 day, 
and severe paraplegia (Jaggi et al., 2011, Colleoni and Sacerdote, 2010).  
Partial nerve lesion models are peripheral nerve injury models, and are amongst the most 
common models of neuropathic pain in use, these include spinal nerve ligation (SNL), 
chronic constriction injury (CCI) and partial sciatic nerve injury (PNI). SNL is performed by 
ligating unilaterally and tightly the spinal nerves at L5 and/or L6. SNL is considered to be a 
model of neuropathic pain with relevant damage and the advantage of having injured and 
intact spinal segments (Kim and Chung, 1997, Colleoni and Sacerdote, 2010, Jaggi et al., 
2011). 
CCI of the sciatic nerve results in a similar neuropathy to injuries in man. CCI is easily 
reproducible as it is formed by three loose ligations that are tied around the common 
sciatic nerve at the mid-thigh level, resulting in the axotomisation of many of the axons. 
The neuropathy produced lasts for up to 7 weeks, and mechanical and thermal 
hyperalgesia (Colleoni and Sacerdote, 2010, Jaggi et al., 2011).  
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PNI is a common animal model for neuropathic pain, performed by tying a tight ligature 
around the diameter of the sciatic nerve (Seltzer et al., 1990, Malmberg and Basbaum, 
1998). Nerve injured animals appear healthy and well groomed, but nonetheless, there is 
a marked decrease in the thermal and mechanical pain thresholds, indicating hyperalgesia, 
which persists for at least 6 weeks (Colleoni and Sacerdote, 2010).  
 
1.2.3. Treatment of Neuropathic Pain. 
 
Neuropathic pain is a particularly difficult condition to treat because there are so many 
mechanisms in which can cause neuropathic pain to arise, and so it is important to try and 
treat the mechanisms and thus cure neuropathic pain. This aside, there are some 
treatments available for neuropathic pain, even though they may not be fully effective, 
with a pain reduction of 30% (measured by questionnaires) considered a successful 
treatment.  
One of the problems with treating neuropathic pain is that there are many different types 
of neuropathic pain, and even though many of the symptoms are the same, this would 
indicate that the mechanisms differ and therefore treatments will vary. Most drug trails 
have taken place with patients with either painful polyneuropathy or postherpatic 
neuralgia (Attal et al., 2006).  
Figure 1.3. A diagram to explore common methods of producing animal models of neuropathic pain, 
including SNL, PNI and CCI, as demonstrated in the hind leg of the animal. Adapted from (Ueda and 
Rashid, 2003) and (Suter et al., 2011) 
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In patients with painful polyneuropathy, several drugs have been trialled, including 
antidepressants, antiepileptics and opioids. Tricyclic antidepressants such as amitrptyline, 
clomipramina and imipramine inhibit the presynaptic reuptake of both noradrenaline and 
serotonin,  and block adrenergic, cholinergic and sodium channels (Abdi et al., 1998, 
Jefferies, 2010).  
Tricyclic antidepressants have shown moderate efficacy as a treatment in trials, whereas 
selective serotonin reuptake inhibitors give clinically insufficient pain relief – although 
serotonin-noradrenaline reuptake inhibitors (venlafaxine, dulexetine) are moderately 
effective (Attal et al., 2006). However, the success of tricyclic antidepressants depends on 
the type of neuropathic pain, as they have been found to be ineffective against 
neuropathic cancer pain, HIV neuropathy and phantom limb pain (Micó et al., 2006, 
Jefferies, 2010).  
Opioid treatment is thought to have a consistent efficacy in the treatment of neuropathic 
pain, however, due to their addictive nature; they are mainly reserved for second- or third-
line drugs. The opioid levorphanol has been found to produce dose-dependent pain relief 
in patients with peripheral or central neuropathic pain (Finnerup et al., 2010). 
The opioids oxycodone and tramadol also produce positive effects; both drugs are µ-opioid 
receptor agonists, with Tramadol also being able to inhibit the reuptake of noradrenaline 
or serotonin. Tramadol is associated with a quick onset of pain relief and has a low abuse 
potential (Attal et al., 2006, Jefferies, 2010). 
The antiepileptic carbamazepine (a voltage-gated sodium blocker) had significant effects 
for patients with diabetic painful polyneuropathy. Oxycarbazepine (voltage gated sodium 
and calcium channel blocker) and Lamotrigine (a presynaptic voltage gated sodium 
channel inhibitor – which inhibits the presynaptic release of excitory neurotransmitters) 
also had a significant effect on pain reduction. Another antiepileptic Topiramate, which 
blocks sodium channels and also inhibits glutamate release by acting on AMPA and kainate 
receptors – which are glutamate receptor ion channels (Dingledine et al., 1999), failed to 
have a significant effect in patients with diabetic painful polyneuropathy (Attal et al., 2006, 
Jefferies, 2010). 
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The best antiepileptics to date for treating neuropathies are gabalin, gabapentin and 
pregabalin. These drugs are thought to work by binding to the α2δ1 subunit of voltage 
dependant calcium channels, thus giving a reduced release of presynaptic transmitters. 
Pregabalin has analgesic, anxiolytic (anti-anxiety) and anticonvulsant properties. It has no 
known drug interactions and has little metabolic steps before it is excreted which increases 
the predictability of drug action. It has shown to be consistent in reducing pain in patients 
with either painful diabetic neuropathy or postherpatic neuralgia with doses ranging from 
150-600mg/day, and gabalin has shown the same effects. One problem with the initial 
pregabalin trials is that non-responders to gabapentin were excluded from the trail and 
the drug functions through the same mechanism resulting in possible bias oftrial results  
(Abdi et al., 1998, Wodarski et al., 2009, Attal et al., 2010, Semel et al., 2010). 
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1.3. Cell Migration 
The ability of cells to migrate is a fundamental biological function, which is known to 
contribute to immune defence, morphogenesis and wound healing, it is also essential for 
tumour formation and metastasis. 
 In 2D, cell migration begins with polarisation in response to an extracellular signal due to 
modifications in the cytoskeleton that leads to the formation of lamellipodia at the leading 
edge, and a uropod at the rear. The leading edge is characterised by actin polymerisation 
and the clustering of integrins, forming focal adhesions with the ECM substrate. Focal 
adhesions disassemble at the trailing edge as the cell moves forward (Horwitz and Parsons, 
1999, Verollet et al., 2011). 
Cells attach to and move across the ECM mainly through the integrin family of cell surface 
receptors (Ref). Proteases of different classes are involved in the direct cleavage on 
integrin extra-cellular domains and in the proteolysis of the ECM, sometimes revealing pro-
migratory cryptic sites (Stringa et al., 2000). In the migrating cell, there are bundles of 
microtubules that form a network within the cytoskeleton, the role of microtubules are 
complex and include determination of direction of migration (Ridley et al., 2003, Verollet 
et al., 2011, Vicente-Manzanares and Horwitz, 2011). 
At the rear of the cell, the uropod is categorised by retraction, where all of the focal 
adhesions are disassembled. This is a process that is led by the GTPase, dynamin, and 
myosin light chain phosphatase, which prevents the phosphorylation of myosin II, which 
transmits a force along actin filaments to adhesion sites. Together, these processes help 
the cell to propel itself forward (Horwitz and Parsons, 1999, Ridley et al., 2003). 
In macrophages, structures known as podosomes are formed which consist of F-actin rich 
structures surrounded by integrins; these podosomes are focused at the leading edge of 
the cell. The degradation of the ECM is dependent on matrix metalloproteinases (see 
chapter 1.7), with the degradation of fibronectin and collagen I being dependent partially 
on the presence of MMP-14 which is a crucial element in both the migration and 
chemotaxis of macrophages (Verollet et al., 2011).  
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1.4. Microglia and Macrophages. 
1.4.1. Microglia. 
 
Microglia have often been described as the macrophages of the nervous system and 
characterised by their role in immune function and the nervous system. They are located 
in nervous tissue and have roles including phagocytosis, cytokine secretion and antigen 
presentation to help protect neurons against infection and injury. Microglia have also been 
shown to play a role in development and are involved in physiological conditions such as 
neuronal function, synaptogenesis and developmental apoptosis. For example, it has been 
shown that nerve growth factor (NGF) (secreted by microglia in retinal tissue) is essential 
for developmental apoptosis in retina (Lobov et al., 2005, Bessis et al., 2007). Microglia 
secrete brain derived neurotrophic factor (BDNF) implicating these cells indirectly in 
synaptic function as BDNF directly regulates synaptic properties in the spinal cord (Coull et 
al., 2005, Bessis et al., 2007). 
Microglia make up around 5-10% of glial cells in the CNS. In the resting state microglia have 
small soma and thin branched processes and act as sensors to changes in normal 
conditions which could threaten homeostasis, such as infection, ischemia or trauma. When 
microglia are activated by these stimuli, they undergo a series of changes in morphology, 
gene expression and function. Several genes are upregulated following activation including 
genes which control cell surface receptors such as CD11b (integrin αM) and CD18 (integrin 
β2). Activated microglia also express MHC complexes (Tsuda et al., 2005). 
During development, microglia infiltrate central nervous tissue at a very early age and form 
a meshed network of cells with the ability to detect and react to changes in the local 
environment. They have been shown to be able to secrete a number of cytokines shown 
to be implicated in neuronal function, and it is thought that the majority of neuronal 
functions are likely to be regulated by microglia (Bessis et al., 2007). 
Glial cells and specifically microglia are of interest in a neuropathic pain context due to 
their underlying roles in synaptogenesis, the immune system and their activation in 
response to nerve injury. Rather than remaining in a dormant state in the healthy CNS, 
microglia are known to be constantly surveying the area to detect and respond to any 
Page | 20  
 
stimuli which pose a threat to physiological homeostasis (Jasmin et al., 2010). There is a 
growing body of evidence that suggests that the enhanced output of dorsal horn 
nociceptive neurons may be at least partially as a result of glia-neuron interactions (Scholz 
and Woolf, 2007, Beggs and Salter, 2010), and perhaps these have increasing importance 
in the development and maintenance of neuropathic pain.  
Microglia and astrocytes show increased activation after either PNS or CNS injury, with the 
morphology of microglia changing from a resting state (cells have a small soma with long 
and thin processes), to an active state, (large soma and amoeboid shape, with short and 
thick processes). The activation of microglia can be demonstrated by staining with Iba1 or 
p38 as these proteins are expressed upon activation (Ito et al., 1998, Wodarski et al., 2009, 
Clark et al., 2010, Toda et al., 2011). 
Further evidence that microglia could be involved in the onset of neuropathic pain is found 
after CCI. After CCI, the release of several cytokines and neurotrophins ensues; this has an 
effect on the primary afferent neurons and increases the excitability of the neurons (Lu et 
al., 2009, Wodarski et al., 2009, Biggs et al., 2010). However, this will be further explored 
later. 
 
1.4.2. Macrophages 
 
Macrophages are phagocytic cells that play an essential role in both innate and acquired 
immunity. First described by Ilya Mechnikov in 1893, they are able to respond to a variety 
of environmental cues by changing their phenotypes and physiologies (Vereyken et al., 
2011). Macrophages have many specialised functions, which include phagocytosis, motility 
and diverse gene expression which are specialised to their role in immunity (Gordon, 
2007). Macrophages are referred to as professional phagocytes and are extremely efficient 
at internalizing particles and pathogens (Aderem and Underhill, 1999).  
Macrophages originate from bone marrow precursors and are present in most, if not all 
tissues and differentiate from circulating peripheral blood mononuclear cells which 
migrate into tissues as part of their steady state activities, or in response to stimuli, such 
as inflammation (Mosser and Edwards, 2008). 
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Macrophages respond to several endogenous stimuli (for example, IFNγ, TNFα, IL-10, IL-
17, ATP) which are released or synthesised directly after injury or infection which in turn 
lead to the activation of macrophages (Mosser and Edwards, 2008). Macrophages are able 
to respond to numerous self and non-self molecules due to the expression of pattern 
recognition receptors on the cell surface, which are able to recognise pathogen associated 
molecular patterns (PAMPs). Amongst the receptors that macrophages express, there are 
complement receptors, integrins, Fc receptors, lectins and scavenger receptors, and Toll-
like receptors.  
 Classically activated macrophages are referred to as M1 and alternatively activated as M2 
macrophages. Typically, M1 macrophages release IL-1β, IL-6 and TNFα, along with TGFα 
and TGFβ , causing tissue damage, whereas M2 macrophages are anti-inflammatory 
producing  IL-10 (Eming et al., 2007) and actively promote proliferation and tissue repair 
(Mills, 2012). However, it is thought that there are more  subtypes of macrophages as they 
are known to have wide roles in a range of processes (for example, wound healing and 
regulating the immune response), although there is some difficulty in determining how to 
characterise them (Mosser and Edwards, 2008).  
As macrophages are present in most tissues and in the circulating blood, they can migrate 
into the site of injury after peripheral nerve injury, and play a part in the onset and 
maintenance of chronic pain conditions (reviewed in Clark et al 2013).  
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1.5. ATP as an Extracellular Signalling Molecule. 
In 1972, Burnstock proposed new roles for nucleotides as neurotransmitters after it was 
shown that ATP was able to act as a transmitter in guinea pig inhibitory nerves, despite it 
being well known that intracellular ATP is the key to free energy. P2 receptors were 
discovered and now these purinoceptors are divided into 2 families – ionotropic P2 
receptors (P2X) and metabotropic receptors (P2Y).  Nucleotides can  leak and be released 
from all cells including damaged neurons, and can be involved in cell to cell communication 
in both normal physiological processes and pathophysiological processes, especially during 
trauma (Burnstock, 1972, Burnstock, 2007). 
Initial opposition to the idea came from the fact that ATP was first recognised for its many 
roles in intracellular biochemical processes – and the intuition that a simple molecule such 
as ATP would be unlikely to be used as an extracellular messenger – given that it is so 
ubiquitous, even though enzymes to break down extracellular ATP were known to exist 
(Burnstock, 1972, Burnstock, 2007). 
Purinergic receptors were first described in 1976, and later 2 receptor subtypes were 
defined, P1 receptors – which are activated by adenosine, and P2 receptors, activated by 
ATP/ADP. P2 receptors were later discovered to have 2 subtypes – P2X – a family of ligand 
gates ion channel receptors and P2Y – a family of G-protein coupled receptors. There are 
known to be 7 P2X subtypes, and 8 P2Y receptors (Burnstock, 1972, Burnstock, 1976, 
Burnstock, 2007). 
Glial cells are thought to be implicated in the so called “purinergic nervous system”.  
Astrocytes express many types of P2X and P2Y receptors and can release ATP in response 
to stimuli, or spontaneously. It is possible for astrocytes to communicate with neurons at 
synapses, microglia and also vasculature. Microglia also express P2X and P2Y receptors and 
are thought to play an important role in pathological conditions in the brain, including 
chronic pain (Jin et al., 2003, Nasu-Tada et al., 2005, Trang et al., 2009, Tsuda et al., 2008, 
Inoue and Tsuda, 2009, Beggs and Salter, 2010, Inoue and Tsuda, 2012, Trang et al., 2012). 
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1.5.1. P1 Receptors 
There are four different P1 receptors, P1A1, P1A2A, P1A2B and P1A3, all of which are 
members of the rhodopsin like family of GPCRs. P1 receptors have been shown to couple 
to adenylate cyclase (enzymes which can convert ATP to cAMP) (Hanoune and Defer, 
2001), and P1A2B has also previously been shown to act through Gg/11 to regulate activity 
of PLC in humans. Null mice for each of the P1 receptors (excluding P1A2B) have been 
bred, although none of these receptor subtypes appear to play a crucial role in 
development. However, the overexpression of both P1A1 and P1A3 has been shown to 
have cardioprotective effects (Burnstock, 2007, Idzko et al., 2014).  
P1 receptors are activated by adenosine, and there are a number of subtype selective 
agonists which have been activated, with most of them closely resembling the structure of 
adenosine. Methylxantines such as caffeine and theophylline are weak P1 receptor 
antagonists (caffeine’s mental stimulation and alertness effect is due to the blocking of P1 
receptors and inhibiting the action of adenosine) (Burnstock, 2007). 
Microglia express P1A1 receptors, along with P1A2A and P1A3 receptors, stimulation of 
the P1A1 and P1A2A receptors has previously been shown to cause activation and 
proliferation, although in some cases, it has also been shown to lead to apoptosis, 
depending on the environment (Hasko and Cronstein, 2013).  
Stimulation of the P1A2A receptor can lead to the upregulation of cyclooxygenase-2 
(COX-2) and the release of the pain-related molecule Prostaglandin E2, which could be 
indicative of a pro-inflammatory role. However, by-products of COX-2 could be 
responsible for the resolve of inflammation – suggesting that this may indeed be a 
neuroprotective role. Stimulation of P1A2A can also lead to the synthesis and release of 
NGF (Abbracchio and Ceruti, 2007, Hasko and Cronstein, 2013). 
Adenosine stimulation of microglia has been shown to inhibit the production of IL-1β and 
MMP-12 in infiltrating macrophages, and up-regulating IL-1, IL-6 and IL-12 in infiltrating 
cells, suggesting a pro-inflammatory phenotype. However, several studies have shown 
the ability of Adenosine to alleviate neuropathic pain behaviours, and to act as an 
analgesic (Belfrage et al., 1995, Guieu et al., 1996, Tsutsui et al., 2004, Haskó et al., 2005, 
Loram et al., 2009, Yamaoka et al., 2013). 
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1.5.2. P2X Receptors 
P2X receptors are thought to be the first purinergic receptors to appear in evolution, and 
have a highly conserved structure (Burnstock, 2007). P2X receptors have three subunits, 
which each possess two transmembrane domains, one of which is involved in ion channel 
gating, and one which is involved in lining the ion pore. P2X receptor N- and C- terminals 
have binding motifs for protein kinases, and the receptor itself has a large extracellular 
loop which contains 10 conserved cysteine residues that are involved in the formation of 
a series of disulphide bridges. Within the P2X receptor, there is also a hydrophobic region 
close to the pore which may be involved in receptor modulation by cations, and an ATP 
binding site. Despite the structure and function of P2X receptors being highly conserved, 
sequence homology is about 30% (Burnstock, 2007, Verkhratsky and Burnstock, 2014). 
There are seven genes which encode for P2X subunits, with the genes for P2X4 and P2X7 
genes being located at the tip of chromosome 12. P2X4 and P2X7 receptors are closely 
related in terms of sequence homology (de Rivero Vaccari et al., 2012). Both P2X4 and 
P2X7 receptors are expressed in both macrophages and microglia. 
1.5.2.1. P2X4 Receptor 
The P2X4 receptor is one of the most predominant receptor subtypes expressed on 
immune and neural cells, and has been shown to be activated by ATP, but not by the 
structural homolog α,β-meATP. P2X4 receptor is known for being potentiated by 
ivermectin, which can increase the effect of activation of P2X4. P2X4 acts as a cation-
selctive channel when exposed to ATP for short amounts of time, however, when the 
exposure to ATP is longer, the channel can become larger and permeable to larger cations 
(Bernier et al., 2012). P2X4 desensitization has been described as intermediate, although 
the recovery time is quick. P2X4 is insensitive to blockade by the antagonists suramin and 
PPADs, and in fact, these antagonists appear to increase currents evoked by activation of 
the P2X4 receptor (Burnstock, 2007, de Rivero Vaccari et al., 2012). 
P2X4 receptors have been reported to be involved in chronic pain conditions, in 2003 
Tsuda et al, reported that P2X4 receptors were markedly upregulated after injury to the 
L5 spinal nerve in rats, and that P2X4 receptors were co-localised with microglia, but not 
astrocytes or neurons. It was observed that treatment with antisense 
oligodeoxynucleotides targeting P2X4 receptors resulted in a marked recovery in paw 
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withdrawal threshold tests – suggesting that P2X4 receptors are essential for mechanical 
tactile allodynia. Spinal administration of ATP stimulated microglia in normal rats also 
produces tactile allodynia dependent on P2X4 receptor. It was demonstrated that tactile 
allodynia can be reversed by the addition of TNP-ATP, a P2X antagonist – thus showing 
that P2X4 stimulation of microglia is sufficient to produce tactile allodynia (Tsuda et al., 
2003). 
Signalling through the p38-MAPK pathway in spinal microglia is also implicated in 
producing allodynia, nerve injury leads to the phosphorylation/activation of p38 MAPK. 
Inhibition of p38 MAPK leads to the suppression of allodynia, suggesting that it is involved 
in generating or maintaining allodynia and neuropathic pain (Jin et al., 2003, Tsuda et al., 
2005). Trang et al in 2009 demonstrated that activation of P2X4 receptors evoked an 
increase in the activation of p38-MAPK activation – which leads to the synthesis and 
release of BDNF (Trang et al., 2009). 
P2X4 receptors are upregulated after spinal nerve injury, for which Lyn has been reported 
as a critical signalling molecule. The fibronectin-integrin system is thought to play an 
important role in the upregulation of P2X4 receptors after spinal nerve injury – in vivo 
studies have shown that after spinal nerve injury the level of fibronectin protein is 
increased after 3-7 days, this is at the same time point that P2X4 receptors are seen to be 
upregulated. Also in primary cultured microglial cells, fibronectin was seen to increase the 
level of P2X4 receptors. Fibronectin has also been injected intrathecally in rats, which 
results in an upregulation of P2X4 receptors and tactile allodynia (Nasu-Tada et al., 2005, 
Tsuda et al., 2008). 
It has been shown that the deletion of P2X4 in mice results in the abrogation of several 
immune responses, including a significant reduction in inflammasome activation. This 
leads to decreased IL-1β, and a reduction in the infiltration of macrophages, along with 
other innate immune cells into the site of injury, after SCI (de Rivero Vaccari et al., 2012). 
 
1.5.2.2. P2X7 Receptor  
The P2X7 receptor is an important and unique member of the P2X receptor family. P2X7 
was first cloned from monocytes and microglia – the P2X7 receptor is, like the P2X4 
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receptor, one of the most predominant receptor subtypes expressed on immune and 
neural cells, it is mainly expressed in peripheral macrophages and microglia. P2X7 is 
different from the other purinergic receptors, in that it is activated only by high 
concentrations of ATP (>100µM), and upon prolonged exposure, forms a large pore which 
is permeable to large dyes such as YO-PRO-1, the prolonged opening of this pore can lead 
to cell death. Prolonged activation of P2X7 can also lead to membrane blebbing and the 
release of inflammatory cytokines (Burnstock, 2007, He et al., 2012).  
P2X7 receptors are also expected to be involved in neuropathic pain. P2X7 is upregulated 
in the dorsal horn after peripheral nerve injury in microglia, but not neurons or astrocytes, 
suggesting that P2X7 receptors mediates activation of microglia in chronic pain conditions 
(He et al., 2012).  
 Recently, structurally unrelated P2X7 agonists have been shown to reduce tactile 
allodynia in 3 different models of neuropathic pain (Tsuda et al., 2010). It has also been 
found that both selective, and non-selective P2X7 antagonists can lead to significantly 
reduced carrageenan-induced mechanical hyperalgesia (Teixeira et al., 2010). 
He et al (2012) showed that CCI induced mechanical allodynia was reduced after treatment 
with the P2X7 receptor antagonist Brilliant Blue G (BBG), although not completely rescued. 
BBG was also successfully partially reducing thermal hypersensitivity (He et al., 2012).  
 
1.5.3. P2Y Receptors 
P2Y receptors differ from P2X receptors as they are linked to GPCRs and also differ in their 
selectivity to nucleotides, for example, some are selective to uracil nucleotides, whereas 
others are activated by adenine nucleotides (Ben Yebdri et al., 2009). As GPCRs, the P2Y 
receptors have a structure with an extracellular N terminus, seven transmembrane motifs 
and an intracellular C terminus. There is very little sequence homology in P2Y receptors 
which may explain their differences in the specificity of ligands (Burnstock, 2007). 
P2Y receptors have different mechanisms of action depending on the G protein they 
couple too. P2Y1, P2Y2, P2Y4 and P2Y6 all bind to Gq/11, and activate phospholipase (PLC) 
– and releasing intracellular stores of Ca2+. P2Y12, P2Y13 and P2Y14 inhibit the adenylate 
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cyclase and therefore reduce cAMP levels by coupling with Gi. It is known that P2Y11 can 
act as part of both of these signalling pathways (Ralevic and Burnstock, 1998). 
1.5.3.1. P2Y6 Receptor 
P2Y6 receptors are selective for UDP, and have a wide tissue distribution and can be found 
in the brain, heart, lungs, spleen, intestines and macrophages. P2Y6 is slow to desensitize 
after activation, and acts by increasing activation of PLC and PKC, which leads to the 
formation of inositol-1,4,5-triphosphate (IP3) and thus mobilization of intracellular calcium 
stores (Mamedova et al., 2004, Yu et al., 2013). It is also thought that P2Y6 activation can 
lead to increased IL-8 production. (Bar et al., 2008). It has previously been shown that the 
antagonism of P2Y6 can lead to the abrogation of inflammatory responses, suggesting that 
P2Y6 may have a role in inflammation (Uratsuji et al., 2012). In microglia, the activation of 
P2Y6 by UDP has been identified as a mediator of microglial phagocytosis (Koizumi et al., 
2007). 
P2Y receptors have a role in chronic pain conditions, P2Y receptors are metabotropic and 
are G-protein coupled receptor linked (Burnstock et al., 2011). It has recently been found 
that microglia express P2Y6, and after peripheral nerve injury the expression of P2Y6 
mRNA is increased in a parallel time course with the development of tactile allodynia. 
Stimulation of the P2Y6 receptor with UDP was found to facilitate microglial phagocytosis 
(Koizumi et al., 2007, Tsuda et al., 2010).  
Recently, P2Y6 receptor antagonists, along with P2Y11 antagonists, were found to 
significantly reduce tactile allodynia in SNL rats. The SNL was also found to increase the 
expression of P2Y6 for up to 21 days after injury. Thus demonstrating that P2Y6 is indeed 
expressed in spinal microglia, and are upregulated in response to nerve injury – which may 
suggest that these receptors play a role in the development and or maintenance of 
neuropathic pain conditions (Barragan-Iglesias et al., 2014). 
1.5.3.2. P2Y12 Receptor 
P2Y12 is activated primarily by ADP, by can also be activated by ATP. P2Y12 is heavily 
expressed in platelets, and is the target of the antiplatelet drug cloprigel, as there is a 
critical role for P2Y12 in platelet activation (Wallentin, 2009, Liverani et al., 2014). P2Y12 
is also found in the brain and glial cells, and in smooth muscle cells. It is thought that P2Y12 
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receptor can indeed regulate microglial activation, as P2Y12 knockout mice possess 
microglia that are unable to polarize, migrate or even extend processes towards sites of 
trauma, thus suggesting that P2Y12 is essential in migration of microglia towards the site 
of injury (Haynes et al., 2006). It is known that P2Y12 has a number of effectors including 
PI3K and PLC, but the signal transduction downstream of P2Y12 is not yet fully understood 
(Irino et al., 2008). 
P2Y12 receptors have a more understood role in neuropathic pain – it is known that the 
P2Y12 receptor regulates a number of effectors including PI3K, adenylate cyclase, 
Phospholipase C (PLC), by signalling through Gi (Guidetti et al., 2008). Irino et al (2008) 
found that Akt activation downstream of PI3K and activation of the PLC pathway was 
necessary for microglia migration in response to an ADP chemoattractant (Irino et al., 
2008).  
P2Y12 receptors have been found to be upregulated in the spinal cord ipsilateral to nerve 
injury, and tactile allodynia can be prevented after treatment with the P2Y12 receptor 
antagonists MRS2395 and AR-C69931-MX. Knockout mice lacking P2Y12 receptor display 
impaired tactile allodynia after peripheral nerve injury whilst basal levels of mechanical 
pain sensitivity do not change. It was also found that the intrathecal administration of AR-
C69931-MX and oral administration of a P2Y12 blocker – clopidogrel to injured rats can 
alleviate tactile allodynia. Taken together, these results suggest that P2Y12 is important in 
the pathophysiology of neuropathic pain, and that blocking the actions of the receptor 
could be a potential treatment for chronic pain conditions (Tozaki-Saitoh et al., 2008). 
The actions of P2Y12 receptor have also been shown to be important in the migration of 
microglial cells. In response to ATP or ADP, microglia were found to display microspike 
processes and lamellipodia, which can suggest that P2Y12 is responsible for mediating 
process extension in microglia – an initial process in migration of microglia. Inhibitors of 
PI3K and PLC were found to block ATP/ADP mediated process extension. Interestingly, it 
was also observed that ATP treatment increases the amount of active β1 integrin in a time 
dependent manner, which is abrogated when P2Y12 is blocked with AR-C69931-MX, 
suggesting that ATP can increase β1 integrin mediated migration through P2Y12 (Ohsawa 
et al., 2010). 
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1.6. The Response of Microglia and Macrophages to Damaged 
Neurons.  
After peripheral nerve injury, or trauma to either the peripheral or central nervous system, 
it is possible for chronic pain conditions to arise. As explored previously, the mechanisms 
by which these conditions arise are complex and as of yet, not fully understood. However, 
recently focus has shifted from neuron-neuron interactions to microglia-neuron 
interactions to determine how neuropathic pain can develop.  
After damage to the peripheral nerves, there is a significant activation of microglia in the 
dorsal horn, this is followed by increased proliferation and expression of proteins such as 
CD4 and CD14. It is thought that chemokines, macrophage colony stimulating factor, 
interleukins, ATP and neurotrophins could all contribute to the onset of neuropathic pain, 
and be involved in neuron-microglia signalling (Tsuda et al., 2005). Similarly, the activation 
and subsequent migration of macrophages into the site of injury is thought to be important 
(Scholz and Woolf, 2007, Ristoiu, 2013). 
 
1.6.1. Platelet Activating Factor 
There is accumulating evidence that platelet activating factor (PAF), and its receptor 
(PAFR) play a role in the mediation of pain signalling. PAF is a phospholipid mediator that 
is known to regulate the functions of a variety of cells in peripheral tissue and the nervous 
system – for example PAF is known to increase calcium concentration in dorsal root 
ganglion neurons, inhibit cAMP production, and activate the p38-MAPK pathway (Ma et 
al., 2010, Okubo et al., 2012, Pethő and Reeh, 2012).  
It is known that an injection of PAF into the periphery enhances pain sensitivity in animals, 
however, when a structurally related but inactive protein, lyso-PAF, is injected, there is no 
response. Yet, PAFR antagonists have been found to produce anti-nociceptive effects in 
inflammatory pain models, and in vivo, PAFR deficient mice show a reduction in p38-MAPK 
signalling in DRG neurons following peripheral nerve injury (Tsuda et al., 2011). 
Whereas wild type mice develop tactile allodynia after nerve injury, it was found that 
PAFR-deficient mice developed a reduced allodynia, and in WT mice, the expression of 
PAFR mRNA was increased in both the DRG and in macrophages, thus peripheral nerve 
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injury may cause the transcriptional upregulation of PAFR in macrophages and the DRG. It 
was also found that PAFR deficient mice demonstrated a marked suppression of the 
upregulation of TNFα and IL-1β – suggesting that the PAF/PAFR system could contribute 
to tactile allodynia via regulation of TNFα and IL-1β in macrophages in the injured DRG 
(Tsuda et al., 2011). There is also evidence to suggest that P2X receptors are involved in 
neuropathic pain, as P2X inhibitors were found to supress PAF-induced tactile allodynia.  
1.6.2. Neurotrophins. 
Neurotrophins are a part of a family of closely related proteins; they are known to control 
survival and development of neurons, and also to influence the function of all neurons, 
and maintain neurons in adulthood. There are four major neurotrophic factors; Nerve 
Growth Factor (NGF), Brain Derived Neurotrophic Factor (BDNF), Neurotrophin-3 and 
Neurotrophin-4, which are all structurally related, however, sometimes Glial Derived 
Neurotrophic Factor and Ciliary Neurotrophic Factor are referred to as neurotrophins 
(Skaper, 2012). 
Neurotrophins signal through one or more of the three members of the tropomyosin-
related kinase (Trk) family of receptor tyrosine kinases – named TrkA, TrkB and TrkC, 
additionally, neurotrophins can signal through the p75 receptor. This section will focus on 
NGF and BDNF. 
1.6.2.1.  Nerve Growth Factor 
Nerve Growth Factor was first defined and characterised by Rita Levi-Montalcini and 
Stanley Cohen throughout the 1950s and is now well characterised. Nerve growth factor 
binds to TrkA, and induces autophosphorylation of TrkA, which in turn can lead to the 
activation of various signalling pathways, including the PI3K/Akt pathway, MAPK/ERK 
pathway and the PLCγ pathway (Hong et al., 2012). 
In the context of neuropathic pain, there are many contradictory reports in the literature, 
with many studies suggesting NGF be used as a treatment to alleviate neuropathic pain, 
whereas some literature suggests that NGF is indeed an agonist of neuropathic pain, and 
that anti-NGF functional antibodies could be used as a treatment. 
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NGF is produced as a mediator in some pain states, and can modulate the expression of 
several pain related transmitters, ion channels and receptors, including substance P. Some 
studies have demonstrated that the systemic administration of NGF can lead to the 
development of thermal hyperalgesia and allodynia in rats (Lewin et al., 1994). Leading on 
from this, Woolf et al in 1996, displayed that an anti-NGF functional antibody could indeed 
reverse hyperalgesia after CFA induced development of neuropathic pain. It was also 
found that anti-NGF antibodies could reverse established pain in the Chung SNL model of 
neuropathic pain (Woolf, 1996, Wild et al., 2007).  
However, it has also been found that intrathecal administration of NGF has been found to 
restore the effectiveness of opioid treatment after CCI (Cirillo et al., 2010) and peripheral 
administration of NGF has been found to be beneficial in trials in patients with sensory 
neuropathy. Also, NGF treatments in rats have shown that after CCI, there was markedly 
reduced activity of microglia and astrocytes, including reduced production of inflammatory 
mediators (Cirillo et al., 2010). 
NGF treated rats also showed a higher tolerance to Von Frey filaments (testing for 
mechanical hyperalgesia) and the plantar test (testing for thermal hyperalgesia), thus NGF 
produced a partial recovery of neuropathic pain behaviour (Cirillo et al., 2010). 
1.6.2.2. Brain Derived Neurotrophic Factor 
BDNF acts through its cognate receptor TrkB, which leads to the phosphorylation of PLCγ, 
leading to the formation of DAG and IP3 and the subsequent release of intracellular 
calcium. BDNF is thought to be key molecule in the signalling pathway for microglia-neuron 
interaction and consequently, a molecule of interest concerning the onset of neuropathic 
pain (Coull et al., 2003, Trang et al., 2009). 
BDNF has roles in cell survival, differentiation and cell migration in the CNS. BDNF has 
previously been linked with neuropathic pain, with studies demonstrating that after 
peripheral nerve injury, the expression of BDNF is increased (Coull et al., 2005, Zhang et 
al., 2012). BDNF is also able to disinhibit neurons in lamina I of the dorsal horn – a group 
of nociceptive neurons. For pain hypersensitivity to occur in lamina I neurons, there is first 
a change in the modal specificity of the output neurons which happens after a disruption 
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of chloride homeostasis – BDNF causes a rise in intracellular [Cl-], which suppresses GABA 
inhibition (Coull et al., 2003, Trang et al., 2009, Beggs and Salter, 2010). 
Damaged afferent neurons show spontaneous activity and release additional cytokines 
and neurotrophins such as ATP and BDNF, which can exert long term effects on dorsal horn 
excitability (Lu et al., 2009, Biggs et al., 2010). 10-20 days of CCI of the sciatic nerve can 
produce a characteristic electrophysiological signature - i.e. a signature of change in the 
synaptic excitation of five different electrophysiologically defined neuronal phenotypes 
(described as tonic, delay, irregular, phasic and transient) in the dorsal horn of rats, the 
signature is described at the percentage of each type of neuron firing in each of the central, 
vertical and radial sections of the substantia geletinosa. The appearance of this 
electrophysiological phenotype as described by Lu et al, 2009 is said to coincide with the 
onset of mechanical allodynia and hyperalgesia – tell-tale signs of neuropathic pain. Lu et 
al, 2009 also showed that exposure to BDNF can produce a similar electrophysiological 
signature to that shown in CCI and also in vitro (Lu et al., 2009).  
Biggs et al, 2010 argue that BDNF may be solely responsible for the development of central 
sensitisation, bringing about the critical step transferring information from activated 
microglia to dorsal horn neurons, and thus developing neuropathic pain. Evidence for this 
is that BDNF and CCI seem to invoke similar electrophysiological injury signatures in the 
different defined neuronal phenotypes explained, but IL-1β, a cytokine thought to be 
involved in neuropathic pain, does not produce this injury signature. Also, BDNF and CCI 
have similar effects on miniature Excitatory Pro-Synaptic Currents (mEPSCs) in relay 
neurons, and BDNF from activated microglia seem to promote dorsal horn excitability, 
which is attenuated when BDNF is sequestered by TrkBd5 (Lu et al., 2009, Biggs et al., 
2010). 
1.6.3. Cytokines and Chemokines 
Cytokines are a large, diverse group of small proteins which can act as signalling molecules 
at small concentrations and work to regulate inflammation and can normally regulate 
growth and survival, along with differentiation. Cytokines can be grouped into having pro- 
(IL-6, TNFα) or anti- inflammatory (TGFβ, IL-10) effects. Chemokines are chemotactic 
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cytokines, and have a generic function to induce cell migration, inducing the migration of 
immune cells to various locations where they are required (Ramesh et al., 2013). 
Chemokines and their receptors are widely expressed in the immune and nervous systems. 
Chemokines are small secreted proteins which act through GPCRs, and have a central role 
in the normal inflammatory response, however, there is increasing evidence that 
chemokines, along with other cytokines can influence chronic pain conditions (White et 
al., 2007, Ramesh et al., 2013).  
In particular, it has been shown that CCL2 (MCP-1), CCL3 (MIP-1α) and CCL5 (RANTES) 
secreted by activated T cells, can produce a dose-dependent tactile allodynia, through a 
direct action of chemokines onto neurons (Oh et al., 2001). Chemokines have also been 
found to excite neurons from the DRG in culture, and promote the release of pain related 
neurotransmitters Substance P, and calcitonin gene-related peptide (Sun et al., 2006).  It 
is thought that the mechanism behind this involves the excitation of TRPV1 and TRPA1 (as 
described earlier), as CCR1 and CCR2 activation can also excite TRPV1 and TRPA1 through 
PLCγ and PKC mediated events (White et al., 2007). 
Interestingly, MCP-1 administration has been found to excite and influence action 
potentials in a group of DRG neurons overexpressing CCR2 as a response to neuropathic 
pain, suggesting that the production of MCP-1 can function as a neurotransmitter in the 
DRG neurons and that MCP-1 production by macrophages and microglia at the site of 
injury could contribute to the onset of neuropathic pain. It appears that chemokines could 
play a key role in the onset of chronic pain as they serve to regulate inflammatory events, 
but can act simultaneously upon neurons in the DRG (Abbadie, 2005, White et al., 2005, 
Sun et al., 2006, White et al., 2007, Miller et al., 2008, Jung et al., 2009). 
1.6.4. Sigma Receptors 
Sigma receptors was originally thought to be a subtype of opioid receptors and were 
initially described in the CNS by Martin et al in 1976, but were later found to be a different 
pharmacological entity (Martin et al., 1976, Su et al., 1988a, Su et al., 1988b). Outside the 
brain, Sigma receptors were found in a number of other tissues including the kidneys, liver, 
testes and intestine. Quirion and colleagues proposed the classification of two subtypes of 
sigma receptor based on the affinity of ligands such as (+)-pentazocine and 
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dextromethorphan binding, with Sigma-1 receptor showing a high affinity, and Sigma-2 
receptor showing low affinity – although there are nonselective ligands, such as 1,3-Di-(2-
tolyl)guanidine (DTG) and haloperidol which show similar affinity to both sigma receptor 
(Quirion et al., 1992, Maurice and Lockhart, 1997). 
The exact functional role of the sigma receptor remains unclear still, with studies 
suggesting that they have a role in antipsychotic activity, prevention of amnesia, 
modulation of neurotensin, inhibition of re-uptake of noradrenalin, the modulation of cell 
surface signalling molecules and the chaperoning and maturation of BDNF (Levant and 
Nemeroff, 1990, Maurice and Lockhart, 1997, Su et al., 2010, Hashimoto, 2013). However, 
Itzhak (1989) demonstrated that binding to sigma-1 receptor is regulated by Gi/o (Itzhak, 
1989, Maurice and Lockhart, 1997). 
Sigma-1 Receptor was cloned in 1996, it is a 223 residue transmembrane protein 
associated with the endoplasmic reticulum, specifically at the endoplasmic reticulum – 
mitochondria interface. Sigma-1 receptor is able to regulate the stability of IP3 receptors 
and calcium signalling between the endoplasmic reticulum and the mitochondria along 
with ion channel firing, neurotransmitter release, inflammation, cellular differentiation 
and neuron survival (Su et al., 2010, Hashimoto, 2013). There have been no other known 
proteins which share sequence homology with Sigma-1 receptor (Su et al., 2010).  
In the dormant state of Sigma-1, the receptor forms a complex with the chaperone, Binding 
immunoglobulin Protein (BiP). However, it is thought that when cells undergo stress, or 
through certain stimulation, sigma-1 receptors can dissociate from BiP, and become 
activated. Activated sigma-1 receptors are able to translocate to the endoplasmic 
reticulum network and to the plasma membrane in order to modulate signalling through 
cell-surface receptors, possibly including sodium channels such as Nav 1.8, or ion channels, 
along with other receptors such as TrkB (Su et al., 2010). Sigma-1 receptor also plays a role 
in the release of BDNF: when the effect of Simga-1 receptor knockdown was explored, it 
was found that the level of secreted mature BDNF was significantly reduced, although no 
effect was observed on intracellular levels of BDNF (Hashimoto, 2013). Furthermore, 
Yagasaki and colleagues found that imipramine can enhance BDNF-induced TrkB signalling 
through PLCγ, but when cells were treated with BD1047 (a sigma-1 antagonist), the 
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potentiation of PLCγ activation through TrkB was attenuated, suggesting that Sigma-1 may 
be able to modulate signalling through TrkB (Yagasaki et al., 2006). 
The sigma receptor modulation of microglial activation has previously been explored, and 
it was observed that Sigma-1 receptors play a role in several aspects in microglial function. 
Sigma-1 was found to regulate the function of microglia by suppressing the release of 
intracellular calcium – although calcium independent regulation of microglial activation 
was also reported.  Altogether, it was reported that the antagonism of Sigma-1 receptors 
with DTG was found to suppress membrane ruffling, inflammatory response (measured by 
observing production of TNFα, IL-10 and NO) and migration in microglia (Hall et al., 2009). 
It is thought that because microglial migration is a calcium dependent process and requires 
an influx of calcium, that DTG, or the antagonism of sigma-1 may inhibit the action of 
purinergic receptors.  
Sigma-1 receptor has also been implicated in the onset and maintenance of chronic pain 
conditions. It has been found that the activation of spinal sigma-1 receptors resulted in 
both thermal and mechanical hyperalgesia, along with the phosphorylation of spinal ERK. 
The antagonism of sigma-1 receptor was reported to lead to the attenuation of pain 
behaviours (de la Puente et al., 2009, Roh et al., 2011, Moon et al., 2013). A study by 
Romero et al, tested the effects of a novel sigma-1 receptor antagonist on neuropathic 
pain, it was found that the antagonism of sigma-1 receptor abrogated ectopic nerve 
activity to the same level as pregabalin , along with alleviating chronic pain-like behaviour 
in formalin-induced neuropathic pain, capsaicin-induced hypersensitivity and SNL (Romero 
et al., 2012).  
In addition, it was found that sigma-1 receptor has a role in chemotherapy (Paclitaxel)-
induced neuropathic pain. In sigma-1 receptor knockout mice, and with the treatment of 
sigma-1 receptor antagonists, paclitaxel failed to induce the phosphorylation of ERK in the 
spinal cord, but not in wild type mice. It was also found that sigma-1 knockout mice did 
not develop cold allodynia or mechanical allodynia (Nieto et al., 2012, Zamanillo et al., 
2013). Taken together, these studies suggest that sigma-1 receptor may play a crucial role 
in the development of chronic pain conditions, and antagonism of sigma-1 could be a 
potential treatment for patients with neuropathic pain.  
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1.7. Matrix Metalloproteinases 
1.7.1. Structure and Activity 
There are five subfamilies of proteinases – serine proteinases, cysteine proteinases, 
aspartic proteinases, threonine proteinases and finally metalloproteinases. Whilst both 
cysteine proteinases and aspartic proteinases are mainly active intracellularly, serine 
proteinases act extracellularly to cleave surrounding ECM components amongst other 
targets. Metalloproteinases can be further subdivided into families including matrix 
metalloproteinases (MMPs), ADAMs (a disintegrin and metalloproteinase), and the 
ADAMTSs (ADAM with a thrombospondin motif) (Ugalde et al., 2010).  
MMPs are zinc dependent endopeptidases known for their ability to degrade extracellular 
matrix components, they also play a role in processing bioactive molecules such as 
chemokines and cytokines. There are 23 human MMPs, which are either secreted into the 
extracellular milieu or anchored onto the cell membrane (Birkedal-Hansen et al., 1993, 
Parks et al., 2004). MMPs can be further divided into groups depending on which ECM 
component they display the highest affinity with; there are gelatinases (MMP-2/MMP-9), 
collagenases (MMP-1, MMP-8, MMP-13, MMP-18) and stromelysins (MMP-3, MMP-10, 
MMP-11), matrilysins (MMP-7, MMP26), membrane-type MMPs (MT-MMPs; MMP-14, 
MMP-15, MMP-16, MMP-17, MMP-24 and MMP-25), as well as currently uncategorised 
MMPs (Wang et al., 2014) (See Table 1.2). 
Traditionally, matrix metalloproteinases were thought to be involved in the remodelling of 
the ECM and allowing cells to migrate in both normal and pathological conditions (Murphy 
and Gavrilovic, 1999). Whilst this has later been shown in several processes, for example 
in migration of vascular smooth muscle cells (Newby, 2006) and macrophage migration in 
inflammatory conditions (Gong et al., 2008), along with general cell migration (Itoh, 2006), 
it is thought that MMPs also have roles in controlling cell behaviour and functions, which 
includes roles in adipocyte differentiation, both pro- and anti-inflammatory effects, 
platelet aggregation and apoptosis (McCawley and Matrisian, 2001, Murphy and Nagase, 
2008).  
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FAMILY NAME OTHER NAMES SUBSTRATE ACTIVATED BY 
COLLAGENASES MMP-1 Collagenase-1 Type-I, II, III, VIII, and 
X Fibrillar Collagens. 
MMP-3, MMP-10, 
Plasmin 
 MMP-8 Collagenase-2,  
Neutrophil      
collagenase 
Type I, II, and III 
Fibrillar Collagens. 
Mouse CXCL5 
MMP-3, MMP-10, 
Plasmin 
 MMP-13 Collagenase-3 Type I, II, III, IV, IX, X, 
XI Collagens, 
Fibronectin, Laminin, 
Gelatin 
Plasmin, MMP-2, 
MMP-3, MMP-10, 
MMP-14, MMP-
15 
GELATINASES MMP-2 Gelatinase A Gelatin, Fibronectin, 
Type I and IV 
Collagen, CCL7, 
CXCL12  
MMP-1, MMP-7, 
MMP-13, MMP-
14, MMP-16, 
MMP-17, MMP-
25 
 MMP-9 Gelatinase B Gelatin,  Latent 
VEGF, Fibrin,   
Plasmin, MMP-2, 
MMP-3, MMP-13 
MATRILYSINS MMP-7 Matrilysin Type IV Collagen, 
Fibronectin, 
Nidogen, Elastin, 
Laminin, Fibrin, 
Fibrinogen 
Plasmin, MMP-3 
 MMP-26 Matrilysin-2 Type IV Collagen, 
Gelatin, Fibronectin, 
Fibrin, Fibrinogen 
MMP-26 
STROMELYSIN MMP-3 Stromelysin-1 Type IV Collagen, 
Fibronectin, 
Aggrecan, Nidogen, 
Laminin, E-Cadherin, 
Latent TGF-β 
Plasmin, Elastase 
 MMP-10 Stromelysin-2 Type IV Collagen, 
Fibronectin, 
Aggrecan, Nidogen 
Plasmin, Elastase 
 MMP-11 Stromelysin-3 α2 macroglobulin, 
type VI collagen  
Furin 
Page | 38  
 
 MMP-19  Type IV Collagen, 
Fibronectin, 
Aggrecan,  
Trypsin 
MEMBRANE TYPE MMP-14 MT1-MMP Type-I, II and III 
Collagen, 
Fibronectin, 
Vitronectin, Laminin, 
Aggrecan, ProMMP2, 
Fibrin 
Plasmin, Furin 
 MMP-15 MT2-MMP Proteoglycans - 
 MMP-16 MT3-MMP Type III collagen, 
Syndecan-1 
- 
 MMP-17 MT4-MMP Gelatin, Fibrin, 
Fibrinogen 
- 
 MMP-25 MT5-MMP Fibronectin, 
Proteoglycan, 
Gelatin 
- 
 MMP-26 MT6-MMP Type IV Collagen, 
Gelatin, Fibronectin 
- 
UNCLASSIFIED MMP-12 Metalloelastase Type IV Collagen, 
Fibronectin, 
Aggrecan, Elastin 
Plasmin 
 MMP-20 Enamelysin Aggrecan - 
 MMP-23 CA-MMP Gelatin - 
 MMP-27 - - - 
 MMP-28 Epilysin Casein - 
Table 1.2. A table to show the MMPs and their ECM substrates, along with their activators. The information from 
which this table was derived was adapted from (Parks et al., 2004), (Nagase et al., 2006) (Murphy and Nagase, 2008) 
and (Groblewska et al., 2012). 
The structure of MMPs varies, as do their substrates and functions, although they do share 
some structural homology. A matrix metalloproteinase typically consists of a conserved 
prodomain of around 80 residues in length, and a catalytic metalloprotease domain, which 
consists of 170 amino acids. Most MMPs (not MMPs -7, -23 or -26) contain a proline rich 
hinge region which varies in length, and a carboxy-terminal hemopexin domain, which acts 
to mediate interactions between the MMP and its substrate (Nagase et al., 2006). 
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In the inactive enzyme the prodomain interacts with the Zn2+ atom in the catalytic domain 
of the MMP and confers a level of control onto the MMP as the prodomain has to be 
cleaved (often by a serine protease or another MMP) for the enzyme to be activated (Parks 
et al., 2004).  
1.7.2. Tissue Inhibitors of Matrix Metalloproteinases 
The activity of metalloproteinases is strictly regulated at several levels, including regulation 
of transcription by growth factors and cytokines, zymogen activation and also by inhibition 
by their endogenous inhibitors, the tissue inhibitors of matrix metalloproteinases, TIMPs 
(Brew and Nagase, 2010).  There are 4 TIMPs in total, which are 184-194 amino acids in 
length, and formed of two domains, which each have three conserved disulphide bonds. 
The N terminal of TIMPs is conserved and responsible for folding, and chelating the Zn2+ 
ion in the active site of MMPs, thus blocking the activity of MMPs, however, the C-terminal 
of TIMPs can vary in length and is responsible for the differing specificity of TIMPs 
(Bourboulia and Stetler-Stevenson, 2010, Perez-Sayans Garcia et al., 2012, Khokha et al., 
2013).  
TIMP-2 and TIMP-3 are known to inhibit all MMPs, TIMP-4 can inhibit most MMPs, but 
TIMP-1 displays a weak affinity for the MT-MMPs (MMP-14, MMP-16, MMP-19 and MMP-
24). TIMP-3 has further differences with the other TIMPs, as it displays a high affinity for 
members of the ADAM and ADAMTS families, and is able to bind to the extracellular 
matrix, whereas the other TIMPs are soluble (Nagase et al., 2006). 
TIMPs can also be important in the activation of MMP-2 and MMP-9, which are secreted 
in their inactive zymogen form of proMMP-2 and proMMP-9. In latent forms of the MMP, 
there is a cleavable propeptide inserted into the catalytic site of the MMP which must be 
removed so that the MMP can be active. These proMMPs bind to TIMPs in between the C-
terminal of the TIMP, and the heamopexin domain of the proMMP, and are activated 
(Murphy, 2011).  For example, MT1-MMP activates proMMP-2 in a process which involved 
a complex of TIMP-2 and MT1-MMP binding proMMP-2 (Bernardo and Fridman, 2003).  
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 It is thought that TIMPs have other biological activities, including the promotion of 
proliferation, synaptic plasticity and both pro-and anti-apoptotic activities,  (Perez-Sayans 
Garcia et al., 2012), although these activities remain controversial..  
1.7.3. Matrix Metalloproteinases in Migration  
Although it is possible for cell migration to be independent of MMPs, the expression of 
MMPs has been found to be crucial in the migration of several cell types, in this section, 
an overview of the role of MMPs in cell migration will be presented.  
In the intima of rat carotid artery, there are no smooth muscle cells, however, after injury; 
it is observed that smooth muscle cells migrate into the carotid artery – during which both 
of the gelatinases – MMP-2 and MMP-9 are found to be upregulated. The broad spectrum 
inhibition of MMPs using GM-6001 was found to almost completely ablate the migration 
of smooth muscle cells into the carotid artery for up to 4 days after injury – thus showing 
that smooth muscle cell migration is dependent on MMP activity (Bendeck et al., 1994, 
Bendeck et al., 1996).  
In the context of ovarian cancer, a highly metastatic disease, it was demonstrated that 
MMP expression was up-regulated, and thought to be involved in the invasion and 
metastasis of ovarian cancer cells. It was found that in ovarian cancer cells, there was an 
upregulation of MMP activation induced by lysophosphatidic acid, in particular MT1-MMP 
and MMP-2, leading to an enhanced invasive phenotype of ovarian cancer cells. This 
suggests that the expression of MMP-2 and MT1-MMP are responsible for invasion as a 
direct result of increased hydrolysis of matrix components  (Fishman et al., 2001). 
The effect of MMP expression in tumour invasion and metastasis has been widely 
researched, as the constant degradation and remodelling of the ECM by MMPs is required 
to allow for invasion of cells. In a lung carcinoma cell line, it was found that the 
overexpression of MT1-MMP resulted in the increased survival of cancerous cells and the 
increased formation of metastatic nodules when the cells were inoculated into mouse tail 
vein. The dependence of cell migration on MMPs was also demonstrated when MMP-1 
was suppressed in malignant melanoma cells, which lead to the inhibition of cells into a 
Matrigel™ matrix (Nabeshima et al., 2002). 
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Furthermore, the dependence of MMPs in migration has been shown in leukocytes. Tester 
et al, demonstrated that MMP-8 was required for the neutrophil response to LPS, and loss 
of MMP-8 led to a marked reduction in chemotaxis towards LPS (Tester et al., 2007). MMP-
8 has also been linked to leukocyte rolling and adhesion on vascular endothelium in 
response to atherosclerosis, suggesting that it is required for the normal monocyte 
response and important in the migration of monocytes into the vessel wall towards MCP-
1 (Laxton et al., 2009). 
1.7.4. Matrix Metalloproteinases in Macrophages and Microglia  
Rapid cell migration is an important feature of all cells involved in the immune system, and 
when they are required, both cell types have to move through complex and diverse 
environments in 3D. As the process of cell migration has been shown to be dependent on 
MMPs in various cell types, it is thought that MMPs may play an important role in the 
migration and invasion in both macrophages and microglia.  
In vivo, it has been found that MMPs are involved in the invasion of macrophages – and it 
has been found that MMP expression is upregulated in macrophages during infiltration, 
and GM-6001 and MMP-2 knockout in asthmatic mice can reduce the influx of 
macrophages into the bronchoalveolar lavage, and result in the loss of normal chemotactic 
ability in these cells This leads to an accumulation of macrophages and other inflammatory 
cells in the lung parenchyma which can in turn lead to airway hyper-responsiveness (Corry 
et al., 2002, Verollet et al., 2011).  
In vitro, MMPs have also been shown to be involved in the migration and invasion of 
macrophages. In 2013, Murray et al, found that MMP-10 was at least partially responsible 
for macrophage migration – in cells transfected with siRNA targeting MMP-10, cell 
migration speed reduced approximately three-fold. It was also observed that bone marrow 
derived macrophages from MMP-10-/- mice migrated over a 2D surface of fibronectin 
significantly slower than WT mice. It was also demonstrated that BMMs from MMP-10-/- 
mice resulted in a significantly reduced level of invasion in a Matrigel™/Fibronectin matrix 
(Murray et al., 2013). 
Microglia have been found to express MMPs, and secrete MMP-3 in response to activation. 
MMP-2 and MMP-9 are also expressed by microglia and are thought to contribute to the 
Page | 42  
 
formation of the glia limitans – a thin barrier of astrocyte foot processes which has many 
functions – including the prevention of over migration by both glial cells and neurons. 
MMPs are thought to play roles in tissue repair, synaptic plasticity and the formation of 
memories (Konnecke and Bechmann, 2013).  
However, MMPs -8 and -9 may be involved in the breakdown of the blood brain barrier in 
pathological conditions (Vandenbroucke et al., 2012, Konnecke and Bechmann, 2013). 
MMP-9 is further expected to be involved in the bioavailability of cytokines and the 
generation of autoimmune epitopes in some pathological conditions, and it is thought that 
the inhibition of MMPs could be beneficial as a therapy in autoimmune conditions 
(Konnecke and Bechmann, 2013). 
It is also thought that MMPs could be involved in neuropathic pain – a study by Kawasaki 
et al suggests that both gelatinases are involved in early and late phase development of 
chronic pain.  It was found that MMP-9 is rapidly upregulated in injured spinal dorsal root 
ganglion primary sensory neurons. MMP-2 however, was found to have a delayed 
response in DRG satellite cells and spinal astrocytes (Kawasaki et al, 2008). It was 
discovered that inhibition of the MMP-9 inhibits the early phases of neuropathic pain, 
whereas MMP-2 inhibits the late phase – suggesting that the MMPs have different roles in 
chronic pain. Further studies show that both MMPs activate interleukin-1β which could 
play a role in chronic pain, but also MMP-9 activates microglia, and MMP-2 activates 
astrocytes (Kawasaki et al., 2008).  
MMPs have also been reported to be upregulated following spinal cord injury in 
macrophages within the spinal cord lesion – with MMP-1 being upregulated in these cells. 
There was also found to be a short induction of MMP-2 expression in these macrophages, 
with both MMP-9 and MMP-12 being upregulated at a later phase, with expression levels 
peaking at 24 days after injury. There was little reported TIMP activity (Buss et al., 2007). 
These studies put forward a compelling argument which suggests that MMP activity may 
indeed be involved in the onset and maintenance of chronic pain conditions.  
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1.8. Atherosclerosis 
1.8.1. Pathogenesis of Atherosclerosis  
Atherosclerosis was first described by Felix Marchand in 1904, defining the hardening of 
arteries with a fatty substance and Nikolai Anichkov first demonstrated the role of 
cholesterol alone in the development of atherosclerosis using a rabbit model in 1913 
(Konstantinov et al., 2006). At the time the research was somewhat dismissed as Anichkov 
could not replicate the results in rats, as they are carnivorous and are better suited to high 
levels of cholesterol.  
In the western world, atherosclerosis is the underlying cause of around 50% of all deaths, 
and is characterised by a fatty occlusion in the arterial lumen. In 1977, Ross et al (Ross et 
al., 1977) set forth the ‘response to injury’ hypothesis, which infers that atherosclerosis is 
a response to injury. More recently, atherosclerosis is thought to be an inflammatory 
disorder (Hansson, 2005).  
The ‘response to injury’ hypothesis states that injury to the vessel wall leads to the 
desquamation of the endothelial cells. There are potentially many sources of injury to the 
vessel wall – such as chronic hyperlipidaemia, infection, mechanical trauma (such as 
increased shear stress due to high blood pressure), or due to chemical factors such as 
homocysteine and oxLDL (Ross et al., 1977). After this initial injury there is dysfunction of 
the endothelium which can lead to the trapping of lipoprotein and the appearance of 
adhesive glycoproteins on the surface of the endothelial cells lining the artery – this leads 
to the adherence of monocytes and lymphocytes and the subsequent migration into the 
vessel wall (Ross, 1993). 
The migrating monocytes differentiate into macrophages and move further into the intima 
towards oxidized LDL (oxLDL), and MCP-1. The macrophages are then able to contribute 
to the recruitment of more macrophages by synthesizing and secreting more MCP-1, along 
with cytokines such as IL-6 and IL-8 (Tedgui and Mallat, 2006). The macrophages in the 
intima then act to engulf the atherogenic lipoproteins present and are unable to process 
them, thus the macrophages become laden with fatty lipoproteins and become foam cells 
(Falk, 2006). The accumulation of foam cells along with leukocytes denotes the formation 
of the fatty streak (Ross, 1993). Continued cell migration into the fatty steak and the 
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accumulation these cells leads to the development of more advanced atherosclerotic 
lesions. Meanwhile, the migrating and proliferating smooth muscle cells form a connective 
tissue matrix which consists of collagens, proteoglycans and elastins (Ross, 1993).   
As a consequence of the continued accumulation and proliferation of the cells in the fatty 
streak, the lumen becomes convoluted. In advanced atherosclerotic lesions there are 
alternating layers of smooth muscle cells and foam cells, which build up and eventually 
lead to the partial, or in extreme cases, complete occlusion of the vessel (Ross, 1993, 
Randolph, 2014). 
 As the rupture of the plaque can lead to many complications, including stroke and 
myocardial infarction, plaque stabilization is an issue. After formation of the 
atherosclerotic plaque, the structure consists of a fibrous cap enclosing the central core of 
lipids and usually necrotic debris, surrounded by foam cells. Whilst the fibrous cap provides 
the stability, the core (or atheroma) is soft and thrombogenic, and so the integrity of the 
fibrous cap is important (van der Wal and Becker, 1999).  
Factors that are of importance in the stabilization of the plaque include matrix synthesis 
and the amount of smooth muscle cells present in the plaque, along with the thickness of 
the fibrous cap. Destabilising factors include the amount of lipids present and 
inflammation, along with the presence of proteases, such as MMPs, which can breakdown 
the matrix synthesised by smooth muscle cells. It is these aspects which are in constant 
balance and ultimately determine if a plaque is indeed vulnerable to rupture (van der Wal 
and Becker, 1999). However, the role of MMPs in atherosclerosis has yet to be determined, 
and will be further explored in this thesis.  
1.8.2. Macrophages in Atherosclerosis  
There is no step in the development of the fatty streak and the atherosclerotic plaque that 
does not involve the participation of macrophages and their precursor monocytes. 
Monocytes infiltrate the vessel wall where they differentiate into macrophages – this 
continued accumulation of macrophages depends on macrophage colony stimulating 
factor and granulocyte colony stimulating factor. Whilst inside the vessel wall, 
macrophages secrete cytokines and chemokines, and metalloproteinases, along with 
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growth factors and other hydrolytic enzymes, which can contribute to the stabilisation of 
the plaque or, if apoptosis occurs, the necrotic atheroma (Ross, 1999). 
During migration, macrophages degrade the ECM components that they need to as to get 
to their destination; this could possibly lead to some plaque destabilisation. Macrophages 
then act to phagocytose any cell debris and pathogens; however, in the context of 
atherosclerosis, macrophages also internalize oxLDL and become foam cells. Foam cells 
are able to re-export cholesterol. Macrophages are capable of producing both pro-
inflammatory cytokines (IL-6, IL-10, TNFα), and anti-inflammatory cytokines (IL-10, TGFβ) 
which can act to either promote or supress the immune response in atherosclerosis. 
Macrophages can also facilitate tissue repair, and promote the proliferation and migration 
of smooth muscle cells into the intima to contribute to the fibrous cap (Johnson and 
Newby, 2009). 
In mice, it has been recognised that there are two distinct subsets of circulating monocytes 
which have differing cell surface markers and chemokine receptor expression patterns – 
characterised by Ly6C (a glycoprotein), CCR2 and CX3CR1 expression levels (Waldo et al., 
2008, Johnson and Newby, 2009). It was found that the migration of monocytes into the 
atherosclerotic plaque depends on both CCL2 and CX3CL1 (fractalkine) expression and that 
the inhibition of these pathways almost abolishes atherosclerosis (Combadière et al., 
2008). However, monocytes that have a low expression of Ly6C show a circulating 
behaviour, and interact with the endothelium without migrating into the intima, thus 
showing a protective effect in atherosclerosis conditions (Johnson and Newby, 2009). 
Johnson and Newby, 2008 outline that the role of macrophages in atherosclerosis can be 
summarised into a series of paradoxical roles. For example, macrophages can display an 
advantageous phenotype – producing granulocyte colony stimulating factor, IL-4 and IL-13 
and thus exiting from lesions and participating in fibrosis and calcification – thus stabilizing 
the atherosclerotic plaque. On the other hand, macrophages can produce macrophage 
colony stimulating factor, TNFα, and IFNγ contributing to the inflammation and leading to 
further invasion into the plaque, phagocytosis and uptake of oxLDL, degradation of 
essential matrix and further cholesterol uptake – leading to the formation of foam cells. It 
has also been shown that the expression of CD14 correlates with complicated, advanced 
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lesions and plaque rupture (Johnson and Newby, 2009, Hermansson et al., 2014) . 
Therefore, it seems that the macrophage genotype and subsequent phenotype expressed 
largely contributes to the stability of the atherosclerotic plaque, and therefore the 
prognosis of the disease (Waldo et al., 2008).  
1.8.3. Matrix Metalloproteinases in Atherosclerosis 
MMPs are thought to play an important role in atherosclerosis, given their ability to 
remodel the extracellular matrix, MMPs can contribute to either the stabilisation or 
destabilisation of the atherosclerotic plaque. The degradation of ECM components is 
required for both the infiltration of monocytes into the intima, and the migration of 
smooth muscle cells (Watanabe and Ikeda, 2004, Bäck et al., 2010). MMP expression could 
lead to the stability of a plaque, or the destruction of the plaque – as plaque rupture results 
from the destruction of the intimal ECM (Newby, 2005). MMPs are also involved in the 
process of plaque angiogenesis, which can be a marker for a vulnerable plaque (Schäfers 
et al., 2010). 
It has been found that MMPs are expressed in atherosclerotic plaques by both smooth 
muscle cells and macrophages/foam cells, and some MMPs – including MMP-1, MMP-2, 
MMP-3, MMP-7 along with MMP-9, MMP-10, MMP-11, and MMP-12 have all been shown 
to be upregulated in the plaque (Galis et al., 1994, Dollery et al., 1995, Ketelhuth and Bäck, 
2011), the overexpression of MMPs is thought to promote plaque rupture (Lancelot et al., 
2008). In macrophages, it is thought that MMP-9 is the most abundant MMP, and it has 
been shown to be upregulated after adhesion to ECM components such as collagen (the 
most abundant ECM component in the atherosclerotic plaque) and fibronectin. Other pro-
inflammatory, pro-atherogenic cytokines such as TNFα can influence the upregulation of 
MMP-14, MMP-15 and MMP-16, and activate MMP-2 (Newby, 2005).  
TIMP expression is also found to be upregulated, perhaps to attempt to limit the activity 
of MMPs – however MMPs are still active, as macrophage and foam cell conditioned media 
has been shown to degrade collagen from fibrous plaque caps in vitro. The MMPs secreted 
from macrophages can also lead to further activation of MMPs secreted by smooth muscle 
cells (Newby, 2005). 
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MMPs are of particular interest in the disruption of the arterial wall and the processes 
which lead up to the rupture of the plaque, especially those belonging to the collagenase 
family. It is suggested that the mechanism behind the increased expression of MMPs is 
driven by oxidative stress, although it is also inferred that thrombin and the plasminogen 
cascade may play a role in the activating of MMPs, the former in a positive feedback loop 
(Galis and Khatri, 2002). Recently, it has been found that MMP-12 overexpression leads to 
accelerated plaque development, whereas in MMP-12-/- mice, plaque development is 
greatly reduced, and selective MMP-12 inhibitors have been shown to promote a stable 
plaque (Johnson et al., 2011, Scholtes et al., 2012). Whilst there are many studies which 
link the expression and activation of MMPs in atherosclerosis, and the promotion of either 
a stable or unstable plaque phenotype, there are still more studies required which address 
the role of specific MMPs and their interactions during atherosclerosis initiation. 
1.8.4. Apolipoprotein E 
Apolipoprotein E (ApoE) was discovered in the 1973 by Shore and Shore (Shore and Shore, 
1973), it is a 34kDa protein consisting of 299 amino acids. ApoE was identified in 
triglyceride rich lipoproteins and was found to be induced in cholesterol feeding in both 
animal and human models. Plasma ApoE is synthesized primarily by the liver, although the 
brain is the second most common site of synthesis – astrocytes produce ApoE, but stressed 
neurons are also capable of synthesising the lipoprotein. Macrophages are also a site of 
synthesis of ApoE (Greenow et al., 2005, Mahley, 1988).  
Upon its discovery, ApoE was reported to be a multifunctional protein involved in lipid 
transport and in cardiovascular disease (a common animal model for cardiovascular 
disease is ApoE knockout mice), and was shown to be a critical ligand in the plasma 
clearance of triglyceride, and cholesterol-rich lipoproteins – including chylomicron 
remnants, high density lipoprotein (HDL) subclasses, very low density-lipoproteins (VLDL) 
and intermediate density-lipoprotein (Curtiss, 2000, Cash et al., 2012, Mahley et al., 2009). 
ApoE is involved in cholesterol efflux from macrophage foam cells, uptake of lipoprotein 
particles in the liver, and the regulation of several immune and inflammatory responses 
(Tiwari et al., 2008). 
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Structurally, ApoE has two separate domains that are connected together via a hinge 
region. The first 191 residues make up the N-terminal domain, which contains the receptor 
binding region between residues 134 and 150 and Arg-174, this forms a four-helix 
antiparallel bundle. Residues 225-299 make up the C-terminal domain, which from 
residues 244-272 contains the lipid binding region (Hauser et al., 2011, Cudaback et al., 
2011). 
There are three common isoforms of ApoE, which are encoded by a gene on chromosome 
19, these are known as E2, E3 and E4, which differ in frequency (Cudaback et al., 2011, 
Mahley et al., 2009). The E2 allele occurs in about 5-10% of individuals, and contains a 
cysteine residue at sites 112 and 158. The E3 allele is the most common allele, occurring 
in around 65-70% of individuals, E3 has a cysteine residue at site 112, and an arginine 
residue at site 158. The E4 allele contains an arginine residue at both 112 and 158, and 
occurs in around 15-20% of individuals. An individual’s genotype can be homogeneous or 
heterogeneous. It is thought that the amino acid differences among the isoforms 
substantially affect their structures and roles in disease (Mahley et al., 2009, Kofler et al., 
2012). This will be further explored in chapter 5. 
1.8.5. Dietary Prevention of Atherosclerosis  
There has been discussion about the link between diet and atherosclerosis since it was first 
discovered that there was a link between cholesterol and the formation of atherosclerosis. 
Currently there is a trend towards the rising obesity of the nation, and as such there is an 
increased interest in the effect of weight loss and the link between diet and cardiovascular 
disease (Parikh et al., 2005). 
Currently, patients with an increased risk of cardiovascular disease are prescribed with 
statins (inhibitors in the cholesterol synthesis pathway), which can have adverse health 
effects and thus attention is now being given to natural products, including plant 
metabolites and by-products such as flavonoids, along with fish oils, as source of n-3 
polyunsaturated fatty acids (PUFAs)   (Salvamani et al., 2014). The nutritional modulation 
of normal immune function is also being explored, and it has been found that n-3PUFAs 
are able to reverse inflammation and act as anti-inflammatory agents (Grimble, 2007). It is 
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thought that a diet containing fish oils could be beneficial, and lead to a reduced risk of 
the development of atherosclerosis and cardiovascular disease. 
It has previously been shown that n-3 PUFAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are able to decrease the expression of adhesion molecules on 
both monocytes and endothelial cells, although the true functional value of this is unclear. 
However, Luu et al, demonstrated that monocytes from human donors receiving a fish oil 
supplement undergo a change which is directly linked to the reduced potential of these 
monocytes to induce an inflammatory response in the vessel wall. This may in part explain 
the beneficial effect that n-3 PUFAs play in reducing the risk of atherosclerosis. Due to the 
reduction of the expression of adhesion molecules on monocytes and endothelial cells 
induced by the fish oil supplemented diet, there would be less extravasion into the vessel 
wall, as monocytes would be unable to adhere to the vessel wall (Luu et al., 2007).  
 
 
 
 
 
 
 
 
 
 
Page | 50  
 
1.9. Hypothesis and Aims 
This thesis shall explore the hypothesis that ATP is partly responsible for macrophage 
migration in pathological contexts. To explore this hypothesis, the following aims will be 
tested: 
 Investigation of macrophage migration by neuropathic pain-relevant stimuli 
including ATP and BDNF 
 To determine the expression of matrix metalloproteinases in macrophages in 
response to migration-modulating stimuli 
 To determine the effects of dietary n3 fatty acids on macrophage migration in vitro 
and to explore if the expression of the ApoE3/4 subtype has an effect on the 
modulation of macrophage migration.  
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Chapter 2: Materials and Methods 
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2.1. Cell Culture 
2.1.1. RAW 264.7 
The Raw 264.7 macrophage cell line (TIB-71, ATCC) was grown using Dulbecco’s Modified 
Eagle Medium (DMEM), with glucose at 4500mg/L (Invitrogen). This media was 
supplemented with 100 units/ml of Penicillin/Streptomycin antibiotics (Invitrogen) and 
5mM L-Glutamine (Invitrogen), along with 10% (v/v) Fetal Calf Serum (FCS).  Cells were 
passaged approximately every 2 days using an 18mm blade cell scraper (Fisher Scientific) 
and incubated at 37°C, and 5% CO2 (v/v). Before experiments, Raw 264.7 were centrifuged 
at 1000 r.c.f for 5 minutes, counted and re-suspended at the density required.  
2.1.2. Isolation and culture of Bone Marrow-derived Macrophages (BMMs). 
The method of isolating bone marrow-derived macrophages was performed as previously 
described (Murray et al., 2013), adapted from (Leverrier and Ridley, 2001). The protocol is 
as follows:  
C57/BL6 mice (age 2 months) were killed by schedule 1. Under sterile conditions, skin and 
tissue was cut away from the hind legs to isolate bone. The end of each bone were cut off, 
and the bone marrow was flushed out with macrophage medium (see below) using a 2ml 
syringe and 25-G needle. Live and dead cells were counted using trypan blue staining, and 
cells were centrifuged at 1000rcf for 5 minutes. The pellet was resuspended at 1x106 
cells/ml with macrophage medium and 10% (v/v) L-cell conditioned media. Where 
possible, 11ml at 1x106 cells/ml were plated onto 10cm bacteriological petri dishes 
(Falcon, cat no. 351029). Cells were incubated at 37°C/5% CO2 (v/v) for 3 days. After 3 days, 
the non-adherent population was collected and the plates gently rinsed with macrophage 
medium. 
The non-adherent cells were counted again, and centrifuged at 1000rcf for 5 minutes, the 
pellet was resuspended at 1x106 cells/ml in macrophage medium with 10% (v/v) L-cell 
conditioned media, and 11ml was plated onto bacteriological petri dishes and further 
incubated for 5-7 days at 37°C/5% CO2 (v/v). The non-adherent population was discarded 
and adherent cells scraped for further study into fresh macrophage medium, constituting 
differentiated BMMs. 
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Macrophage Medium consisted of RPMI 1640 (GIBCO), 1% (v/v) Sodium Pyruvate 
(Invitrogen), 1% (v/v) Non-Essential Amino Acids (GIBCO), 100 units/ml of 
Penicillin/Streptomycin antibiotics (Invitrogen) and 5mM L-Glutamine (Invitrogen), and 
10% (v/v) of each Fetal Calf Serum, and L-929 cell conditioned medium (a source of 
macrophage colony stimulating factor). 0.00002% (v/v) of β-mercaptoethanol was also 
added to the media. 
To determine the purity of the resulting macrophage population, immunocytochemistry 
to display the macrophage marker F4/80 (following procedures outlined in 2.11) was 
performed. The purity of the macrophage population was found to be >90%, photographs 
of F4/80 staining are shown in figure 2.2. 
2.1.3. Culturing L-929 cells for conditioned media. 
L-929 were used as a source for M-CSF-1 (Leverrier and Ridley, 2001). Briefly, L-929 cells 
were thawed into non-vented tissue culture flasks (TPP, cat no. 90075) until confluent. 
Cells were passaged using trypsin EDTA and expanded as required. Cells were allowed to 
adhere for 24 hours and the flasks were locked to seal the flasks. Cells were allowed to 
condition media with CSF-1 for 2-3 weeks. Cells were checked and media was collected 
into 50ml Falcon tubes. Tubes were centrifuged at 1000rcf for 5 minutes to remove debris, 
supernatants were pooled together and filters with a 0.2µm single use filter and aliquoted 
into 5ml bijoux. Aliquots were stored at -20°C. 
L-929 cells were grown in media consisting of High Glucose Dulbecco’s Modified Eagle 
Medium (Invitrogen), 1% (v/v) Sodium Pyruvate and 100 units/ml of 
Penicillin/Streptomycin antibiotics (Invitrogen) and 5mM L-Glutamine (Invitrogen), and 
10% (v/v) of Fetal Calf Serum. 
2.2. Humanised ApoE Knock-in mice 
Mice that were homozygous for either the human ApoE3 gene or the human ApoE4 gene 
in a targeted replacement of the endogenous murine ApoE gene (first described in 
(Sullivan et al., 1997) and (Knouff et al., 1999) respectively) were purchased from Taconic. 
At 13-14 weeks, ApoE3 and ApoE4 mice were randomly selected to be fed a palletised high 
fat diet containing 45% of calories from fat (Research Diets, New Brunswick), or a high fat 
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diet containing supplements of eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) (30g EPA + DHA/kg at a 2:3 ratio) (Research Diets, New Brunswick). Mice were fed 
on these diets for 8 weeks before being sacrificed. The fish oil supplementation led to a 
daily intake of 1500mg EPA and 2250mg DHA.  
2.2 Cell Viability Testing 
The cell suspension tested was diluted 3:4 with Trypan blue – a vital dye solution. Dead 
cells take up the dye and appear blue under the microscope, whereas live cells remain 
unstained. The resulting cell suspension was measured using a haemocytometer and the 
numbers of both dead and live cells were counted, allowing a percentage viability to be 
calculated.  
2.3. Macrophage Treatments 
All experiments that were carried out in either BMMs or Raw 264.7 were performed using 
the relevant tissue culture medium described in 2.1, and in the presence of 0.2% (v/v) FCS, 
unless stated otherwise.  
2.3.1. ATP 
Adenosine 5’-triphosphate disodium salt hydrate (ATP; Sigma) purified from E.Coli, was 
dissolved to a 0.1M stock solution in ddH2O for storage at -20°C until later use. This stock 
solution was later diluted to 10mM and then 10µM in the appropriate media and added 
to either the top of a Transwell® or onto adhered macrophages in a Nunclon™ coated 
MultiWell™ plate. Macrophages remained exposed to ATP for the duration of the 
experiment before imaging, RNA extraction or protein extraction. 
2.3.2. BDNF 
Endotoxin free lyophilised active human BDNF full length protein (expressed in E.coli; 
Abcam) was dissolved in ddH2O to a concentration of 100µg/ml stock solution and stored 
at 20°C until later use. This stock solution was later diluted to 100ng/ml in the appropriate 
media and added to either the top of a Transwell® or onto adhered macrophages in a 
Nunclon™ coated MultiWell™ plate. Macrophages remained exposed to BDNF for the 
duration of the experiment before imaging, RNA extraction or protein extraction. 
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2.3.3. LPS 
A 1mg/ml stock solution of Lipopolysaccharide (LPS) (purified from E.coli; R&D systems) 
was diluted into the respective media to a concentration of 100ng/ml  was added into the 
top of a Transwell®, or onto adhered macrophages in a Nunclon™ coated MultiWell™ 
plate. Macrophages continued to be exposed to the LPS for the duration of the 
experiment.  
2.3.4. Bradykinin 
Bradykinin acetate salt (Sigma) was dissolved in 0.1M acetic acid to a stock concentration 
of 0.1M and stored at -20°C until later use. Bradykinin was then diluted to 1mM in the 
appropriate media and added onto adhered macrophages in a Nunclon™ coated 
MultiWell™ plate. The cells were exposed to Bradykinin throughout the experiment until 
RNA extraction.  
2.3.5. Interleukin-10 
Endotoxin free Recombinant murine Interleukin-10 (expressed in E.coli; Cell Signaling 
Technology) was diluted in PBS containing 0.2% (v/v) BSA to a concentration of 100µg/ml 
and stored at 4°C. This stock solution was later diluted to 100ng/ml in the appropriate 
media and added onto adhered macrophages in a Nunclon™ coated MultiWell™ plate. The 
cells remained exposed to IL-10 throughout the course of the experiment.  
2.3.6. MCP-1 
Endotoxin free recombinant murine MCP-1/CCL2 (expressed in E.coli; R&D systems) was 
diluted in PBS containing 0.2% (v/v) BSA to a concentration of 100µg/ml and stored at -
20°C, this stock solution was later diluted to 100ng/ml in the appropriate media and added 
either to the top of a Transwell® or onto adhered macrophages in a Nunclon™ coated 
MultiWell™ plate. The cells remained exposed to MCP-1 throughout the course of the 
experiment.  
2.3.7. PPADs 
The selective P2 antagonist PPADs was dissolved in ddH2O to a stock solution at 100mM. 
This stock solution was diluted to a working stock of 100nM which was added to the lower 
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well of a Transwell® for 1 hour to pre-treat the macrophages with this antagonist before 
being washed off. 
2.3.8. Suramin 
The P2 antagonist Suramin was dissolved in ddH2O to a stock solution at 100mM. This stock 
solution was diluted to a working stock of 100nM which was added to the lower well of a 
Transwell® for 1 hour to pre-treat the macrophages with this antagonist before being 
washed off. Suramin is also capable of blocking calmodulin binding to recognition sites, 
and G-protein coupling to G protein coupled receptors (La Rocca et al., 1991). Suramin is 
actively currently used as a treatment for sleeping sickness, caused by trypanosomes, and 
has previously been investigated as a possible treatment for prostate cancer (La Rocca et 
al., 1991). 
2.3.9. BBG 
The selective P2X4/P2X7 antagonist PPADs was dissolved in ddH2O to a stock solution at 
30mM. This stock solution was diluted to a working stock of 30nM which was added to the 
lower well of a Transwell® for 1 hour to pre-treat the macrophages with this antagonist 
before being washed off. 
2.3.10. DTG 
The Sigma-1 receptor agonist, DTG (1,3-Di-(2-tolyl)guanidine; Tocris) was dissolved to a 
25mM stock solution in DMSO and stored at -20°C. This stock solution was later diluted to 
100µM in the appropriate media and added to either the bottom of a Transwell®, or onto 
adhered macrophages. DTG was exposed to the cells throughout the course of the 
experiment. 
2.3.11. IPAG 
The Sigma-1 receptor antagonist, IPAG (Tocris) was dissolved to 100mM in DMSO as a 
stock solution and stored at -20°C. This stock solution was later diluted to 30µM in the 
appropriate media and added to either the bottom of a Transwell®, or onto adhered 
macrophages. IPAG was exposed to the cells throughout the course of the experiment.  
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2.3.12. siRNA. 
5nmol of lyophilised SMARTpool ON-TARGET siRNAs (Dharmacon) targeting the mouse 
gene for Sigma-1 receptor (OPRS1) was dissolved in 250µl siRNA suspension buffer (Fisher) 
to a concentration of 20µM, which was mixed by vortexing. The SMARTpool ON-TARGET 
siRNA and Allstars negative siRNA control scrambled siRNA conjugated with Alexa 488 
(Qiagen) were stored at -20°C. The siRNAs were then diluted further to a working 
concentration of 50nM in the appropriate media containing 10% (v/v) FCS, and 60µl/ml of 
HiPerFect transfection reagent (Qiagen) was added into the mixture – which was mixed 
well and allowed to incubate for 5 minutes to allow transfection complexes to form.  
Macrophages were seeded at a density of 0.5 x 106 cells/well in a 6 well plate, 24 hours 
prior to transfection. 400µl of the siRNA and HiPerFect mixture was added to each well in 
a ‘drop-wise’ manner, and remained on the cells for 30 minutes before an additional 2ml 
of culture media was added onto the cells. The samples were then incubated for a further 
24 hours before being using in an inverted invasion assay, or being made quiescent to be 
lysed for use in a western blot experiment.  
 
Table 2.1. siRNA sequences as supplied by Dharmacon. 
 Sequence 5’-3’ 
SMARTpool ON-TARGET siRNA “Sigma-1 
Receptor”. 
GGCUUGAGCUUACCACCUA 
 GAGAAGAAAUAGCGCAGCU 
 GAAAGAGGGCACCACGAAA 
 UAUUCAGACAGCAGCGUAU 
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2.4. Total RNA Purification 
Total RNA was purified from macrophage cell lysates as part of the process of using the 
RNeasy Minikit (Qiagen), according to the manufacturer’s instructions. Briefly, culture 
medium was aspirated from the adherent cells and washed with PBS, before being lysed 
with buffer RLT – a cell lysis buffer containing guanidium isothiocyanate and supplemented 
with 10% (v/v) β-mercaptoethanol. Cell lysates were further homogenised by trituration 
before being transferred to a gDNA eliminator column. After centrifugation, an equal 
volume of 70% (v/v) Ethanol was added to the sample to promote RNA precipitation and 
binding to the silica-gel based membrane of the RNeasy mini-spin column. The spin column 
was washed repeatedly using high salt buffers to further purify the RNA. RNA was then 
eluted in RNase-free water and stored at -20°C. RNA yield was measured using the 
Nanodrop 2000 spectrophotometer (Thermo Scientific) at 230nm, 260nm and 280nm 
wavelengths. RNA concentration was measured at 260nm and the ratios of absorbance at 
260/280, and 260/230 were used to determine the quality of the RNA. Samples with a 
260/280 ratio of over 1.8 were deemed to be of acceptable purity. 
Later, in chapter 5, we used a Cells to CT™ kit (Ambion) to isolate RNA and reverse 
transcribe RNA in a one-step reaction. The kit was used in accordance with the 
manufacturer’s instructions, Briefly,  cell medium was removed and DNase I and a lysis 
solution was added to cells, this mixture was incubated at room temperature for 5 
minutes, and then Stop solution was added, thus ceasing lysis. The lysate mixture was then 
added to an RT master mix and ran through a thermal cycle, the samples were then ready 
to be used for qRT-PCR. As this method does not allow for a standard curve, results were 
analysed using a 2-∆∆Ct method.  
2.5. Reverse Transcription 
500ng-1µg of isolated mRNA in a 15µl volume (diluted with dH2O) was reverse transcribed 
to complementary DNA (cDNA) using random primers (Invitrogen), dNTP mix (Bioline) and 
Maloney Murine Leukaemia Virus (M-MLV; Promega) reverse transcriptase in a 25µl 
reaction according to the manufacturer’s instructions. Briefly, 250ng/ml random primers 
were added to each sample, and heated to 70°C for 10 minutes to denature the secondary 
structure of the mRNA. Samples were immediately placed on ice to prevent the secondary 
structures from reforming and to allow the random primers to anneal. Then, 0.2mM dNTP 
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mix and 200units/µg RNA M-MLV was added to the primed RNA, and reverse transcription 
was promoted by heating the samples to 42°C. Enzyme activity was stopped by destroying 
the enzyme with a step of heating to 70°C for 10 minutes. Samples were stored at -20°C 
until further use. 
2.6. Quantitative Reverse Transcription Polymerase Chain Reaction 
(qRT-PCR) 
Quantitative real-time RT-PCR reactions were performed using a 7500 Fast RT-PCR system 
(Applied Biosystems) according to the manufacturer’s protocol. Briefly, five nanograms of 
cDNA was loaded into each well of an Applied Biosystems Taqman® plate, along with 
8.33µl of 2x qRT-PCR MasterMix (Applied Biosystems) and 100nM each of the forward and 
reverse primer, and 200nM of probe in a 25µl reaction.  
Standard Taqman® cycling conditions were used as follows, samples were heated to 95°C 
for 10 minutes to activate the Taq polymerase component of the MasterMix, which was 
followed by 40 cycles of 15 seconds melting at 95°C and 1 minute of annealing, extending 
and data collection.  
The ribosomal 18S gene or ywhaz was used as an endogenous control to for normalisation, 
to account for differences in total cDNA in each sample, and the relative amount of target 
cDNA was determined using a standard curve, which for each reaction was prepared using 
a range from 0.625ng-20ng cDNA. Data is represented as a level of target mRNA relative 
to 18s, and as a fold change of the control condition value. As a quality control, all samples 
which were shown to express 18s or ywhaz at ±1.5 CT values from the mean were excluded 
from the analysis.  
2.7. Protein Extraction 
Cell cultures were made quiescent at least 24 hours prior to stimulation and protein 
extraction. Cell cultures were then washed twice in ice-cold PBS before being lysed in 
Reverse Phase Protein Array (RPPA) buffer, containing; 1% (v/v) Triton X-100, 5mM HEPES, 
150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 1mM Na3VO4, 10mM Na 
Phosphatase, 10% (v/v) Glycerol at pH 7.4, before using 1x PhosStop phosphatase inhibitor 
cocktail tablet (Roche) and 1x cOmplete ULTRA protease inhibitor tablet was added per 
10ml to the buffer. Cells were incubated on ice in RPPA buffer for at least 20 minutes and 
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occasionally shaken. For further homogenisation, samples were scraped with individual 
18mm blade cell scrapers before being transferred to an Eppendorf tube. All samples were 
centrifuged at 4°C at 13,000 r.p.m for 10 minutes and the supernatant transferred to a 
fresh Eppendorf tube. Samples were stored at -20°C until use.  
2.8. Western Blotting 
2.8.1. Protein Quantification 
To measure the amount of protein in a lysate, a Coomassie plus kit (Pierce) was used 
according to the manufacturer’s instructions. This kit is designed so to that protein binds 
to a coomassie dye in the acidic environment provided by the reagent, resulting in a colour 
change from reddish-brown to blue, which can be measured by the absorbance at 595nm.  
Briefly, protein standards of known concentrations ranging from 0.125mg/ml to 2mg/ml 
were prepared and 10µl of each plated in duplicate in a 96 well plate. The same volume of 
samples containing an unknown amount of protein were also plated in duplicate, then 
240µl of coomassie plus reagent was added to each well and incubated for 15 minutes at 
room temperature. Absorbance at 595nm was then read in a spectrophotometer plate 
reader (Omega). 
Protein concentration was then calculated by preparing a standard curve from the known 
protein samples.  
2.8.2. Preparation of Protein Samples 
RPPA extracted protein samples were diluted 5x with 5x reducing sample buffer 
(containing 0.625M Tris, 2% (v/v) SDS, 10% (v/v) Glycerol, 20% (v/v) β-mercaptoethanol 
and 2% (v/v) Bromophenyl blue). Samples were then denatured by boiling for 5 minutes 
at 95°C. The concentration of protein was typically standardised to 5-10µg per sample.  
2.8.3. Protein resolution by SDS-PAGE 
5-10µg protein was loaded into each well of a SDS-polyacrylamide gel (Usually 10% 
resolving gel with a 5% stacking gel) along with a well containing a Spectra Multicolour 
Broad Range Protein Ladder (10kDa – 260kDa; Pierce). Gels were run at constant current 
(30mA per gel) until proteins were deemed to be adequately resolved, using the protein 
ladder as a marker. 
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2.8.4. Semi-dry transfer 
Polyvinylidene Flouride (PVDF; BIO-RAD) membranes were activated by briefly soaking in 
100% methanol for 5 minutes. Activated PVDF, and thick filter paper (BIO-RAD) were 
equilibrated in semi-dry transfer buffer. The resolving polyacrylamide gel was then 
sandwiched between thick filter paper and the PVDF membrane. Semi-dry transfer was 
performed using a Transblot SD Semi-Dry Transfer Cell (BIO-RAD), at 15V for 35 minutes.  
2.8.5. Immunodetection of Proteins 
Immunodetection of proteins was performed as described in (Baker et al., 2012). Typically, 
membranes were blocked for 3hr at room temperature in TBS-T containing 5% (v/v) BSA. 
Membranes were then incubated with the primary antibody diluted in TBS-T containing 
5% (v/v) BSA overnight at 4°C. After incubation with the primary antibody, membranes 
were washed 5x over the course of 50 minutes in TBS-T, and then incubated with the 
secondary antibody (conjugated with HRP), diluted in TBS-T containing 5% (v/v) BSA. 
Membranes were further washed 5x over the course of 60 minutes in TBS-T before 5 
minutes of incubation with in-house ECL solution, which reacts with the HRP enzyme 
bound to the membrane via the secondary antibody. The resulting chemiluminescence 
was measured by exposure to Amersham Hyperfilm ECL (GE Healthcare), a photosensitive 
film. The photosensitive film was then developed in an autoradiograph film processor 
(Xograph Healthcare Ltd). A full range of antibodies used for western blotting can be found 
in table 2.2. 
Table 2.2. A full list of antibodies used in Western Blot experiments. 
ANTIBODY CONCENTRATION SUPPLIER 
RABBIT ANTI ERK1/2 1:1000 Cell Signaling Technology 
RABBIT ANTI P-ERK1/2 1:1000 Cell Signaling Technology 
RABBIT ANTI P38 1:1000 Cell Signaling Technology 
RABBIT ANTI P-P38 1:1000 Cell Signaling Technology 
RABBIT ANTI SIGMA-1 
RECEPTOR 
1:50 Abcam 
GOAT ANTI-RABBIT-HRP 1:2000 Dako 
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2.9. Cell Migration and Time-Lapse Microscopy 
Cell migration experiments using time-lapse microscopy was performed as described in 
(Murray et al., 2013). Briefly, 24 well plates were coated with Matrigel™ (BD Biosciences) 
and Fibronectin from bovine plasma (Sigma) at the concentration of 10µg/ml Matrigel, and 
10ng/ml Fibronectin for experiments described in chapter 3. However, for experiments in 
chapter 5, 24 well plates were uncoated, and cells were exposed to the Nunclon™ surface 
of the multiwell plates. Macrophages were seeded into the wells at a density of 10x104, 
and then incubated at 37°C, 5% (v/v) CO2 and allowed to adhere for 3 hours. Treatments 
were administered as described.  
Cells were imaged over the course of 17 hours at 10 minute intervals with a monochrome 
Axioplan CCD camera (Zeiss) attached to a widefield, Axiovert 200M inverted light 
microscope (Zeiss), which used Axiovision software. Cell migration velocity and distance 
was tracked and analysed using ImageJ software (NIH), and the ‘Manual Tracking’ plug-in 
(F. Corderlieres, Institue Curie, France), and the ‘Chemotaxis and Migration Tool’ available 
from Ibidi (Trapp and Horn, Ibidi GmbH). 
2.10. Inverted Invasion Assay 
A normal invasion assay involves the invasion of cells from the top of a thin gel matrix 
down to the underside of a solid membrane towards a chemoattractant. The invasion 
assay can also be inverted, which is slightly more complex to perform but ultimately allows 
for a different analysis of results which can be quantified (Hennigan et al., 1994, Kim et al., 
2008, Murray et al., 2013). 
In the inverted invasion assay, once the matrix plug is set, the Transwell is inverted and 
cells are seeded directly onto the underside of the polycarbonate filter membrane. Cells 
are allowed to adhere and then the Transwell is inverted once more, so that now it is the 
right way up, although cells are already on the bottom of the membrane. A 
chemoattractant is then added to the top of the matrix plug and cells are allowed to invade 
up through the matrix plug. Live cells can be imaged with Calcein AM and then the entire 
Transwell can be imaged using confocal optical sectioning, this allows us to view where 
cells have travelled to in the matrix plug, and allows for better quantification of results. 
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Figure 2.1. A diagram to show the steps of the inverted invasion assay. Once finished, a confocal microscope is used 
so it is possible to see how far the cells in question have travelled through the matrix. 
Inverted invasion assays were performed to measure chemotaxis of cells towards different 
chemoattractants. Matrigel™ (BD Biosciences) was diluted with ice cold PBS to 4mg/ml, 
100µl of the Matrigel solution was added to each Transwell® with 8µm pores (Corning) and 
allowed to set at 37°C for 1 hour. Transwells® were then inverted and 1x105 cells (Raw 
264.7 or BMMs) in 100µl DMEM + 10% (v/v) Fetal Calf Serum were seeded directly onto 
the underside of the Transwell® filter. The Transwell® inserts were then covered with the 
base of a 24 well plate (Falcon) and cells were allowed to adhere for 3 hours at 37°C and 
5% (v/v) CO2. Once the cells adhered the Transwells® were turned once more and washed 
twice in wells containing 1ml of media in the lower well (DMEM + 0.2% (v/v) Fetal Calf 
Serum), before being placed in the lower well containing 1ml of DMEM + 0.2% (v/v) Fetal 
Calf Serum.  100µl of chemoattractant was then added to the upper side of the Transwell® 
- in identical medium to the lower well. The Transwells® were then incubated at 37°C + 5% 
(v/v) CO2 for 48 hours to allow invasion of cells into the Matrigel™.  
After invasion, cells were stained with 4mM Calcein AM and incubated for 1 hour before 
being imaged on a Leica TCS SP2 UV system confocal microscope at 40x magnification – 
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invasion can then be quantified. For each invasion Transwell®, 3 z-stacks were taken to 
cover 210µm through the Matrigel™ matrix, accounting to 15 images taken 15µm apart. 
Invasion is demonstrated as a percentage of cells that have migrated over 30µm. To 
determine this, the ‘Area Calculator’ plug-in for Image J (NIH) was used to demonstrate 
the number of fluorescing pixels on each slice of the z-stack above a set threshold level of 
fluorescence. The number of pixels from all images above 30µm were then calculated as a 
percentage of the total number of fluorescing pixels in the z-stack.  
2.11. Immunocytochemistry 
 Immunocytochemistry was carried out essentially as described in (Murray et al., 2013); 
roughly 40,000 cells were plated per 13mm glass coverslip (VWR) in 24 well plates and 
allowed to adhere for 1 hour before the addition of 500µl of the appropriate cell culture 
media was added. Cells were then incubated at 37°C, 5% (v/v) CO2 overnight. Coverslips 
with then fixed in a 4% (v/v) paraformaldehyde solution and washed in PBS. Non-specific 
binding was blocked by incubating the cells for 1 hour in NGS, followed by incubation for 
1 hour with a rat anti-F4/80 primary antibody diluted 1:1000 (AbD Serotec) without 
washing. Coverslips were then washed at least 3x with PBS to remove unbound primary 
antibody. Coverslips were then incubated with an anti-rat Alexa Flour-488 (Abcam) 
conjugated secondary antibody diluted at 1:1000 for 1 hour before washing 3x with PBS. 
Cells were then incubated with DAPI and washed quickly before mounting on microscope 
slides with Hydromount mounting solution. Example photographs of F4/80 staining are 
shown in Figure 2.2. 
 
 
Figure 2.2.  Photographs of BMM populations prepared using the method outlined in section 2.1.2, captured at x200 
demonstrating the nuclear stain, DAPI (blue) and the macrophage marker F4/80 (Green).  
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2.12. Statistical Analysis 
Unless otherwise stated, statistical analyses were a two-sample unequal variance two-
tailed Students’ t test and were performed using Microsoft Office Excel 2010. A p-value of 
less than 0.05 was deemed to be significant.  
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Chapter 3: ATP as a Chemoattractant to 
Macrophages 
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3.1 Introduction 
3.1.1. Macrophage Migration in Neuropathic Pain. 
Migration of cells is a basic biological function that contributes towards normal 
development and differentiation. Macrophages, neutrophils and microglia rely heavily on 
migration, as they are professional phagocytes (Krause, 2000). It is an essential role of 
these cells to migrate towards and engulf invading organisms such as bacteria, and 
apoptotic cells. Recent findings explore the importance of extracellular nucleotides such 
as ATP in the migration of professional phagocytes towards their intended targets 
(Corriden and Insel, 2012).  
In chemotaxis – the directed migration of a cell towards a chemical cue, there are three 
distinct processes, motility, polarization and gradient sensing. Cell motility is driven by 
actin extension of microtubules which enable random and directed migration. Polarization 
is dictated by the recognition of extracellular clues which leads to the rearrangement of 
the cell cytoskeleton that promotes the formation of a leading edge of a cell and 
disintegration of the integrin formations at the rear of the cell (Iglesias and Devreotes, 
2008).   
Directional movement of cells towards an area can be regulated by ATP, ADP and 
adenosine, along with other nucleotides, (Corriden and Insel, 2012). After injury, ATP is 
released from all cells in millimolar concentrations, which can promote the release of other 
chemoattractant cytokines from surrounding cells, and thus amplify the chemoattractant 
signals that drive cell migration. However, there is currently debate over whether these 
nucleotides act as a “touch me” chemokinetic factor or a “find me” signal, thus promoting 
phagocytic activity (Elliott et al., 2009, Chekeni and Ravichandran, 2011). 
 
3.1.2. Purinergic Signalling. 
There are known to be 7 P2X subtypes, and 8 P2Y receptors (Burnstock, 1972, Burnstock, 
1976, Burnstock, 2007). It is thought that purines can induce directed migration in 
microglia and macrophages towards sites of injury (Kurpius et al., 2007, Irino et al., 2008, 
Lambert et al., 2010). P2X4, P2X7, P2Y6 and P2Y12 receptors are thought to have links with 
microglial and macrophage migration.  
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3.1.3. BDNF 
BDNF signals through its receptor TrkB, and can also signal through p75. BDNF is able to 
signal through MAPK, PI3K and PLCγ pathways, and is thought to have many 
neuroprotective effects. For example, BDNF has been found to be able to reverse synapse 
loss, improve learning and memory and normal cell signalling, and normalise gene 
expression in Alzheimer’s disease in rats and primates (Nagahara et al., 2009). The 
administration of BDNF has also been shown to be able to improve cognitive function in 
aged animals. 
BDNF has been shown to have neuroprotective effects by leading to the decrease of 
expression of pro-inflammatory cytokines such as TNFα, and leads to the increase of the 
expression anti-inflammatory cytokines such as IL-10. It has also been found that BDNF can 
protect against glutamate toxicity and ethanol-induced damage in neurons, and that BDNF 
enhances neural regeneration (Chen et al., 2013). However, it has also been found that 
BDNF may contribute to the formation of neuropathic pain (Beggs and Salter, 2010) by the 
disinhibition of lamina I neuron signalling. 
Hetman et al suggested that the neuroprotective effects of BDNF were due to mechanisms 
downstream of ERK and PI3K (Hetman et al., 1999).  
3.1.4. Sigma-1 receptor. 
Sigma receptors are a 223 amino acid transmembrane protein (Su et al 2010) that 
regulates a variety of cellular functions, including IP3 Ca2+ signalling, ion channel firing, 
neurotransmitter release, differentiation, neuronal survival, and inflammation. In its 
native state on the endoplasmic reticulum, Sigma-1 receptor associates with the 
chaperone binding immunoglobulin protein (BiP) (Su et al 2010, Hashimoto 2013). It is 
thought that Sigma-1 can play a role in chaperoning proBDNF and misfolded proteins.  
In 2009, Hall et al discovered that activation of Sigma receptor via the agonist DTG, 
suppressed many of the functions of primary microglial cells, such as morphology changes, 
migration, phagocytosis calcium influx and nitric oxide production.  Gannon et al, 2001, 
also demonstrated that activation of Sigma-1 receptor inhibited nitric oxide production in 
response to LPS.  
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It is thought that the agonism of sigma-1 receptor could lead to the modulation of signalling 
through several cell surface receptors including sodium channels, TrkB and possibly purinergic 
receptors. 
3.2. Hypothesis and Aims 
This chapter shall explore the hypothesis that ATP can modulate the migration of macrophages in 
a context of neuropathic pain. In this chapter, the following aims will be investigated: 
 ATP can act as a chemoattractant and thus be responsible for macrophage migration.  
 To explore the mechanism behind ATP-induced migration of macrophages.  
 To determine if other neuropathic pain related stimulants such as BDNF can influence 
macrophage migration, and to explore the mechanisms behind this.  
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3.3. Results 
 
3.3.1. ATP acts as a chemoattractant to Raw 264.7 cells and primary Bone Marrow-
derived Macrophages in a Matrigel™/Fibronectin matrix. 
Using the inverted invasion assay technique, the chemoattractive ability of Adenosine 5’-
Triphosphate (ATP) to Raw 264.7 macrophages was explored, in part to investigate the role 
of purinergic receptors in the migration of macrophages towards the site of peripheral 
nerve injury.  10µM ATP was chosen as a concentration as it is an ideal concentration for 
the activation of P2X4 receptor, which is of interest (Tsuda et al, 2006). 
Raw 264.7 cells were allowed to invade into the Matrigel™ matrix, supplemented with 
10µg/ml Fibronectin, towards 10µM ATP for 48 hours before being stained with Calcein-
AM and imaged by confocal microscopy. It was found that 10µM ATP significantly 
increased invasion into the Matrigel™/Fibronectin matrix by approximately 2.5 fold, when 
compared to the control condition (Figure 3.1). Whilst the result shown is from one 
experiment, this result is representative of 22 separate experiments. 
Whilst initially planning to confirm this result in microglial cells isolated from either spinal 
cord, or cortex tissues, isolating microglial cells proved not to yield the number of cells 
required and the focus shifted to investigate with primary bone-marrow derived 
macrophages. To confirm this result in primary macrophages, murine bone marrow-
derived macrophages were differentiated from bone marrow stromal cells. Here we report 
that BMMs respond to ATP in a similar manner to Raw 264.7 cells. BMMs invaded into 
Matrigel™/Fibronectin over 48 hours, ATP increased the invasion of BMMs 2 fold when 
compared to the control condition (Figure 3.2). Figure 3.2 shows a result that is 
representative of 4 separate experiments.  
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Figure 3.1 ATP significantly increases Raw 264.7 invasion through a Matrigel™/Fibronectin matrix. Raw 264.7 
were allowed 48 hours to invade into a Matrigel™/Fibronectin matrix, after which all live cells were stained 
with a Calcien-AM dye and Transwells™ were imaged using a Leica confocal microscope every 15µm through 
210µm, a representative of images taken from each condition is shown beneath the graph. Invasion over 
30µm was then quantified using ImageJ image analysis software. Each bar represents the mean ± 1 S.E.M. N = 
6 (3 fields from 2 separate Transwells™). P value calculated by students’ t-test * = p ≤ 0.05. 
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Figure 3.2. ATP significantly increases BMM invasion through a Matrigel™/Fibronectin Matrix. BMMs were 
allowed 48 hours to invade into a Matrigel™/Fibronectin matrix, after which all live cells were stained with a 
Calcien-AM dye and Transwells™ were imaged using a Leica confocal microscope every 15µm through 210µm, 
a representative of images taken from each condition is shown beneath the graph. Invasion over 30µm was 
then quantified using ImageJ image analysis software. Each Bar represents the mean ± 1 S.E.M. N = 6 (3 fields 
from 2 separate Transwells™). P value calculated by students’ t-test * = p ≤ 0.05. 
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The next step of investigation was to determine the receptor responsible for ATP-induced 
invasion is Raw 264.7 and BMMs. As ATP acts through purinergic receptors, broad-
spectrum pharmacological inhibitors of purinergic receptors, Pyridoxalphosphate-6-
azophenyl-2’,4’-sisulfonic acid (PPADs), and Suramin were used, along with the 
triphenylmethane dye, Coomassie Brilliant Blue G-250. PPADs is a non-selective inhibitor 
of purinergic channels P2X1, P2X2, P2X3, P2X5, P2Y2 and P2Y4 channels, Suramin is also a 
non-selective P2 antagonist, capable of blocking P2X1, P2X2, P2X3, P2X5, P2Y2, P2Y4 and 
P2Y6. Coomassie Brilliant Blue G-250 (BBG) is an inhibitor of the P2X7 receptor and a weak 
inhibitor of P2X4. 
Using the inverted invasion assay, Raw 264.7 cells were pretreated with the 
pharmacological inhibitors for 10 minutes, before washing the cells and adding the 
chemoattractant to the assay.  The Raw 264.7 were allowed 48 hours to invade into the 
Matrigel™/Fibronectin matrix before being imaged. The results, shown in Figure 3.3, 
demonstrate that all three P2 receptor antagonists reduce invasion towards 10µM ATP. In 
Figure 3.3, suramin is shown to have the most potent effect on invasion, dramatically 
reducing invasion of Raw 264.7 cells over 30µm 15-fold. BBG and PPADs are also shown to 
have an effect on ATP induced invasion, significantly reducing invasion approximately 2.4 
fold, it should be noted that suramin was originally developed as an anti-microbial agent 
and can affect cells using other mechanisms such as antagonism of several GPCRs, and so 
its action may not entirely be limited to P2 receptor antagonism.  
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Figure 3.3. Invasion of Raw 264.7 through a Matrigel™/Fibronectin Matrix after pre-treatment with P2 
antagonists. Raw 264.7 were allowed 48 hours to invade into a Matrigel™/Fibronectin matrix after 10 minute 
pre-treatment with P2 receptor antagonists BBG, PPADS and Suramin. After 48hrs all live cells were stained with 
a Calcien-AM dye and Transwells™ were imaged using a Leica confocal microscope every 15µm through 210µm, 
a representative of images taken from each condition is shown beneath the graph. Invasion over 30µm was then 
quantified using ImageJ image analysis software. Each Bar represents the mean ± 1 S.E.M. N = 6 (3 fields from 2 
separate Transwells™). P value calculated by students’ t-test * = p ≤ 0.05, ** = p ≤ 0.01. 
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3.3.2. Brain-Derived Neurotrophic Factor can attenuate ATP induced invasion in Raw 
264.7 cells and BMMs. 
 
In 2005, Coull et al discovered that ATP stimulation of microglia causes the release of Brain-
Derived Neurotrophic Factor (BDNF), and that BDNF was a crucial signalling molecule 
between microglial cells and neurons. It was shown that ATP-stimulated microglia signal 
to lamina 1 neurons, which, through disruption of the transmembrane anion gradient may 
be responsible for tactile allodynia. Upon the blockade of BDNF signalling, tactile allodynia 
was reversed. Later, Trang et al (2009), further elucidated that ATP-induced release of 
BDNF in microglia was through P2X4 mediated activation of the p38-MAPK pathway.  
These findings mused the possibility that BDNF may impact upon macrophage invasion, 
therefore we determined the effects of the combination of ATP and BDNF on the migration 
of macrophages. The results in Figure 3.4 show that 10µM ATP significantly increases from 
the control condition (by nearly 4-fold), whereas BDNF alone has no effect when compared 
to the control condition. Interestingly, ATP in combination with BDNF does not differ 
significantly from the control, but when compared to ATP alone, displays a significant 1.8 
fold reduction in invasion. Figure 3.4 shows a representative of 11 separate experiments.  
To confirm the result in primary macrophages, we exchanged Raw 264.7 cells for BMMs, 
and repeated the experiments. Figure 3.5 shows that unsurprisingly, BMMs respond in a 
similar manner. 10µM ATP significantly increases invasion over 30µm compared to the 
control condition (from 20.8% in the control condition to 47.8% ATP), BDNF alone has no 
effect, but, when compared to ATP alone the combination of ATP+BDNF significantly 
reduces invasion by 1.65-fold. In this experiment, 100ng/ml of the TLR4 agonist 
Lipopolysaccharide (LPS) was added to act as a positive control – which leads to a 
significant increase compared to the control condition.  
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Figure 3.5. BDNF attenuates ATP induced invasion in Bone Marrow-derived Macrophages cells through a 
Matrigel™/Fibronectin matrix. BMMs were allowed 48 hours to invade into a Matrigel™/Fibronectin matrix 
towards 10µM ATP, 100ng/ml BDNF or the combination of ATP + BDNF, in this experiment, 100ng/ml LPS was 
also included as a positive control. Afterwards all live cells were stained with a Calcien-AM dye and 
Transwells™ were imaged using a Leica confocal microscope every 15µm through 210µm, a representative of 
images taken from each condition is shown beneath the graph. Invasion over 30µm was then quantified using 
ImageJ image analysis software. Each bar represents the mean ± 1 S.E.M. N = 6 (3 fields from 2 separate 
Transwells™). P value calculated by students’ t-test * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
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Figure 3.4. BDNF attenuates ATP induced invasion in Raw 264.7 cells through a Matrigel™/Fibronectin matrix. Raw 
264.7 were allowed 48 hours to invade into a Matrigel™/Fibronectin matrix towards 10µM ATP, 100ng/ml 
BDNF or the combination of ATP + BDNF. Afterwards all live cells were stained with a Calcien-AM dye and 
Transwells™ were imaged using a Leica confocal microscope every 15µm through 210µm, a representative of 
images taken from each condition is shown beneath the graph. Invasion over 30µm was then quantified using 
ImageJ image analysis software. Each bar represents the mean ± 1 S.E.M. N = 6 (3 fields from 2 separate 
Transwells™). P value calculated by students’ t-test * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
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3.3.3. The potential involvement of Sigma Receptors in Macrophage Migration 
towards ATP, and the subsequent attenuation of invasion by BDNF. 
The next steps of investigation involved elucidating the mechanisms by which BDNF 
attenuates ATP induced invasion in both Raw 264.7 cells and primary bone marrow-
derived macrophages, during which, Sigma-1 receptor became of interest to our 
investigation.  
Due to the findings that sigma-1 can supress a range on microglial activities, and its link 
with BDNF processing, we investigated the effect of agonism and antagonism of the Sigma-
1 receptor using pharmacological methods.  
The effect of the Sigma-1 receptor agonist, DTG on the invasion of Raw 264.7 cells was 
explored in Figure 3.6. As previously characterised in figure 3.4, ATP is shown again to 
significantly increase invasion of Raw 264.7 cells, and the combination of ATP + BDNF 
shows an abrogation of invasion. Upon treatment with 100µM DTG, there was no change 
in the amount of invasion on the control or with BDNF when cells were also treated with 
DTG. However, the amount of invasion was markedly less with cells in the ATP + DTG 
condition – with invasion at 33.3% over 30µm in ATP alone conditions – reduced 16-fold 
with ATP + DTG. Also, invasion was further reduced in ATP + BDNF conditions – from 18.5% 
invasion in ATP + BDNF, reduced by 4-fold when these cells were treated with DTG.  
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Figure 3.6. The effects of the Sigma receptor agonist, DTG on the invasion of Raw 264.7 cells through a 
Matrigel™/Fibronectin matrix. Raw 264.7 cells were allowed 48 hours to invade into a Matrigel™/Fibronectin 
matrix towards 10µM ATP, 100ng/ml BDNF or the combination of ATP + BDNF, with or without the addition 
of 100µM DTG. Afterwards all live cells were stained with a Calcien-AM dye and Transwells™ were imaged 
using a Leica confocal microscope every 15µm through 210µm, a representative of images taken from each 
condition is shown beneath the graph. Invasion over 30µm was then quantified using ImageJ image analysis 
software. Each bar represents the mean ± 1 S.E.M. N = 6 (3 fields from 2 separate Transwells™). P value 
calculated by students’ t-test * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
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The effect of DTG on the random migration of Raw 264.7 was also explored to determine 
if Sigma-1 receptor was also involved in 2D migration. Raw 264.7 were cultured in 2D on a 
thin coating of Matrigel™ and Fibronectin for 3 hours before addition of the tested 
stimulants and subsequent time-lapse microscopy was performed. Phase-contrast images 
were captured every 10 minutes for 17 hours and cells were later tracked using the Manual 
Tracking plugin for Image J (NIH). 
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Figure 3.7 DTG suppresses migration. Raw 264.7 cells were plated in wells of a 24 well plate at a concentration 
of 1x10/well and stimulated with either (A) Control, (B) 10µM ATP, (C) 100ng/ml BDNF, (D) 10µM ATP + 
100ng/ml, (E) 100µM DTG, (F) 100µM DTG + 10µM ATP, (G) 100µM DTG + 100ng/ml BDNF or (H) 100µM DTG 
+ 10µM ATP + 100ng/ml BDNF. Cells were observed migrating over a period of 17 hours at 37°C and 5% CO2. 
and tracked using the Manual Tracking plugin software and ImageJ. N=15 tracks per condition 
A B 
C D 
E F 
G H 
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Figure 3.8 shows that the average speed of randomly migrating Raw 264.7 cells was 
significantly reduced when cells were treated with DTG, although it should be noted that 
migration speeds are quite low. Figure 3.7 A and E show the trajectories of these 2 
conditions which reflect this observation. 10µM ATP was shown to increase random 
migration speed of cells from 10.8µm/hr to 15.1µm/hr, again 100µM DTG was shown able 
to supress migration significantly (Figure 3.7 tracks B and F) down to 7.7µm/hr. 
Interestingly, the combination of ATP + BDNF was found to increase random migration 
speed from the control (from 10.8µm/hr to 17.1µm/hr – Figure 3.7 tracks A and D), whilst 
DTG reduced migration speed of this condition significantly. DTG was shown to have no 
effect on the speed of BDNF stimulated cells. When cells are exposed to DTG, they appear 
to move around on the spot without migrating to a different point, hence decreasing the 
Euclidean distance. This data is representative of 3 separate experiments.  
The effect of antagonising the Sigma-1 Receptor was explored with the antagonist IPAG on 
the migration of Raw 264.7 cells through a Matrigel™ and Fibronectin matrix. Cells were 
treated to 30µM IPAG in the lower well for one hour prior to the chemoattractant being 
added. After 48hrs invasion, it was observed that treatment with IPAG significantly 
increased the amount of invasion over 30µm in the control condition - leading to a four-
fold increase in the amount of invasion. As seen previously in Raw 267.4 cells, 10µM ATP 
was also found to have an increase in the amount of invasion, and IPAG treatment had no 
further effect. IPAG was also shown to significantly increase the invasion in cells attracted 
to 100ng/ml BDNF by 3-fold. Interestingly, an increase in invasion was seen when ATP + 
BDNF attracted cells were treated with IPAG, although this observation was not significant, 
there was a definite trend towards the rescue of invasion, similar to levels seen with ATP 
attraction alone (a 4.7 fold increase in invasion over 30µm, p=0.07). This is representative 
of 3 experiments, IPAG at this concentration had no effect on cell viability. 
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Figure 3.8 DTG supresses migration. Raw 264.7 cells were plated in wells of a 24 well plate at a concentration of 1x104 
cells/well and stimulated with 10µM ATP, 100ng/ml BDNF and a combination of ATP and BDNF, with or without 100µM 
DTG. Cells were observed migrating over a period of 17 hours at 37◦C and 5% CO2. Cells were tracked using the Manual 
Tracking plugin software and ImageJ. N=15 tracks per condition. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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The next step of inquiry was to characterise the effects of Sigma-1 antagonism and 
agonism on invasion of primary bone marrow-derived macrophages. In BMMs cells 
exposed to IPAG invade into the Matrigel™/Fibronectin matrix significantly 2.5-fold more 
than in the control condition (Figure 3.10). DTG also significantly decreased invasion as 
shown previously. Invasion over 30µm in ATP + BDNF conditions again showed a significant 
decrease when compared to ATP alone (2.2-fold). There was no change in invasion towards 
ATP + BDNF when cells were treated with DTG, but interestingly, when cells were treated 
with IPAG, invasion towards ATP + BDNF was significantly increased 2-fold, thus potentially 
rescuing the BDNF effect in this condition. Figure 3.10 shows results representative of 3 
separate experiments. 
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Figure 3.9. The effects of the Sigma receptor antagonist, IPAG on the invasion of Raw 264.7 cells through a 
Matrigel™/Fibronectin matrix. Raw 264.7 cells were allowed 48 hours to invade into a Matrigel™/Fibronectin 
matrix towards 10µM ATP, 100ng/ml BDNF or the combination of ATP + BDNF, with or without the addition of 
30µM IPAG. Afterwards all live cells were stained with a Calcien-AM dye and Transwells™ were imaged using a 
Leica confocal microscope every 15µm through 210µm, a representative of images taken from each condition 
is shown beneath the graph. Invasion over 30µm was then quantified using ImageJ image analysis software. 
Each bar represents the mean ± 1 S.E.M. N = 6 (3 fields from 2 separate Transwells™). P value calculated by 
students’ t-test * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
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Figure 3.10. The effects of Sigma receptor agonism, by DTG, and antagonism, by IPAG on the invasion of BMM through a 
Matrigel™/Fibronectin matrix. BMMs were allowed 48 hours to invade into a Matrigel™/Fibronectin matrix towards 
10µM ATP, 100ng/ml BDNF or the combination of ATP + BDNF, with or without the pre-treatment of either 
100µM DTG or 30µM IPAG. Afterwards all live cells were stained with a Calcien-AM dye and Transwells™ were 
imaged using a Leica confocal microscope every 15µm through 210µm, a representative of images taken from 
each condition is shown beneath the graph. Invasion over 30µm was then quantified using ImageJ im
analysis software. Each bar represents the mean ± 1 S.E.M. N = 6 (3 fields from 2 separate Transwells™). P 
value calculated by students’ t-test * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. N.E = not tested. 
N.E 
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3.3.4. Elucidating mechanisms behind ATP-induced invasion and the attenuation of 
migration via BDNF, and Sigma-1 receptor agonism. 
It was of interest to explore the cell signalling mechanisms behind ATP-induced invasion, 
and BDNF attenuation of ATP-induced invasion, initially focusing on the p38-MAPK 
pathways, which was previously implicated in ATP signalling (Trang et al., 2009).  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
40 
35 
p38 
50 
40 
35 
p-p38 
U
n
tr
ea
te
d
 
Control 10µM ATP 
 15m        60m  15m        60m 
50 
40 
35 
50 
40 
35 
U
n
tr
ea
te
d
 100ng/ml  
BDNF 
 ATP  
+ BDNF 
 15m        60m  15m        60m 
p38 
MW 
MW 
p-p38 
Figure 3.11. p38 is activated after 15 minutes stimulation with ATP, and repressed with 
ATP+BDNF stimulation. Activation of p38 was explored using western blotting methods. Here we 
show the total p38 (expected size 41 kDa), and activated phosphorylated form p-p38 in response 
to stimulation with 10µM ATP, 100ng/ml BDNF or a combination of ATP + BDNF for either 5, 15, 30 
or 60 minutes before cell lysis and protein extraction. This figure has been determined from 1 gel, 
n=1. 
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Raw 264.7 cells were grown until confluent then made quiescent in serum free growth 
media. Cells were then treated with stimulants including 10µM ATP, 100ng/ml BDNF or a 
combination of ATP + BDNF. Control conditions received a media change, whereas the 
untreated control did not receive a media change. Cells were then lysed as described on 
chapter 2. 
At 15 minutes of ATP stimulation, an increase of phosphorylation was seen when 
compared to the untreated control, and the control conditions (Figure 3.11), at 60 minutes 
of ATP stimulation; the level of phosphorylation appears reduced, but not returned to 
control levels. BDNF stimulation does not appear to have much of an effect on 
phosphorylation levels at either 15 or 60 minutes. After 15 minutes stimulation, the 
phosphorylation in ATP+BDNF is markedly reduced from the level of phosphorylation 
resulting from ATP alone. However, at 60 minutes, the phosphorylation appears to be at 
the same level as ATP alone, suggesting a short term effect in cells treated with both ATP 
and BDNF.  
Figure 3.12 explores the activation of ERK1/2 (expected size 42/44kDa, respectively) 
upstream of. In this blot although the exposure of the gel is weak, we see increased 
phosphorylation in the control condition at 30 minutes stimulation; however, this may be 
due to an increased level of total ERK1/2 (possibly due to an increased level of protein 
loaded into the gel). When stimulated with 10µM ATP, phosphorylation appears to be 
increased at 60 minutes, but at no time-point before this. In the combination of ATP + 
BDNF, there appears to be a very slight phosphorylation, which is sustained until 30 
minutes, but reduced back to untreated control levels by 60 minutes – and thus markedly 
reduced when compared to the phosphorylation seen with ATP alone.  
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Figure 3.12. BDNF abrogates ATP-induced ERK1/2 phosphorylation after 60 minutes of stimulation. Activation of 
ERK1/2 was explored using western blotting methods. Here we show that the total ERK 1/2 (expected size 42/44 
kDa respectively), and its activated form pERK1/2 in response to stimulation to 10µM, 100ng/ml BDNF or a 
combination of ATP + BDNF for either 5, 15, 30 or 60 minutes before cell lysis and protein extraction. This figure is 
a representative of 1 gel. N=1. 
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3.3.5. Investigating the effects of Sigma-1 receptor on the invasion and signalling of 
Raw 264.7 macrophages. 
To further explore the effects of Sigma-1 receptor in macrophage invasion, the next step 
was to employ siRNAs targeting Sigma-1 to knock down the expression of the receptor. 
Raw 264.7 cells were transfected using a set of four siRNAs each targeting different regions 
of the OPSR1 gene (sequences published in chapter 2), or siRNAs with a scrambled 
sequence.  
After 48hrs exposure to the siRNAs, cell lysates were collected to ensure that the sigma-1 
receptor protein levels were indeed reduced. Figure 3.13 shows the resulting blot from 
this experiment.  
 
 
 
 
 
 
 
 
 
25 
35 
+v
e 
co
n
tr
o
l 
C
o
n
tr
o
l 
Sc
ra
m
b
le
 
K
n
o
ck
d
o
w
n
 
Figure 3.13. Western blot to determine Sigma-1 receptor expression in Raw 264.7 cells. After 48 hours treatment 
with siRNAs targeting the OPRS1 gene, encoding Sigma-1 receptor, cell lysates were collected prior to Western 
blotting for sigma-1 receptor. Lane 1: Lysate from growing Raw 264.7 cells. Lane 2: Control, cells treated with 
transfection reagent alone. Lane 3, Scramble: cells treated with siRNAs with scrambled sequences. Lane 4, 
Knockdown: cells treated with siRNAs targeting OPRS1, n=2 separate experiments. 
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In Figure 3.13, a strong signal in the positive control, from a lysate of exponentially growing 
Raw 264.7 cells was observed. Weaker signals in both the scramble and control conditions 
and thus it is difficult to draw firm conclusions but in the knockdown condition, there is a 
very weak signal for sigma-1 receptor suggesting possible silencing of sigma-1 receptor 
protein levels. 
Using cells treated with siRNAs targeting sigma-1 receptor, and those with scrambled 
sequences, an inverted invasion assay was performed, using ATP and ATP + BDNF as 
chemoattractants. In the scramble conditions, the cells behave as previously seen, with 
cells attracted to ATP resulting in a 2.7-fold significant increase compared to the control 
condition. ATP + BDNF leads to a 1.6-fold significant decrease in invasion compared to ATP 
conditions, similar to data previously shown (Figure 3.14). 
However, with cells transfected with siRNAs targeting OPSR1, it was found that there was 
an overall increase in the amount of invasion when compared to those cells with scrambled 
siRNA. This resulted in a 3-fold increase between scramble control and knockdown control, 
and a rescue of the ATP + BDNF scramble condition, up 2.1-fold (Figure 3.14). This 
experiment is representative of 3 separate experiments. 
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Figure 3.14. Investigating the effect of a Sigma-1 knockdown using siRNAs on the invasion of Raw 264.7 through a 
Matrigel™/Fibronectin matrix towards ATP and BDNF. Cells were allowed 48 hours to invade into a Matrigel™/Fibronectin matrix 
towards 10µM ATP, 100ng/ml BDNF or the combination of ATP + BDNF, with the prior transfection of either Scramble 
siRNAs or siRNA targeting OPSR1 (Sigma-1 receptor). Afterwards all live cells were stained with a Calcien-AM dye and 
Transwells™ were imaged using a Leica confocal microscope every 15µm through 210µm, a representative of images taken 
from each condition is shown beneath the graph. Invasion over 30µm was then quantified using ImageJ image analysis 
software. Each bar represents the mean ± 1 S.E.M. N = 6 (3 fields from 2 separate Transwells™). P value calculated by 
students’ t-test * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
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3.4. Discussion 
In this chapter invasion and migration of macrophages in response to the extracellular 
nucleotide ATP was explored, along with invasion in response to BDNF and the 
combination of ATP and BDNF. Certain mechanisms which may underlie these 
observations were explored including the possible role of the Sigma-1 Receptor in 
macrophage migration. 
It was found that ATP significantly increased invasion of Raw 264.7 cells and primary bone 
marrow-derived macrophages through a Matrigel™/Fibronectin matrix. This is supported 
by several other studies such as Lambert et al¸ 2010, who discovered that both adult and 
fetal human microglial migrated towards ATP in a Boyden chamber assay, and that human 
monocyte migration was enhanced with a low concentration of ATP (1-10µM). Ohsawa et 
al, 2010 observed microglia extending processes towards ATP in a Boyden chamber assay, 
and suggest that integrin-β1 may play an important role in the migration of microglia 
towards ATP (Ohsawa et al., 2010, Lambert et al., 2010). However, it has been suggested 
that ATP is released at the leading edge of neutrophils, and acts only as a chemokinetic 
factor, and guides circulating leukocytes to other chemoattractants (Chen et al., 2006). 
Kronlage et al, (2010) showed that macrophage migration towards C5a depends on 
autocrine release of ATP and direct activation of relevant purinergic receptors resulted in 
membrane ruffling reminiscent of lamellpodial formation (Kronlage et al., 2010). However 
in a subsequent study these authors reported that ATP was not chemoattractive for 
murine peritoneal macrophages in 2D or 3D (Isfort et al., 2011).  
Purinergic receptor antagonists BBG, Suramin and PPADs on ATP significantly decreased 
invasion towards 10µM ATP. These results suggest that macrophage migration towards 
ATP is dependent on a number of purinergic receptors – including P2X4, P2X7, P2Y2, P2Y6 
and P2Y12. There is some supporting evidence in the literature, P2Y12 is thought to be 
responsible for microglial process extension, although it has also been suggested that P2Y6 
and P2Y2 are also important in migration of microglia (Ohsawa et al., 2010, Koizumi et al., 
2013, Kim et al., 2012). In addition, P2X4 and P2X7 receptors have also been suggested to 
be of importance in cell migration (Horvath and DeLeo, 2009, Beggs et al., 2012, Nasu-Tada 
et al., 2006). From this experiment it is not possible to determine which receptor is 
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responsible for ATP-induced invasion, but future studies exploiting specific purinergic 
receptor blockade, such as 5-BDBD (a P2X4 receptor antagonist) or A-438079 (a specific 
P2X7 antagonist) may prove insightful (He et al., 2007, Balázs et al., 2013) in addition to 
siRNA approaches. 
It has been reported that P2X4 receptor activation by ATP results in the release of BDNF 
(Trang et al., 2009) and relating this to the scenario of neuropathic pain it was 
hypothesised in this thesis that macrophages at the site of injury will be exposed to both 
ATP and BDNF. It was found that the a combination of  BDNF caused a repression in the 
level of ATP-induced invasion of both Raw 264.7 and BMMs and this apparently novel 
observation could suggest a feedback mechanism to prevent further macrophage 
recruitment. BDNF may thus be neuroprotective, since fewer macrophages migrating to 
the site of injury would limit the release of pro-inflammatory cytokines and chemokines, 
which trigger neuronal damage or apoptosis. 
There are several reports to suggest that BDNF is neuroprotective. It has been reported 
that P2X7 receptors and BDNF, along with NMDA converge on the PI3K pathway at GSK3 
in a PKC dependent manner and consequently lead to neuronal survival by reducing PI3K 
inhibition (Ortega et al., 2010). The ERK pathway has also been shown to play a role in 
BDNF neuroprotection, and activation of ERK was revealed to prevent cortical neuron 
apoptosis (Hetman et al., 1999, Almeida et al., 2005). Reduced levels of BDNF have also 
been linked to reduced neuroprotection in MS (Azoulay et al., 2008). 
BDNF signals through TrkB, which then leads to the phosphorylation of PLCγ, and can also 
lead to the phosphorylation of MAPK and PI3K, causing a cascade of intracellular signalling 
and result in a range of activities. Once PLCγ is activated, the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate occurs, thus producing diacylglycerol (DAG) and 
inositol 4,5-triphosphate (IP3). DAG  activates protein kinase C and IP3 can release calcium 
from its intracellular stores (Yoshii and Constantine-Paton, 2010).  
Signalling mechanisms underpinning the repression of ATP-induced invasion by BDNF 
revealed that BDNF treatment in combination with ATP suggest reduced activation of ERK 
1/2 and p38 MAP kinases. ATP has been shown to invoke phosphorylation of ERK 1/2 and 
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p38 in various cell types previously (Trang et al., 2009, Tsuda et al., 2012, Inoue and Tsuda, 
2009, Beggs and Salter, 2010).  
Mizoguchi and colleagues previously found that BDNF increased intracellular calcium 
concentration though PLCγ activation and also sustained this increase in microglia, unlike 
ATP, which resulted in a transient increase in calcium levels. It is suggested that BDNF may 
have an unknown additional mechanism to activate microglia (Mizoguchi et al., 2014).  
The effects of Sigma-1 receptor were also examined. Sigma-1 receptor has previously been 
found to supress many functions of microglia (Hall et al., 2009) and also has links with 
BDNF. Sigma-1 Receptor has been found to be neuroprotective in some scenarios such as 
hypoxia and β-amyloid neurotoxicity (Ruscher et al., 2011). Fujimoto and colleagues in 
2012 discovered that Sigma-1 agonism can potentiate post-translational processing of 
BDNF. It has also been proposed that Sigma-1 receptor is capable of modulating inter-
organelle signalling, and thus altering reactions to certain extracellular signals (Fujimoto et 
al., 2012, Su et al., 2010). 
The effects of the agonism of Sigma-1 receptors by DTG were investigated, the results of 
which were that DTG supresses both Raw 264.7 cell invasion and migration, and can 
supress the invasion of BMMs. These findings are similar to the findings of Hall et al, 2009, 
where it was found that sigma-1 agonism by 100µM DTG could reduce microglial 
migration. Antagonism of Sigma-1 by IPAG was also explored, it was observed that sigma-
1 antagonism induced macrophage invasion into a Matrigel™/Fibronectin matrix, but did 
not enhance ATP-induced invasion. Interestingly, we also report that in BMMs, (and at 
least a trend in Raw 264.7 cells) IPAG was able to overcome the suppression of invasion 
observed with BDNF + ATP, suggesting a possibility that Sigma-1 receptor could be involved 
in BDNF abrogation of ATP-induced invasion. It should be noted however that IPAG 
treatment alone also induced Raw 264.7 cell invasion – this may be because IPAG has 
previously been shown to be invoke calcium signalling (Brimson et al, 2011). 
The role of Sigma-1 receptor in invasion was further explored using a gene silencing 
approach. The knockdown of Sigma-1 receptor resulted in the increase of invasion of Raw 
264.7, and was able to rescue the abrogation of ATP-induced invasion by BDNF. BDNF is 
known to signal through PLCγ, and sigma-1 receptor has been reported to be able to 
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modulate Trk B signalling though PLCγ, suggesting a potential mechanism of cross-talk 
between BDNF and Sigma-1 receptor (Yagasaki et al., 2006), see figure 3.15. 
 
Figure 3.15. A Diagram to demonstrate the potential mechanism for ATP-induced invasion and BDNF 
attenuation. ATP, which is quickly broken down to ADP by apyrase, activated purinergic receptors and leads 
to activation of ERK1/2-p38 MAP kinase pathway, which in turn leads to increased cell migration. Trang et 
al, 2009 also observed a release in BDNF after activation of this pathway. BDNF acts through TrkB which leads 
to activation of PLCγ, leading to an increased intracellular calcium. In this chapter, it is speculated that Sigma-
1 receptor is agonised and translocates to modulate TrkB signalling, which could lead to the abrogation of 
ATP-induced cell migration through currently unknown mechanisms.  
Here, we report for the first time (to our knowledge) that BDNF is capable of reducing the 
invasion of macrophages through a mechanism linked to the activation of Sigma-1 
receptor, however, the mechanism remains yet to be elucidated. Since microglia and 
possibly macrophages produce BDNF endogenously, one could speculate that the 
reduction in invasion would result in a reduction in recruitment of further microglia, could 
result in an overall reduction in further BDNF production. The reduction of BDNF produced 
would reduce the risk of the disinhibition of lamina 1 neurons and therefore a reduction 
in painful signalling.  
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Chapter 4: Exploring the Matrix 
Metalloproteinase response of 
Macrophages upon ATP stimulation. 
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4.1. Introduction 
4.1.1. Matrix metalloproteinases and their inhibitors.  
Matrix Metalloproteinases (MMPs) were thought to act primarily to catabolise 
components of the extracellular matrix and can thus be divided into groups dependent on 
their extracellular matrix specificity, including, collagenases, stromelysins, matrilysisns and 
gelatinases, along with the membrane type MMPs (Parks et al., 2004, Gill and Parks, 2008). 
MMPs have previously been associated with cell migration, having a role in cells to break 
down matrix components, and thus migrate through the cellular microenvironment. 
Recently, however, it has been found that MMPs can cleave a wide variety of extracellular, 
bioactive substances and regulate the activity of these proteins – including, but not limited 
to; the release of growth factors from the extracellular matrix or the cell membrane, the 
shedding of cell adhesion molecules, activation of other MMPs and cleavage of growth 
factor receptors (Parks et al., 2004, Nuttall et al., 2007, Gill and Parks, 2008, Wolf et al., 
2013, Murray et al., 2013). 
The function of MMPs in vivo depends on the balance between them and their inhibitors. 
Tissue Inhibitors of Metalloproteinases (TIMPs) are the endogenous inhibitors of MMPs, 
of which there are four members. TIMPs inhibit MMPs through interaction of the N-
terminal domain of the TIMP, which co-ordinates with the Zn2+ containing catalytic site of 
the MMP, thus binding in a similar manner to the MMP and its intended substrate (Gill and 
Parks, 2008, Parks et al., 2004). However, there are other inhibitors of MMPs such as α2-
macroglobulin (an inhibitor of many proteinases), which is produced in the liver and found 
in circulating blood (Kessenbrock et al., 2010, Hopps and Caimi, 2012). 
4.1.2. MMPs in cell migration.  
Interstitial cell migration is a multistep process, consisting of pseudopod protrusion at the 
leading edge of the cell; integrin mediated adhesion of the cell to the extracellular matrix, 
cleavage of extracellular matrix by cell-surface expressed proteases, contraction of the cell 
body and then a rear retraction and translocation of the cell body (Wolf et al., 2013, Fisher 
et al., 2009). In mesenchymal derived cells, interstitial invasion is controlled by MMPs, in 
particular MMP-14 (Miyazawa et al., 2013, Wolf et al., 2013).  
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MMPs are also crucial in leukocyte migration – the process by which leukocytes adhere to 
endothelial cells by first rolling, then adhering, and finally extravasation through the vessel 
wall into the extracellular matrix. It has previously been found that monocytes and other 
peripheral blood leukocytes require the production of MMPs to move through basement 
membranes, with specific importance attributed to the role of the gelatinases – MMP-2 
and MMP-9, which are capable of degrading specific proteins in the basement membrane 
(Robinson. S.C., 2002). 
As macrophages are a key cell in the innate immune system, it is of fundamental 
importance that they have the ability to mobilise in response to external signals, such as 
cytokines and trauma, and therefore, MMPs may play a major role in the remodelling of 
the extracellular matrix to allow macrophages and circulating monocytes to follow these 
signals. Robinson et al, established that the exposure of peripheral blood monocytes to 
chemoattractants could indeed result in the increased expression of MMPs.   
 4.1.3. MMPs in Neuropathic Pain. 
There appears to be an early and late phase response to spinal nerve ligation in DRG 
satellite cells, and MMP-9 has been seen to be swiftly upregulated (Kawasaki et al., 2008, 
Lakhan and Avramut, 2012, Tsuda et al., 2012, Chattopadhyay et al., 2007, Buss et al., 
2007), followed by a late-phase response increase of MMP-2. Vereyken et al, 2011 argues 
that after peripheral nerve injury, the MMP response could lead to increased axonal 
damage (Vereyken et al., 2011). Bradykinin, implicated in pain responses, can modulate 
MMP expression in a number of cell types (Yoo et al., 2011) including macrophages 
(Abdulkhalek et al., 2012). In the CNS, BDNF expression has been correlated with that of 
MMP9 (Colak et al., 2012) and of interest is the recent observation that MMP9 can degrade 
the BDNF receptor, TrkB (Navaratna et al., 2013). 
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4.2. Hypothesis and Aims 
Hypothesis: Since ATP induced the invasion of both primary macrophages and Raw 264.7 
cells through a Matrigel™/Fibronectin matrix it is possible that MMPs may be regulated in 
this context. 
Aims: 
To explore if ATP could act by inducing the expression of MMPs and to determine the 
response of macrophages to other stimuli, including the inflammatory pain related 
molecule Bradykinin and BDNF, alongside the well-known MMP regulator, bacterial 
pathogen associated molecular pattern marker, LPS. 
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4.3. Results 
4.3.1. MMP expression is altered after 24 hours stimulation with ATP, Bradykinin and 
LPS.  
 
The expression of MMPs explored by Raw 264.7 cells was explored in response to 
stimulation with physiologically relevant concentrations of the extracellular signalling 
molecule ATP, the pain-associated molecule - Bradykinin, and the TLR4 agonist and 
pathogen associated molecule – LPS. Bradykinin was chosen to be explored due to its 
known role in inflammatory pain, and as such, it was intended to explore any similarities 
between the modulation of MMP expression between ATP and Bradykinin.  
The expression of all matrix metalloproteinases and tissue inhibitors of metalloproteinases 
was investigated in response to either a control condition (serum-starved for 24hrs) or 
24hr stimulation with 1mM ATP, 1mM Bradykinin or 100ng/ml LPS. A summary of MMP 
and TIMP expression change can be seen in Figure 4.1. As it was desired to focus on the 
expression levels of MMPs in more detail, and to focus primarily on genes which displayed 
a change in expression, figure 4.1 and 4.2 display the results of the only experiment. For 
reference, figure 4.2 displays the findings of this experiment as a 2ΔCT change. Later it was 
desired to focus solely on the alterations of MMP expression in response to ATP, a “heat 
map” of MMP and TIMP expression in response to either ATP or LPS only was produced 
and can be found in the appendix.  
In figure 4.1, it is highlighted that there is a significant increase in the levels of expression 
of MMP-8 in response to ATP and Bradykinin, whereas MMP-13 expression is significantly 
increased in response to stimulation with ATP and LPS. It is also evident that TIMP-2 is the 
only detectable TIMP in Raw 264.7 cells, and this expression is significantly increased in 
response to 1mM ATP stimulation. These findings are elucidated in further detail in figure 
4.2. 
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Condition 1mM ATP 1mM Bradykinin 100ng/ml LPS 
McolA Not Expressed Not Expressed Not Expressed 
McolB Not Expressed Not Expressed Not Expressed 
MMP-2 ↔ Not Expressed Not Expressed 
MMP-3 Not Expressed Not Expressed Not Expressed 
MMP-7 Not Expressed Not Expressed Not Expressed 
MMP-8 ↑* ↑* ↑ 
MMP-9 ↔ ↔ ↔ 
MMP-10 ↔ ↔ ↓ 
MMP-11 Not Expressed Not Expressed Not Expressed 
MMP-12 ↔ ↔ ↔ 
MMP-13 ↑* ↑ ↑* 
MMP-14 ↑ ↑ ↑ 
MMP-15 ↔ ↑ ↑ 
MMP-16 Not Expressed Not Expressed Not Expressed 
MMP-17 Not Expressed Not Expressed Not Expressed 
MMP-19 ↔ ↔ ↑ 
MMP-20 Not Expressed Not Expressed Not Expressed 
MMP-21 ↔ ↔ ↔ 
MMP-23 Not Expressed Not Expressed Not Expressed 
MMP-24 Not Expressed Not Expressed Not Expressed 
MMP-25 ↔ ↑ ↑ 
MMP-28 ↑ ↑ ↔ 
---- ---- ---- ---- 
TIMP-1 Not Expressed Not Expressed Not Expressed 
TIMP-2 ↑* ↑ ↔ 
TIMP-3 Not Expressed Not Expressed Not Expressed 
TIMP-4 Not Expressed Not Expressed Not Expressed 
 
Figure 4.1. A table to show the expression of MMPs in response to 24hr stimulation with either ATP, 
Bradykinin or LPS in relation to the unstimulated control. Gene expression of the murine family of MMPs 
was explored using Taqman gene expression assays in the Raw 264.7 cell line in triplicated samples. Any 
samples in which the cycle threshold (CT) was below 40 or undetected are shown as “Not expressed”. In this 
table “↑” represents an increase in gene expression from the control, whereas “↓” represents a decrease 
in gene expression from the control, “↔” represents when gene expression remains unchanged from the 
control. “↑*” represents when the gene expression is significantly increased from the control condition. 
Significance was measured using Student’s t-test and significance assumes a p value of ≤0.05, n=3. 
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Figure 4.2. A graph to show the expression of MMPs in response to 24hr stimulation with either ATP, 
Bradykinin or LPS in relation to the unstimulated control. Gene expression of the murine family of MMPs 
was explored using Taqman gene expression assays in the Raw 264.7 cell line in triplicated samples in a 
graphical form, with raw CT values expressed as 2ΔCT. “*” represents when the gene expression is significantly 
increased from the control condition. Significance was measured using Student’s t-test and significance 
assumes a p value of ≤0.05, n=3 
 
Figure 4.3 explores the expression of the MMPs with a significant change in gene 
expression from the control, which consists of MMP-8, MMP-13 and TIMP-2. MMP-8 was 
found to be expressed in Raw 264.7 cells under control conditions with a CT value of 33.9, 
whereas treatment for 24 hours with 1mM ATP significantly increased the expression of 
MMP-8 two-fold, and lowers the CT value to 32.8. 24 hour treatment with Bradykinin was 
found to also significantly increase the relative level of MMP-8 almost five-fold. 24 hour 
treatment with LPS did not significantly alter the expression of MMP-8, but was found to 
slightly increase the relative level of expression.  
MMP-13 was shown to be well expressed in Raw 264.7 cells in control conditions with a CT 
value of 27.1, 24 hour treatment with 1mM ATP was found to significantly double the 
expression of MMP-13. After treatment with Bradykinin, there is a slight increase in the 
level of MMP-13 expression, although this is not significant. Treatment with LPS also leads 
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to a dramatic significant increase in the level of MMP-13 in Raw 264.7, leading to 
expression 80 times higher than that found in the control condition. 
Tissue Inhibitor of Metalloproteinases – 2 was found to be the only TIMP to be expressed 
in Raw 264.7 cells. 24hr treatment with ATP was shown to increase the relative expression 
levels 2.5 fold. Bradykinin and LPS are shown not to have a significant effect on the 
expression of TIMP-2.
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Figure 4.3. MMP-8, -13, and TIMP-2 show a significant altered level of expression in Raw 264.7 cells when stimulated with ATP, Bradykinin or LPS. This figure summarises the sections of significant data that 
was found when the expression of MMPs and TIMPs was explored in Raw 264.7 cells in response to stimulation. qRT-PCR was performed on cDNA extracted from stimulated Raw 264.7 cells fter 24 hour 
stimulation with either 1mM ATP, 1Mm Bradykinin or 100ng/ml LPS. Statistical significance was determined using Student’s t-test. * = p ≤ 0.05, n=3. 
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Figure 4.4. MMP expression levels in Raw 264.7 cells after 24 hours treatment with either 10µM ATP, 1mM Bradykinin or 
100ng/ml LPS. Gene expression of the murine family of MMPs was explored using Taqman gene expression 
assays in the Raw 264.7 cell line in triplicated samples. This figure shows the gene expression changes for 
MMPs which were found to have insignificant changes regardless of treatment with ATP, LPS or Bradykinin. 
Statistical significance was measured using student’s t-test, n=3.  
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Figures 4.4 and 4.5 demonstrate a graphical representation of the results of the gene expression 
screen demonstrated in Figure 4.1. Figure 4.4 shows that Raw 264.7 expression of MMP-2 
decreases in expression with 24 hours treatment of all tested substances, to the point where it is 
no longer detectable. MMP-9 is shown to be unchanged by ATP or LPS treatments, but expression 
is found to rise by 3 fold with Bradykinin treatment. MMP-10 expression is relatively unchanged 
with ATP or Bradykinin treatment, although with LPS treatment, there appears to be a twofold 
decrease in expression when compared to the control.  
Figure 4.4 D shows the expression levels of MMP-12 in Raw 264.7 cells, with treatment of 
ATP for 24 hours resulting in a threefold increase in the expression of MMP-12, similarly, 
treatment with Bradykinin appears to increase expression to 5x the level of the control 
condition. LPS also induces expression to a level similar to the level seen in ATP induction 
of MMP-12. Levels of MMP-14 seem to remain relatively unchanged after stimulation and 
Figure 4.5. MMP expression levels in Raw 264.7 cells after 24 hours treatment with either 10µM ATP, 1mM Bradykinin or 
100ng/ml LPS. Gene expression of the murine family of MMPs was explored using Taqman gene expression assays 
in the Raw 264.7 cell line in triplicated samples. This figure shows the gene expression changes for MMPs which 
were found to have insignificant changes regardless of treatment with ATP, LPS or Bradykinin. Statistical 
significance was measured using student’s t-test, n=3. 
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with MMP-15, there is indeed a slight decrease in expression after treatment with ATP, 
although Bradykinin and LPS appear to slightly increase the expression of MMP-15. 
Figure 4.5 displays the results of the remaining matrix metalloproteinases, where trends 
in modulation of expression were observed. MMP-19 is shown to be relatively unchanged 
after 24 hours treatment with either ATP or Bradykinin, but after treatment with LPS, 
displays a 400fold increase. MMP-21 expression is relatively unchanged in any condition. 
MMP-25 was shown to be increased threefold in both Bradykinin and LPS conditions. 
Finally, MMP-28 expression was potentially increased threefold with ATP and LPS 
treatment, and twofold with Bradykinin treatment. 
 
4.3.2. MMP expression in response to stimuli over time.  
To investigate in more detail those MMPs expressed at detectable levels, the expression 
of MMPs in Raw 264.7 in response to ATP was explored through a time-course. 
Treatment with two concentrations of ATP, firstly at 10µM, included exploring potential 
effects of the activation of the P2X4 receptor, and 1mM ATP – to determine effects of the 
activation of the P2X7 receptor. LPS was also included as a positive control and to confirm 
findings as the effects of LPS stimulation on MMP expression is well characterised.  
Figure 4.6 shows a table summary of the results of the MMP time-course investigation. . It 
is of interest to note that both MMP-14 and MMP-28 were found to be undetected, 
considering their expression in the previous experiment summarised in figures 4.1 – 4.4. 
There is an increase in the level of MMP-8 at 8hrs in the control condition1, and an increase 
at both 4 and 8 hours with both 10µM ATP and 1mM ATP stimulation, where LPS provides 
a significant increase at both 24hrs and 48hrs after initial stimulation. MMP-10 was also 
found to be upregulated at 8 hours in both the control condition and after stimulation with 
10µM ATP. MMP-12 was found to be upregulated at 4 hours after stimulation with ATP at 
either concentration and MMP-13 was found to be upregulated at 8 hours in the control, 
                                                          
1 The control condition in these experiments is classed as a media change at the investigated time-point. As 
ATP can be released from all cells after stress (even as small as a media change), it is important to replicate 
these stress conditions. 
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4 hours with 10µM ATP and at 4 hours and 8 hours 1mM ATP. These results will be further 
analysed in figures 4.7 to 4.16. 
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Condition Control 10µM ATP 1mM ATP 100ng/ml LPS 
Time (hrs) 4 8 24 48 4 8 24 48 4 8 24 48 4 8 24 48 
MMP-8 ↔ ↑* ↔ ↔ ↑* ↑* ↔ ↔ ↑* ↑* ↔ ↑ ↑ ↑ ↑* ↑* 
MMP-10 ↔ ↑* ↔ ↑ ↑ ↑* ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↑ ↑ 
MMP-12 ↔ ↑ ↑ ↑ ↑* ↑ ↔ ↔ ↑* ↑ ↔ ↔ ↑ ↑* ↑ ↑ 
MMP-13 ↔ ↑* ↔ ↔ ↑* ↔ ↔ ↓ ↑* ↑* ↔ ↔ ↑ ↑ ↑ ↑ 
MMP-14 Not Expressed Not Expressed Not Expressed Not Expressed 
MMP-19 ↔ ↔ ↔ ↔ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 
MMP-28 Not Expressed Not Expressed Not Expressed Not Expressed 
TIMP-2 ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↓ ↑ ↔ ↔ ↔ ↔ 
Figure 4.6. Expression of MMPs over the course of 48hr stimulation with either 10µM ATP, 1mM ATP or 100ng/ml LPS in relation to the control. Gene expression of the 
murine family of MMPs was explored using Taqman gene expression assays in the Raw 264.7 cell line in quadruplicate samples. Any samples in which the cycle threshold (CT) 
was below 40 or undetected are shown as “Not expressed”. In this table “↑” represents an increase in gene expression from the control, whereas “↓” represents a decrease 
in gene expression from the control, “↔” gene expression remains unchanged from the control. “↑*” gene expression is significantly increased from the control condition. 
Significance was measured using Student’s t-test and significance assumes a p value of ≤0.05, n=4. 
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Figures 4.7 and 4.8 explore how the expression of MMP-8 changes over time in response 
to ATP and LPS stimulation. After the initial screen shown previously, bradykinin was no 
longer explored, whilst ATP was explored at 2 different concentrations - 10µM and 1mM 
– to determine if there is any difference between the activation of P2X4, and other 
purinergic receptors with 10µM ATP, or the desensitization of many purinergic receptors 
and the activation of P2X7 by 1mM ATP. Both figures show MMP expression as a fold 
change when compared to the ‘baseline expression’ of the MMP in Control conditions after 
4 hours after the media change. Figure 4.6 explores the expression of MMP-8 in response 
to stimulation over time, clustered to allow observation of changes caused by stimulant at 
a particular time-point, whereas 4.7 shows expression clustered per stimulant, to allow 
observation of the effect of time. 
From Figure 4.7, it is shown that MMP-8 (Collagenase-2) is significantly upregulated after 
stimulation with ATP at both 10µM ATP and 1mM ATP at 4hrs from 1, to 48.61 and 18.27 
respectively, indicating that ATP induces an increased transcription of MMP-8. LPS at 4hr 
stimulation leads to an insignificant rise in MMP-8 expression. ATP at both 10µM and 1mM 
concentrations leads to a further rise in expression of MMP-8 after 8 hours of stimulation, 
four-fold with 10µM ATP, and almost ten-fold with 1mM ATP.  
After 24hrs, the significant rise in MMP-8 by ATP falls down to less than control levels – 
with a 2-fold decrease from control conditions seen at 24hrs stimulation with 10µM ATP. 
However, at 24hrs stimulation with LPS leads to a 12 fold increase in expression when 
compared to the control conditions. After 48 hours, MMP-8 expression is raised by 
stimulation with both 1mM ATP, and LPS.  
Figure 4.8 demonstrates the changes that occur over time within groups of stimulation. In 
the control conditions (which at each time point represent a media change), lead to an 11-
fold rise in MMP-8 expression at 8hrs, which falls to a 2-fold increase at 24hrs. 10µM ATP 
stimulation leads to an early rise in MMP-8 expression (48 fold the control levels at 4hr), 
which remains stable until 24hrs, when there is a significant decrease in MMP-8 expression 
to 1.2 fold control levels (at 4hrs).  
1mM ATP expression over time shows an early rise in MMP-8 levels, compared to the 
control – with a 4hr level of 18-fold control levels, which peaks at 8hr at 108 fold. Similarly 
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to 10µM ATP, 1mM ATP stimulation leads to a fall in MMP-8 expression at 24hrs, but there 
is a slight increase seen at 48hrs, to almost 10 fold control levels. LPS, shows an 
insignificant rise in MMP-8 expression, until 48hrs, when there is a significant increase in 
MMP-8 expression, suggesting that LPS drives a late-phase response of MMP-8 expression.  
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Figure 4.7. Expression of MMP-8 over 48 hours expressed in time-clusters. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS on the expression of MMP-8 were 
explored over 48 hours. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as a fold change when compared to the expression at 4 hours. Statistical significance 
was determined using Student’s t-test, * = p<0.05. n=4. 
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Figure 4.8. Expression of MMP-8 in response to stimuli over time. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS were explored, and MMP expression measured 
after 4hrs, 8hrs, 24hrs, and 48hrs. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as a fold change relevant to the unstimulated control level. Statistical 
significance was determined using Student’s t-test, * = p<0.05. 
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Figures 4.9 and 4.10 demonstrate the response of MMP-10 expression in Raw 264.7 cells 
during the time-course. Whilst the majority of expression changes in response to stimuli 
appear insignificant, at 8 hours, it is possible to see a significant three-fold increase in the 
expression of MMP-10 after stimulation with 10µM ATP (but not 1mM ATP), although at 
other time points, expression remains relatively unchanged.  
LPS leads to a trend increase in expression of MMP-10 at 24hrs and 48hrs (to 35 fold 
control levels at this time-point), again indicative of a late-phase response, however, 
neither of these changes were found to be significant. 
Figure 4.10 displays MMP-10 changes in response to time per stimulant. Here, it is 
possible to observe a significant change between the control condition at 4 and 8 hours 
up two-fold, and then back down to baseline levels at 24 hours. Whilst 10µM ATP 
stimulates Raw 264.7 cells to express MMP-10 highly at 4 and 8 hours, after 24 hours 
there is a significant drop at 24 hours back to control baseline levels – suggesting an early 
phase response. A similar early phase response pattern can be seen after stimulation 
with 1mM ATP.  
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Figure 4.9. Expression of MMP-10 over 48 hours expressed in time-clusters. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS 
on the expression of MMP-10 were explored over 48 hours. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as a fold 
change when compared to the expression at 4 hours. Statistical significance was determined using Student’s t-test, * = p<0.05. n=4. 
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Figure 4.10. Expression of MMP-10 in response to stimuli over time. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS were explored, and MMP 
expression measured after 4hrs, 8hrs, 24hrs, and 48hrs. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as a fold change relevant to the 
unstimulated control level. Statistical significance was determined using Student’s t-test, * = p<0.05. 
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The expression profile of MMP-12 was next explored, the results of which are shown in 
figures 4.11 and 4.12. Figure 4.11 demonstrates the effect of stimuli at multiple time-
points, at the 4hr point, there is a significant increase from the control condition to 10µM 
ATP to 11.4-fold, and a similar increase after 1mM ATP stimulation to 6.2-fold control 
levels.  
Throughout the time-course experiment, there is an increased expression of MMP-12 after 
LPS stimulation of Raw 264.7 cells, although this increase is more marked (but p>0.05) 
towards the late-stage of the time-course, at 8hrs, there is a significant increase at 8 hours 
when compared to the control value.  
Figure 4.12 shows that there is relatively little change in MMP-12 expression levels in 
stimuli clusters dependent on time, although there is a slight increase after 8hrs 
stimulation with 1mM ATP. LPS mediated expression of MMP-12 rises dramatically 
towards the 48 mark, however, these results were not found to be significant.  
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Figure 4.11. Expression of MMP-12 over 48 hours expressed in time-clusters. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml 
LPS on the expression of MMP-12 were explored over 48 hours. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as a 
fold change when compared to the expression at 4 hours. Statistical significance was determined using Student’s t-test, * = p<0.05. n=4. 
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Figure 4.12. Expression of MMP-12 in response to stimuli over time. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS 
were explored, and MMP expression measured after 4hrs, 8hrs, 24hrs, and 48hrs. MMP expression was normalised to the housekeeping gene YWHAZ, 
and is displayed as a fold change relevant to the unstimulated control level. Statistical significance was determined using Student’s t-test, * = p<0.05. 
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The expression of MMP-13 after stimulation in Raw 264.7 cells was next explored, the 
results of which are displayed in figures 4.13 and 4.14. In these figures, due to large 
changes in the expression of MMP-13 throughout the time-course period, the data is 
expressed on a logarithmic scale.  
From figure 4.13, it is possible to see that at 4hrs, stimulation with ATP at either 
concentration tested leads to a significant increase in the expression of MMP-13. 10µM 
ATP leads to an increase in MMP-13 expression to 57.5-fold that of control levels, whereas 
1mM ATP leads to a 75-fold increase in the expression of MMP-13. LPS is also shown to 
increase MMP-13 expression, however, this result was not found to be significant.  
At 8hrs, the effect of MMP-13 expression induced by stimulation with 10µM ATP is lost, 
and falls back to control levels (however, figure 4.14 displays that at 8hrs, the control 
condition influences a significant increase in the expression of MMP-13 – possibly due to 
the stress exerted on cells by a media change). 1mM ATP is shown to retain a significant 
increase in the expression of MMP-13 at 8 hours. Similarly, LPS is shown to retain an 
increase in stimulation, but this is not significant until 24 hours – where LPS is 120-fold that 
of the control levels at this time-point. A further increase can be seen at 48 hours, 
however, error bars are large and thus the result was found to be not significant.  
Figure 4.14 shows a range of changes seen over time in response to stimulation. From this 
graph, it is possible to see significant increases from the control at 4hrs at the 8hr time-
point, which then significant falls at 24 hours. The expression profile of MMP-13 in 
response to 10µM ATP shows an early-phase response profile – whereby there is a 
significant down-regulation of MMP-13 expression at 24 and 48hr time-points, when 
compared to 4 and 8 hour time-points. This pattern can also be seen when Raw 264.7 cells 
are stimulated with 1mM ATP.  
LPS is shown to lead to consistently high levels of expression, starting at 47-fold control 
levels at 4hours, there is an increase in the expression of MMP-13 in LPS stimulated cells 
at 24 hours, again, this suggests that LPS stimulation of Raw 264.7 cells leads to a later-
stage MMP-response. 
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Figure 4.13. Expression of MMP-13 over 48 hours expressed in time-clusters. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS 
on the expression of MMP-13 were explored over 48 hours. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as a fold 
change when compared to the expression at 4 hours. Statistical significance was determined using Student’s t-test, * = p<0.05. n=4. 
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Figure 4.14. Expression of MMP-13 in response to stimuli over time. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS were 
explored, and MMP expression measured after 4hrs, 8hrs, 24hrs, and 48hrs. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as 
a fold change relevant to the unstimulated control level. Statistical significance was determined using Student’s t-test, * = p<0.05, ***= p<0.001. 
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Next, the expression of TIMPs was explored, it was found from the previous screen that 
only TIMP-2 was expressed in Raw 264.7 cells. Figure 4.15 and figure 4.16 display the 
results of the TIMP-2 expression time-course.  
Figure 4.15 demonstrates that the expression level of TIMP-2 remains largely unchanged 
in the early phases of the time-course, however, at 24 hours, in contrast to the result found 
in figure 4.1 and figure 4.2, it is possible to see a significant reduction from the control 
level of TIMP-2, to the level of TIMP-2 expression when cells are stimulated with 1mM ATP. 
Although general expression is found to rise at 48 hours, there is a notable significant 
decrease in the expression of TIMP-2 in 10µM ATP stimulated cells, and 1mM ATP 
stimulated cells from the control level.  
Figure 4.16 demonstrates that in the control conditions, at 48hours, the expression of 
TIMP-2 is significantly induced 2.5 fold when compared to earlier expression levels. It is 
also shown that there is a rise in TIMP-2 expression after stimulation with 1mM ATP at 48 
hours, when compared to the level seen at 24 hours.  
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Figure 4.15. Expression of TIMP-2 over 48 hours expressed in time-clusters. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS on the 
expression of TIMP-2 were explored over 48 hours. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as a fold change when compared 
to the expression at 4 hours. Statistical significance was determined using Student’s t-test, * = p<0.05. n=4. 
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Figure 4.16. Expression of TIMP-2 in response to stimuli over time. The effects of an unstimulated control, 10µM ATP, 1mM ATP and 100ng/ml LPS were explored, and 
MMP expression measured after 4hrs, 8hrs, 24hrs, and 48hrs. MMP expression was normalised to the housekeeping gene YWHAZ, and is displayed as a fold change 
relevant to the unstimulated control level. Statistical significance was determined using Student’s t-test, * = p<0.05, ***= p<0.001. 
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4.3.3. The Effects of BDNF on MMP Expression. 
In an attempt to confirm the findings of the previous sections, and to also explore the 
effects of BDNF stimulation on Raw 264.7 macrophages, the expression of key MMPs 
MMP-8. MMP-12, MMP-13 and TIMP-2 were explored after 8 hours of treatment with 
10µM ATP and 100ng/ml BDNF, in combination and alone in 3 separate experiments. The 
results of a representative experiment in each case (aside from MMP8 where amplification 
was only seen in one further experiment) can be seen in Figure 4.17. 
 
Figure 4.17 The effects of 8hr stimulation of Raw 264.7 cells with ATP and BDNF. Gene expression of the murine 
family of MMPs was explored using Taqman gene expression assays in the Raw 264.7 cell line in 
quadruplicated samples. In this figure, MMP-8, MMP-12, MMP-13 and TIMP-2 gene expression was 
explored. Statistical significance was measured using student’s t-test, n=4. 
 
MMP-8 expression was shown to have a decrease in expression after stimulation with 
BDNF, or the combination of ATP and BDNF. However, all changes were shown to be 
insignificant. MMP-12 expression remains unchanged after treatment with ATP, and the 
combination of ATP and BDNF, although with BDNF treatment there is an 18-fold increase 
in MMP-12 when compared to the control condition. 
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MMP-13 expression is shown to be upregulated 3-fold by both ATP and BDNF treatments, 
although this is not significant, but in combination, these stimulants appear to show no 
change in MMP-13 expression. TIMP-2 has a trend increase to 4-fold the levels of the 
control, although this was found to be insignificant. 
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4.4. Discussion  
 
In this chapter, the expression levels of several MMPs in response to stimulation with ATP 
and LPS, including Bradykinin for the first part, were explored. A preliminary expression 
screen was performed to explore which MMPs were expressed in Raw 264.7 cells, and how 
ATP and LPS affected these levels. It was found that out of 12 expressed MMPs in Raw 
264.7, only MMP-8, and -13, were regulated by stimulation with ATP and/or LPS. 
The increase of MMPs upon stimulation with ATP could be responsible for the increased 
invasion seen in both Raw 264.7 and BMMs previously described in chapter 3. It would be 
ideal to measure the MMP expression of cells inside the invasion assay, however, to 
expose the cells to harsh treatment such as dispase could have an effect on MMP 
expression itself. However, measuring the MMP expression profile of cells inside the 
invasion assay should be considered in future studies.  
We observed that the expression levels of MMP-8, MMP-13 and TIMP-2 were all 
significantly altered after 24 hours stimulation with 1mM ATP. MMP-8 is also known as 
collagenase-2, whereas MMP-13 is collagenase-3. TIMP-2 is an inhibitor of matrix 
metalloproteinases, but also has a wider role in the activation of other MMPs (Hernandez-
Barrantes et al., 2002). 
MMP-8 is known as a tumour suppressive gene which has a variety of substrates ranging 
from collagen to non-matrix proteins such as angiotensin and chemokines – such as 
interleukins 6 and 8. Laxton et al, 2009, showed that by knocking out MMP-8 reduced 
atherosclerosis in mice, and that MMP-8 promotes atherosclerosis by increasing leukocyte 
rolling and thus migration into the blood vessel wall (Laxton et al., 2009). Quillard et al, 
2014 argues that MMP-8 may also be partially responsible for plaque rupture in 
atherosclerosis, as it serves to breakdown the wall of the atherosclerotic plaque. MMP-8 
has also been shown to play a role as a negative regulator of tumour progression in breast 
cancer, by activating interleukins 6 and 8 (Quillard et al., 2014, Thirkettle et al., 2013). 
MMP-8, along with MMP-12, is also thought to be involved in the regulation of 
inflammation due to its ability to cleave CXCL11 (Cox et al., 2008, Kessenbrock et al., 2010). 
CXCL11, also known as I-TAC, is a lymphocyte attracting chemokine, when cleaved at the 
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N-terminal there is an inactivation of the chemokine, but if cleaved again at the C-terminal 
by MMP-8, the chemokine is once more activated and is solubilised from the ECM (thus 
attracting lymphocytes).  
Despite reports that MMP-8 can modulate leukocyte migration, there have been no 
previous reports that macrophage stimulation with ATP can lead to an increase in the 
levels of MMP-8. In this model, it is speculated that an increase in MMP-8 can lead to an 
increase in inflammation, and could, for example, exacerbate the inflammation after nerve 
injury or in atherosclerosis by increased processing of pro-inflammatory cytokines and 
chemokines. 
MMP-13 is thought to be the main collagenase in mice, and is capable of hydrolysing many 
different collagen types, along with gelatin, aggrecan and Fibronectin, and MMP-13 is 
expressed in several tissues (Li et al., 2010, Waldman et al., 2010). MMP-13 is thought to 
also play a role in atherosclerosis and plaque rupture – predominating over MMP-8 as the 
functional collagenase in mouse atheroma (Quillard et al., 2014). It is also thought that 
collagenases such as MMP-8 and MMP-13 are important in facilitating nerve repair after 
peripheral injury as excess collagen is produced, which hinders the growth of new axons 
and thus limits regeneration attempts (Koopmans et al., 2009). 
In this chapter, it is reported that after stimulation with ATP, there is indeed an increase in 
the expression of MMP-13 in Raw 264.7 macrophages. Previous studies have shown that 
in bovine articular oesteoclasts, high doses of ATP elicited a two-fold increase in the 
expression of MMP-13 – a similar result to that shown in figure 4.3 (Waldman et al., 2010). 
It has also been shown that extracellular ATP enhances the invasion of prostate cancer 
cells in vitro, via a mechanism of activating Rho GTPase and upregulating MMP-13 (Zhang 
et al., 2010) - thus providing support for the hypothesis that ATP promotes invasion of 
macrophages through the increased expression of MMPs.   
TIMP-2 is also upregulated after 24 hours stimulation with 1mM ATP, which could possibly 
suggest that the increased MMPs were simply being inhibited, and thus inactive in inducing 
invasion. However, TIMP-2 can also indirectly lead to an enhancement of pro-MMP-2 
activation by presentation to  MT1-MMP (MMP-14) facilitating processing of pro-MMP2 
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to its active form, thus supporting pericellular proteolysis and in fact, enhancing invasion 
(Hernandez-Barrantes et al., 2002, Parks et al., 2004).  
The expression levels of these MMPs over time were also explored. These results do not 
strictly agree with the results from the previous screen of MMP expression (figures 4.1-
4.4), in that neither MMP-14 and MMP-28 are undetected in the time-course experiment, 
and that the expression of MMP-8 and MMP-13 is no longer significantly upregulated at 
24 hours when stimulated with 1mM ATP – although a significant increase is seen at an 
earlier time-point. Nonetheless, it is important to note that MMP-8 and MMP-13 are 
indeed expressed very highly in relation to the control conditions at earlier time-points, 
and thus be worthy of further investigation in ATP-induced invasion of macrophages.  
In the time-course experiment performed, it was found that there are significant changes 
within the control condition over time. As the control condition represents a media change 
at the specific time-point, this can result in cellular stress which can include a release of 
intracellular ATP at small levels. Any changes in the control conditions may be due to the 
effects of the cellular stress of a media change. During the course of investigation, the 
measurement of ATP release was attempted using a bioluminescence assay for 
quantitative determination of ATP based on the mechanism of luciferase ATP requirement 
to produce light. However, these attempts were unsuccessful (data not shown).  
It should also be noted that there are no significant expression level changes to TIMP-2 
found in this time-course experiment. 
MMP-10 is shown to be elevated when compared to the control at 8 hours when 
stimulated with 10µM ATP. MMP-10 is also known as stromelysin-2, and has previously 
been found to be essential for the migration and invasion of macrophages (Murray et al., 
2013), and is also thought to contribute to monocyte migration and blood brain barrier 
disruption in cerebral adrenoleukodystrophy (Thibert et al., 2012).  
MMP-12 (macrophage metalloelastase) expression levels were shown to be expressed at 
a significantly higher level than that seen in the control conditions after 4 hour stimulation 
with both high and low doses of ATP. MMP-12 has previously been shown to be essential 
for macrophage infiltration, with mutations leading to a lack of macrophage migration 
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(Haq et al., 2011). Taken together, this result provides further evidence that MMPs may 
be involved in ATP-induced invasion of macrophages. 
ATP stimulation has previously been found to influence the activity of MMPs, for example, 
it has been found that the stimulation of BV2 microglial cells leads to an increase in the 
level of urokinase-type plasminogen activator (uPA), which is known to influence MMP 
activation. ATP induced uPA increase was found, in this system to lead to the upregulation 
of MMP-9 activity (Shin et al., 2010). ATP has previously been found to induce the 
migration of glial cells via activation of P2X7 receptor. In a study by Murphy and Lynch, the 
upregulation of MMP-9 produced in microglia by ATP was shown to be accompanied by a 
decrease in TIMP-1. It was found that ATP also induced the activation of Cathepsin B, which 
in turn degrades TIMP-1, thus inducing glial cell migration by an increase in MMP activation 
and a decrease in TIMP-1 activity (Murphy and Lynch., 2012). 
The effects of BDNF on MMP expression observed were mixed with a trend towards 
reduced MMP8 expression (where BDNF was added with ATP) but enhanced MMP12 
expression (where BDNF was added alone). 
In conclusion, MMP expression is apparently regulated in Raw 264.7 macrophages by 
exogenous ATP and some of the trends observed may correlate with enhanced invasion. 
BDNF may suppress certain MMP expression but seems to be context-dependent. It would 
also be of interest to determine if the macrophage migration seen is MMP-dependent 
using broad spectrum MMP inhibitors such as GM-6001, and other specific MMP inhibitors 
– such as blocking antibodies to specific MMPs, before moving onto knockdown 
experiments using siRNAs. Overall further study is required since there were 
inconsistencies between experiments. 
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Chapter 5: An exploration into the 
effects of Apolipoprotein E subtype and 
a Fish Oil supplemented diet on primary 
macrophage migration. 
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5.1. Introduction 
5.1.1. ApoE in Atherosclerosis.  
Atherosclerosis is the major underlying cause of heart attacks and strokes, and thus is 
responsible for over 50% of all deaths in the western world. Although atherosclerosis is a 
multifactorial disease, it can be considered an inflammatory disease, caused by injury to 
the endothelial lining of the artery wall – thus leading to changes in the permeability in the 
arterial wall, increased expression of cell surface adhesion molecules and production of 
cytokines (Kleemann et al., 2008, Guns et al., 2010, Koupenova et al., 2012, Li et al., 2014b). 
The progression of atherosclerosis is fully outlined in chapter 1.  
ApoE is thought to be potently anti-atherogenic, and it has been found that in humans and 
other animals that decreased expression of ApoE is associated with a pro-atherogenic 
lipoprotein profile and atherosclerotic disease (Mahley and Rall, 2000, Greenow et al., 
2005, Curtiss, 2000). As mentioned earlier, ApoE knockout mice are prone to 
atherosclerosis and extremely hypercholesterolaemic compared to wild type mice – the 
hypercholesterolaemia is due to impaired clearance of lower density lipoproteins, with 
complex atherosclerotic lesions forming even if the ApoE null mice are fed a low fat diet. 
In ApoE knockout mice, atherosclerosis regresses when ApoE is restored (van den Elzen et 
al., 2005, Greenow et al., 2005, Brown et al., 2008). 
Although ApoE is usually absent in normal vessels, its expression is high in atherosclerotic 
plaques (Greenow et al., 2005, Cudaback et al., 2011), where it is believed to be 
synthesized locally by resident macrophages. The anti-atherogenic role of ApoE is 
multifaceted, with ApoE playing a role in several processes, including (but not limited to): 
reverse cholesterol transport and hepatic uptake of lipoprotein particles, inhibition of LDL 
oxidation, anti-inflammatory activity, and the inhibition of T-lymphocyte activation and 
proliferation, platelet aggregation, and both smooth muscle cell and endothelial cell 
proliferation. ApoE has a key role in the regulation of overall lipoprotein metabolism and 
transport and thus is an important protein in anti-atherogenic function (Mahley et al., 
2009, Mahley and Rall, 2000, Quillard et al., 2014).  
The Framingham Heart Study (2004) showed that there is a connection between the ApoE 
genotype and the onset of carotid atherosclerosis, which was defined as intimal-medial 
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thickness (IMT). Whilst it was found that the ApoE2 homozygous genotype showed the 
lowest thickness, whereas ApoE3 displayed a slightly thicker IMT. Individuals with the 
ApoE4 genotype displayed the largest IMT, suggesting that ApoE4 is related to a higher risk 
of atherosclerosis, with ApoE2 having the lowest risk (Elosua et al., 2004).  
Mahley et al, 2009 suggests that the structural changes in ApoE isoforms are due to the 
polymorphisms in the alleles are the cause of their altered function, thus causing 
differences between how the N- and C-terminals interact. The C-terminal domain of ApoE 
is predicted to form amphipathic α-helices that are responsible for lipid binding. ApoE2 
and ApoE3 preferentially bind small, phospholipid rich HDL, whereas ApoE4 binds 
preferentially to large triglyceride rich VLDL (Mahley et al., 2009).  
X-ray crystallography reveals differences in ApoE isoforms in the orientation of side chains 
and alterations in the rearrangements of salt bridges. In ApoE4, Arg-112 and Glu-109 form 
a salt bridge – this causes the Arg-61 side chain to extend away from the helix bundle, 
whereas in ApoE3, the side chain is buried.  The orientation of Arg-61 in ApoE4 encourages 
domain interaction with Glu-255 in the lipid binding region, thus causing ApoE4 to have a 
more compact conformation than ApoE3. Domain interaction is a key structural property 
in all proteins, in ApoE4, this domain interaction could be important in many of its 
pathogenic effects (Mahley et al., 2009, Mahley and Rall, 2000).  
 
5.1.3. Fish Oils. 
There have been many epidemiological and observational studies on the effects of omega-
3 polyunsaturated fatty acids (PUFAs) on cardiovascular disease outcomes. Most evidence 
of the benefits of omega-3 PUFAs were obtained from eicosapentaenoic acid (EPA) and 
docosahexanoic acid (DHA). Humans get omega-3 PUFAs from fish oils, although the 
original source of omega-3 is marine microorganisms (Monk et al., 2013). 
PUFAs are thought to be beneficial because they are known to reduce hepatic synthesis of 
triglycerides and increase hepatic fatty acid oxidation. Although total cholesterol levels are 
unaffected by the consumption of PUFAs, the concentrations change – LDL cholesterol 
concentrations tend to rise by 5-10%, and HDL cholesterol levels rise by 1-3%, Serum 
Page | 136  
 
triglycerol concentrations are found to decrease by 25-30% (Marai and Massalha, 2014, 
Bargut et al., 2014).  
Low levels of cardiovascular disease in populations with high fish intake – such as those 
seen in Alaskan natives, Japanese, and Greenland Eskimos suggests that there may be a 
link between the consumption of fish and protection against cardiovascular disease (von 
Schacky et al., 1985). A large body of epidemiologic data from randomised control trails 
suggests that EPA and DHA relay a cardioprotective action. Thus, there is a case to propose 
that the intake of fish oils such as EPA and DHA are indeed beneficial to those at risk from 
cardiovascular disease (Calder, 2006, Grimble, 2007). 
The current American Heart Association dietary guidelines recommend combined EPA and 
DHA at a dose of 1000mg/day, which equates around 2 oily fish meals per week, for the 
secondary prevention of coronary heart disease (Marai and Massalha, 2014). It is also 
thought that a high intake of fish oil may lower blood pressure in hypertensive patients, 
and be beneficial to patients with inflammatory diseases such as rheumatoid arthritis 
(Calder, 2001).  
5.1.4. MMPs. 
As explored in Chapter 1, MMPs are of particular interest in the disruption of the arterial 
wall and the processes which lead up to the rupture of the plaque, especially those 
belonging to the collagenase family. It is suggested that the mechanism behind the 
increased expression of MMPs is driven by oxidative stress, although it is also inferred that 
thrombin and the plasminogen cascade may play a role in the activating of MMPs, the 
former in a positive feedback loop (Galis and Khatri, 2002).  
Recently, it has been found that MMP-12 overexpression leads to accelerated plaque 
development, whereas in MMP-12-/- mice, plaque development is greatly reduced, and 
selective MMP-12 inhibitors have been shown to promote a stable plaque (Johnson et al., 
2011, Scholtes et al., 2012). Whilst there are many studies which link the expression and 
activation of MMPs in atherosclerosis, and the promotion of either a stable or unstable 
plaque phenotype, exploration of dietary aspects remains limited.  
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5.2. Hypothesis and Aims.  
Hypothesis: dietary n3-fatty acids can have effects on macrophage migration and MMP-
expression which are revealed in ex vivo analysis. 
Aims: 
To determine the effect of the ApoE subtype, as well as the effect of the intake of fish oils 
on macrophage migration, in response to ATP, MCP-1 and Interleukin-10 (IL-10) in these 
cells. It is also an aim to determine the expression of certain MMPs in these primary 
macrophages from diet-fed mice and to explore how the treatments described previously 
can modulate MMP regulation. 
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5.3. Results 
 
5.3.1. The Effect of ApoE subtype and a fish oil-supplemented high fat diet on 
macrophage migration.  
 
The effect of ApoE subtype, diet and stimulation on the random migration of primary 
murine macrophages was explored. Primary murine macrophages were isolated from 
adult mice with a homozygous humanized ApoE3 or ApoE4, which were fed on either a 
High Fat Diet (HFD), or a High Fat Diet supplemented with Fish Oils EPA and DHA (HFD+FO). 
Bone marrow-derived macrophage precursors were differentiated in vitro in accordance 
to the protocol outlined in Chapter 2.1.2 and purity was determined by staining with F4/80, 
as outlined in Chapter 2.11.  
After differentiation, the macrophages were cultured in 2D on plastic for 3 hours before 
addition of the tested stimulants and subsequent time-lapse microscopy was performed.  
The average speed of macrophages from mice with the ApoE3 genotype and a HFD, the 
speed remained similar regardless of stimulation with MCP-1, ATP and MCP-1 + IL-10 It is 
interesting here to note that the macrophages taken from mice fed on a diet 
supplemented with fish oils travel around significantly faster (1.8-fold) than their 
counterparts fed on HFD alone. Again, macrophages from ApoE3 mice fed on a HFD+FO 
diet, macrophages migrated at a similar speed regardless of stimulation – although at 
around 42µm/hr – with the exception of macrophages stimulated with MCP-1, which 
migrated more slowly than untreated cells (not significant).  
The migration speed of ApoE4-mouse derived macrophages was similar to that seen in the 
ApoE3 cells. Migration speeds for macrophages from mice in the ApoE4 + HFD diet range 
from 20µm/hr to 25µm/hr, with no significant differences between the different stimulus 
conditions.  
Fish Oil dietary supplementation led to a significant increase in macrophage migration 
speed when compared to ApoE4 + HFD diet cells. As in ApoE3 mouse derived cells, the 
effect of the fish oil diet was to increase macrophage migration speed by 2-fold in all 
conditions. In the MCP-1 condition,  MCP-1 treatment was the only condition which also 
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demonstrated a difference between ApoE subtype – with the ApoE4 subtype + fish oil 
supplementation leading to a 1.3 fold increase compared to the condition for that of ApoE3 
+ Fish oil.  
Since no effect was seen in random migration experiments, some preliminary data was 
obtained using chemotaxis assays, which shows that IL-10 was able to abrogate MCP-1 
induced chemotaxis (See appendix). Unfortunately many cells died in the Ibidi chambers 
and thus further analysis was not possible.  
Figure 5.1. A graph to show the average migration speed (µm/hr) of primary murine macrophages 
derived from mice with a humanised ApoE3 or ApoE4 knock-in, fed on either a HFD or a HFD+FO 
diet (standard high fat diet supplemented with EPA and DHA  fish oils). Macrophages were 
subjected to control conditions (blue bar), stimulation with 100ng/ml MCP-1 (red bar), stimulation 
with 10µM ATP (green bar) and a combination of 100ng/ml Interleukin-10 and 100ng/ml MCP-1 
(purple bar). This graph is the combination of the results from three separate experiments (with 3 
mice in each), in which 10 individual cells from three separate wells were tracked, thus giving an 
n=90 cells in all conditions unless otherwise stated in the individual bars. Bars shown are mean ±1 
S.E.M *** = p<0.001 when compared to the results from the control diet value from the same 
stimulation. 
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5.3.2. The Effect of ApoE subtype and a fish oil-supplemented high fat diet on 
macrophage production of MMPs. 
 
 MMP expression of the isolated primary macrophages was measured and is reported in the 
following section. Figure 5.2 demonstrates the expression of MMP-13 in the primary 
macrophages explored in this chapter, after challenging with the stimulants MCP-1, ATP, 
IL-10 and a combination of MCP-1 and IL-10. There was a slight increase in the expression 
of MMP-13 in both ATP and IL-10 stimulated cells, although these are not significant 
(Figure 5.2.A). When the combination of MCP-1 and IL-10 is added to the ApoE3 HFD cells, 
there is a decrease in the expression of MMP-13 which is significantly less than the level 
when compared to stimulation of cells with just MCP-1.  
The effects of stimulation on the expression of MMP-13 in ApoE4 HFD cells are 
demonstrated in Figure 5.2.B, no difference in the expression of MMP-13 after 8 hours 
stimulation was observed with MCP-1, ATP, IL-10 or the combination of MCP-1 and IL-10. 
In cells from ApoE3 mice fed on a HFD+FO diet, expression does increase to 1.5-fold when 
the cells are stimulated with ATP, IL-10 and the combination of MCP-1 and IL-10, but this 
does not reach significance. In figure 5.2.D, the expression of MMP-13 remains at the level 
of the control with all tested stimulants.  
Reanalysis of the data in terms of diet for ApoE3 cells (Figure 5.3.A) revealed significant 
changes in the expression of MMP-13 in untreated, ATP- and MCP-1 treated cells, In ApoE4 
cells (Figure 5.3.B), FO diet resulted in an apparent 5-fold suppression of MMP-13 
expression in cells stimulated with MCP-1, ATP or IL-10. 
 
Page | 141  
 
 
 
Figure 5.2. Expression of MMP-13 in primary murine macrophages. Graphs show 
expression of MMP-13 in either (A) Primary macrophages derived from mice with a 
humanised ApoE3 knock-in fed on a high fat diet (B) Primary macrophages derived from 
mice with a humanised ApoE4 knock-in fed on a high fat diet (C) Primary macrophages 
derived from mice with a humanised ApoE3 knock-in fed on a high fat diet supplemented 
with EPA and DHA, or (D) Primary macrophages derived from mice with a humanised 
ApoE4 knock-in fed on a high fat diet supplemented with EPA and DHA. MMP-13 
expression was measured using Taqman on RNA derived using a cells to CT© kit and 
analysed using the 2ΔΔCT method, results are normalised to 18s and displayed as a fold 
change relative to the control condition, these graphs represent the result of one 
experiment. n=4. Bars shown are mean ± 1 S.E.M *** = p<0.001. 
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Figure 5.3. MMP-13 expression in comparison to either diet or ApoE subtype. (A) shows the comparison between MMP expression in both High Fat Diet or in High Fat 
diet supplemented with Fish Oils (EPA and DHA) in ApoE3 knock in macrophages (B) shows the comparison between MMP expression in both High Fat Diet or in High Fat 
diet supplemented with Fish Oils (EPA and DHA) in ApoE4 knock in macrophages. (C) shows the comparison between MMP expression in both ApoE3 knock-in and ApoE4 
knock-in macrophages from mice fed on a high fat diet, whereas (D) shows the comparison between MMP expression in both ApoE3 knock-in and ApoE4 knock-in 
macrophages from mice fed on a high fat diet supplemented with fish oils. MMP-13 expression was measured using Taqman on RNA derived using a cells to CT© kit and 
analysed using the 2ΔΔCT method, results are normalised to 18s and displayed as a fold change relative to the high fat diet result in A and B, or to the E3 result in C and D 
, these graphs represent the result of one experiment. n=4 unless otherwise stated, bars shown are mean ± 1 S.E.M.
Page | 143  
 
Comparison of MMP-13 expression by ApoE subtype in the HFD fed mice revealed that 
there were no significant differences between the ApoE3 macrophages and the ApoE4 
macrophages derived from mice fed on the HFD diet (Figure 5.3.C).  The response of ApoE4 
macrophages to ATP, MCP-1 or IL-10 were apparently more sensitive to the FO diet than 
ApoE3 cells (Figure 5.3.D). This contrasts with the observations on macrophages from mice 
on HFD alone (see above). 
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Figure 5.4. Expression of MMP-15 in primary murine macrophages. Graphs show 
expression of MMP-15 in either (A) Primary macrophages derived from mice with a 
humanised ApoE3 knock-in fed on a high fat diet (B) Primary macrophages derived from 
mice with a humanised ApoE4 knock-in fed on a high fat diet (C) Primary macrophages 
derived from mice with a humanised ApoE3 knock-in fed on a high fat diet supplemented 
with EPA and DHA, or (D) Primary macrophages derived from mice with a humanised ApoE4 
knock-in fed on a high fat diet supplemented with EPA and DHA. MMP-15 expression was 
measured using Taqman on RNA derived using a cells to CT© kit and analysed using the 2ΔΔCT 
method, results are normalised to the value for 18s and displayed as a fold change relative 
to the control condition, these graphs represent the result of one experiment. n=4 unless 
otherwise stated. Bars shown are mean ± 1 S.E.M * = p<0.05. 
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Figure 5.4 shows the expression of MMP-15 in response to stimulation from all four sets 
of cells. MMP-15 is also known as MT2-MMP, and is responsible for cleavage of 
proteoglycans, it was chosen to be further investigated due to a moderately high 
expression seen in experiments performed in Chapter 4.  Figure 5.4 A shows the response 
from the ApoE3 HFD macrophages. MMP-15 expression appears unchanged by MCP-1 or 
IL-10 treatment, but, in the combination of IL-10 + MCP-1, there is a 2-fold significant 
decrease when compared to MCP-1 treatment alone. Expression of MMP-15 in ApoE4 cells 
from mice fed on a HFD diet is largely unchanged in response to all treatments (Figure 
5.4.B) thus indicating a potentially altered response of ApoE4 cells to MCP1+ IL10..  
The expression of MMP-15 in ApoE3 cells derived from mice fed on a HFD + FO diet is 
shown in Figure 5.4.C. In this figure, although observations are not significant it is possible 
to see that after stimulation with MCP-1, MMP-15 expression drops to around 0.4 fold the 
control value, whereas in ATP, IL-10 and IL-10 + MCP-1, the expression of MMP-15 rises to 
around1.8 fold the level of the control conditions.  
In ApoE4 cells from mice fed on a HFD+FO, there appears to be a 1.5-fold increase in MMP-
15 when cells were stimulated with MCP-1 and ATP. Stimulation with IL-10 and a 
combination of IL-10 + MCP-1 also results in a slight increase in expression of MMP-15 (1.5 
fold and 1.3 fold control levels respectively), however, no changes were significant. 
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Figure 5.5. Expression of MMP-15 in comparison to either diet or ApoE subtype. (A) shows the comparison between MMP expression in both High Fat Diet or in High Fat diet 
supplemented with Fish Oils (EPA and DHA) in ApoE3 knock in macrophages (B) shows the comparison between MMP expression in both High Fat Diet or in High Fat diet 
supplemented with Fish Oils (EPA and DHA) in ApoE4 knock in macrophages. (C) shows the comparison between MMP expression in both ApoE3 knock-in and ApoE4 
knock-in macrophages from mice fed on a high fat diet, whereas (D) shows the comparison between MMP expression in both ApoE3 knock-in and ApoE4 knock-in 
macrophages from mice fed on a high fat diet supplemented with fish oils. MMP-15 expression was measured using Taqman on RNA derived using a cells to CT© kit and 
analysed using the 2ΔΔCT method, results are normalised to 18s and displayed as a fold change relative to the high fat diet result in A and B, or to the E3 result in C and D , 
these graphs represent the result of one experiment. n=4 unless otherwise stated, bars shown are mean ± 1 S.E.M 
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In figure 5.5.A it is observed that in control conditions, the HFD + FO fed mice lead to 
macrophages with a 2-fold reduction in MMP-15 expression than in those cells that were 
derived from mice on the HFD diet, a similar story is seen in MCP-1 stimulated cells, with 
the HFD + FO cells expressing less than a fifth MMP-15 than seen in the HFD cells. In ATP 
stimulated cells however, there appears to be no difference. In IL-10 and IL-10 stimulated 
cells, MMP-15 is only slightly decreased in the HFD+FO condition (0.8 fold and 0.95 fold 
respectively). 
In Figure 5.5.B, we see the effect of the diet in ApoE4 cells, here it appears that there is no 
change when cells are stimulated with MCP-1. However, when stimulated with ATP, MMP-
15 expression is decreased by 10 times in HFD+FO cells, this decrease was not found to be 
significant, a trend change was seen. There are negligible changes to MMP-15 expression 
in both IL-10 and IL-10 + MCP-1 conditions. 
Next, the effect of ApoE subtypes was explored. In figure 5.5.C, the difference in HFD cells 
is explored; however, there are minimal changes dependent on the ApoE subtype.  
Figure 5.5.D shows the difference in HFD+FO cells between the ApoE3 variant and ApoE4 
variant cells. There is a similar pattern to that of Figure 5.5.B, in which there is a small 
decrease of MMP-15 expression in the control conditions between E4 cells and E3 cells, 
and almost no difference in the MCP-1 stimulated cells. However, in ATP there is a large 
decrease of MMP-15 in E4 cells when compared to E3 cells. There are small insignificant 
changes in the MMP-15 expression levels between E3 and E4 cells in the IL-10 and IL-10 + 
MCP-1 conditions.  
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Figure 5.6. Expression of TIMP-2 in primary murine macrophages. Graphs show expression 
of TIMP-2 in either (A) Primary macrophages derived from mice with a humanised ApoE3 
knock-in fed on a high fat diet (B) Primary macrophages derived from mice with a humanised 
ApoE4 knock-in fed on a high fat diet (C) Primary macrophages derived from mice with a 
humanised ApoE3 knock-in fed on a high fat diet supplemented with EPA and DHA, or (D) 
Primary macrophages derived from mice with a humanised ApoE4 knock-in fed on a high fat 
diet supplemented with EPA and DHA. TIMP-2 expression was measured using Taqman on 
RNA derived using a cells to CT© kit and analysed using the 2ΔΔCT method, results are 
normalised to the value for 18s and displayed as a fold change relative to the control 
condition, these graphs represent the result of one experiment. n=4 unless otherwise stated. 
Bars shown are mean ± 1 S.E.M * = p<0.05. 
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As seen in figure 5.6.A, in ApoE3 HFD cells, there is no change in the expression of TIMP-2 
in MCP-1 and ATP conditions, when compared to the control condition. However, in both 
IL-10 and IL-10 conditions, there appears to be a decrease in the TIMP-2 expression level, 
to 0.6 times that of the control level in IL-10 stimulated conditions, and 0.7 times that of 
the control levels in IL-10 + MCP-1 stimulated cells.  
Figure 5.6.B shows TIMP-2 expression in ApoE3 HFD+FO cells, here it is observed that MCP-
1 stimulation leads to a decrease in the amount of TIMP-2 expressed, down to 0.4 times 
that seen in the control value. There is a very minor decrease in the level of TIMP-2 after 
stimulation with ATP. In both IL-10 and IL-10 + MCP-1, compared to the control conditions, 
there is a decrease in TIMP-2 expression, to half that of the control conditions. 
In figure 5.6.C, we explore the effect of stimulation of ApoE4 HFD cells, in MCP-1 and ATP 
stimulated cells, it is possible to see an increase in the level of TIMP-2 expression up to 3 
fold, and 3.5 fold the control levels respectively. In IL-10 stimulated cells, there is also a 
rise in the level of TIMP-2 expression, up to 1.8 fold, and there is also a rise in TIMP-2 
expression seen in IL-10 + MCP-1 stimulated cells, up to 2 fold the expression of TIMP-2 in 
the control cells.  
Figure 5.6.D investigates the TIMP-2 expression in ApoE4 cells derived from mice fed on a 
HFD+FO diet. After 8 hours of MCP-1 stimulation, there is a slight increase in the expression 
of TIMP-2, although in ATP stimulated cells there appears to be very little difference. 
Stimulation of these cells with IL-10 leads to a decrease down to around half the amount 
of TIMP-2, when compared to control conditions. IL-10 + MCP-1 conditions were shown to 
raise TIMP-2 expression, up to 1.5 times the control level. 
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Figure 5.7. Expression of TIMP-2 in comparison to either diet or ApoE subtype. (A) shows the comparison between TIMP expression in both High Fat Diet or in High Fat diet supplemented 
with Fish Oils (EPA and DHA) in ApoE3 knock in macrophages (B) shows the comparison between TIMP expression in both High Fat Diet or in High Fat diet supplemented with 
Fish Oils (EPA and DHA) in ApoE4 knock in macrophages. (C) shows the comparison between TIMP expression in both ApoE3 knock-in and ApoE4 knock-in macrophages from 
mice fed on a high fat diet, whereas (D) shows the comparison between TIMP expression in both ApoE3 knock-in and ApoE4 knock-in macrophages from mice fed on a high fat 
diet supplemented with fish oils. TIMP-2 expression was measured using Taqman on RNA derived using a cells to CT© kit and analysed using the 2ΔΔCT method, results are 
normalised to 18s and displayed as a fold change relative to the high fat diet result in A and B, or to the E3 result in C and D , these graphs represent the result of one experiment. 
n=4 unless otherwise stated, bars shown are mean ± 1 S.E.M 
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Figure 5.7.A displays the comparison of TIMP-2 between ApoE3 mice fed on either a HFD 
or a HFD+FO diet. Here it is possible to see a 0.7-fold decrease in the expression of TIMP-
2 in the control condition, which falls to 0.4-fold upon MCP-1 stimulation – although this 
was found to be not significant. The fish oil supplemented diet leads to a slight reduction 
of TIMP-2 expression in other stimulants.  
Figure 5.7.B shows the difference in diet in ApoE4 mice. In these cells, large decreases in 
TIMP-2 expression are shown after stimulation with MCP-1, ATP and IL-10, however, these 
were not significant. 
The difference between macrophages obtained from ApoE3 and ApoE4 mice fed on a HFD 
are little, although in the control condition, it can be observed that ApoE4 mice express 
0.5-fold TIMP-2 levels than ApoE3 mice (Figure 5.7.C). 
Again, Figure 5.7.D shows the difference between macrophages from ApoE3 and ApoE4 fed on a 
HFD+FO diet, which shows a similar pattern to 5.7.B. 
However, when the raw CT values from this experiment are displayed as a 2ΔCT expression graph, it 
is possible to see significant differences in the levels of TIMP-2 expressed between HFD and 
HFD+FO fed mice (figure 5.8). 
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Figure 5.8. Expression of TIMP-2 in comparison to either diet or ApoE subtype. (A) shows the comparison between TIMP expression in both High Fat Diet or in High Fat diet 
supplemented with Fish Oils (EPA and DHA) in ApoE3 knock in macrophages (B) shows the comparison between TIMP expression in both High Fat Diet or in High Fat diet 
supplemented with Fish Oils (EPA and DHA) in ApoE4 knock in macrophages. (C) shows the comparison between TIMP expression in both ApoE3 knock-in and ApoE4 knock-
in macrophages from mice fed on a high fat diet, whereas (D) shows the comparison between TIMP expression in both ApoE3 knock-in and ApoE4 knock-in macrophages 
from mice fed on a high fat diet supplemented with fish oils. TIMP-2 expression was measured using Taqman on RNA derived using a cells to CT© kit and results are expressed 
as the raw 2^deltaCT and displayed as a fold change relative to the high fat diet result in A and B, or to the E3 result in C and D, these graphs represent the result of one 
experiment. n=4 unless otherwise stated, bars shown are mean ± 1 S.E.M.
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In unstimulated cells derived from HFD+FO fed mice, there was an apparent 5-fold 
decrease in the expression of TIMP-2, although this did not reach significance. With all 
stimuli there was a 10-fold decrease in TIMP-2 expression in HFD+FO derived cells, when 
compared to HFD derived cells (Figure 5.8.A). 
Similarly, in ApoE4 cells, with all stimulated conditions, there was a 20-fold significant 
reduction in the levels of TIMP-2 in HFD+FO cells (Figure 5.8.B). TIMP-2 expression is 
apparently lower in ApoE4 cells than in ApoE3 cells (Figure 5.8.C), although no conditions 
reveals significance. 
The fish oil diet resulted in dramatic reduction in TIMP-2 expression in ApoE4 cells under 
all conditions compared to ApoE3 cells, although there is no significance in these 
reductions (Figure 5.8.D). 
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5.4. Discussion 
5.4.1. The Effect of Stimulation on migration and MMP expression of Primary Macrophages. 
In this chapter, the characteristics of primary macrophages derived from mice with a 
humanised ApoE3 knock-in, or a humanised ApoE4 knock-in gene were explored. In wild-
type mice, there is only 1 allele for ApoE, which is not identical to any human ApoE gene – 
but is thought to act similarly to ApoE4, therefore this could be responsible for some 
differences seen.   
5.4.1.1. Cell Migration: Effects of Exogenous Stimuli in vitro 
No significant differences in random migration speed were observed between stimulants 
in each set of macrophages studied. In essence, this suggests that each of these stimulants 
have no effect on the primary macrophages. However, it should be noted that MCP-1 is 
widely known to stimulate macrophage chemotaxis, and ATP is also widely known as a 
stimulus for macrophages (as seen in Chapters 3 and 4) (Hall et al., 2009, Kawamura et al., 
2012, Li et al., 2014b, Wang et al., 2014, Vogel et al., 2014). IL-10 is an anti-inflammatory 
cytokine, and an effect would be expected based on previous literature (Kleemann et al., 
2008). 
Here, it is suggested that in this particular migration experiment, with these particular 
conditions, that there is no change in the overall migration speed between stimulant 
effects, although this does not suggest no change in migration overall. Although, it is noted 
that perhaps in a chemotaxis assay, one would see an effect in which MCP-1 and ATP are 
seen to be chemoattractants, and thus affect the directionality of the migration. In the 
appendix, data is presented to support this hypothesis. Chemotaxis assays were 
performed on ApoE3 HFD derived macrophages, where it was seen that MCP-1 and ATP 
induced chemotaxis, but with the addition of IL-10 to MCP-1, preliminary data shows that 
the chemotactic ability of MCP-1 was completely and significantly abolished (See 
Appendix). Thus, suggesting that the addition of the anti-inflammatory cytokine can 
influence the migration of macrophages towards chemoattractants (Takayama et al., 
2001).  
5.4.1.2. The Effect of Exogenous Stimuli on MMP Expression 
Despite there being no changes in migration with the stimulants, there are some effects 
when MMP expression is observed, although due to time constraints, these are 
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preliminary data arising from experiments with cells from one mouse from each genotype 
and diet condition only. 
Interleukin-10 is a well-studied anti-inflammatory cytokine, and is usually 
immunosuppressive and can inhibit the production of pro-inflammatory cytokines such as 
TNFα, IL-1 and IL-6 and thus terminating the immune response (Lippitz, 2013). One would 
hypothesize that that IL-10 would limit the invasive/migratory capabilities of the primary 
macrophages studied – although this effect was not observed, the down-regulation of both 
MMP-13 and MMP-15 (collagenase-3 and MT2-MMP respectively) in ApoE3 HFD 
macrophages by IL-10 could be related to modulation of a migration phenotype in 3D or 
chemotaxis (see appendix). This regulation could also suggest that IL-10 could, in the 
context of atherosclerosis, work to make a plaque more stable – as collagen is the most 
abundant ECM component in the plaque. 
Previously, Interleukin-10 has been found to be able to modulate MMP-9 and TIMP-1 
expression in human macrophages and in peripheral blood mononuclear cells through the 
upregulation of TIMP-1, acting through adiponectin (Nold et al., 2003, Kumada et al., 
2004). 
It should be noted that in these experiments, ATP did not induce MMP-13 expression as 
previously seen in Raw 264.7 cell line (Chapter 4), but in this chapter, macrophages are 
derived directly from mice. 
 
5.4.2. The Effect of diet on macrophage migration and MMP expression.  
In this chapter, the effect of fish oils in a diet was explored in primary macrophages, and 
the data gathered has presented an argument in a favour of the hypothesis that diet can 
indeed affect the characteristics and behaviour of primary macrophages in vitro. 
5.4.2.1. Macrophage Migration and Diet 
The fish oil supplemented diet perhaps surprisingly resulted in primary macrophages with 
an increased migration speed in both ApoE3 and ApoE4 macrophages, irrespective of the 
exogenous stimuli. This is a novel finding, and although there are reports which indicate 
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that PUFA administration can affect macrophage migration and even tumour cell migration 
(Li et al., 2014a), there is no previous data available using an in vitro model.  
One would hypothesize that the increased migration of macrophages derived from mice 
fed with a HFD+FO have an increased speed due to increased surveillance or circulation. 
In the context of atherosclerosis – it is suggested that perhaps macrophages do not invade 
into the intima and continue to circulate, or move away from the atherosclerotic lesion. 
To our knowledge, the effect of a HFD on macrophage migration compared to a normal 
diet is unreported in the literature, therefore, it is unknown if HFD results in a change in 
migration compared to macrophages derived from mice on a normal diet, and in future 
experiments, a control should be added to test this effect. 
 
5.4.2.2. MMP Expression and Diet 
There is also evidence that the supplementation of a high fat diet with fish oil has an effect 
on the MMP production of macrophages. For example, in ApoE4 cells, there is a trend 
towards a decrease in the expression in MMP-13 in MCP-1, ATP and IL-10 treated cells, in 
those cells derived from mice fed on a fish oil supplemented diet. MMP-13 is collagenase-
2, and an increased expression would lead to plaque instability as more collagen would be 
lysed. Therefore the same is true for the opposite, and the decrease in MMP-13 could be 
beneficial, and therefore infer more stability into the plaque. However, this decrease in 
MMP-13 expression is only seen in ApoE4 expressing macrophages, and not ApoE3 
expressing macrophages - indicating that ApoE4 macrophages respond better to the FO 
diet. 
The most surprising result, however is the reduction of TIMP-2 expression by the fish oil 
diet, we observe that in both ApoE3 and ApoE4 cells, with all exogenous stimuli, there is a 
significant decrease in the level of TIMP-2 expressed (with TIMP-2 expression being at least 
tenfold less than in HFD conditions), and a trend decrease in the control conditions, when 
the raw CT values were analysed. This offers a potential mechanism behind why the 
HFD+FO macrophages migrate faster than the cells derived from HFD fed mice. As TIMP-2 
can inhibit all MMPs, a reduction in the level of TIMPs would mean more MMPs can be 
Page | 157  
 
active and thus contribute to the remodelling of the extracellular matrix, allowing 
macrophages to invade and migrate. 
The suggestion that n3 PUFAs can have long lasting effects upon the body was implied to 
as early as the 1980s.(Mahley, 1988, Calder and Kew, 2002) and many dietary intervention 
studies have further implicated PUFAs in beneficial roles.  
Previously, it has been found that n-3 PUFAs can be immunosuppressive, as they are able 
to decrease superoxide production, and leads to the replacement of arachodonic acid with 
EPA – meaning that instead of the well-known inflammatory molecule – prostaglandin E2, 
the less bioactive prostaglandin E3 is synthesized, thus leading to a decrease in 
inflammation (Thies et al., 2001, Grimble, 2007, Ohara et al., 1995, Warnholtz et al., 1999). 
Thies and colleagues found that a fish oil supplemented diet induced a decrease of 
expression of adhesion molecules such as sVCAM-1 and sE-selectin, thus suggesting that 
n-3 PUFAs act to decrease endothelial activation (Thies et al., 2001). It is important to note 
that the expression of adhesion molecules in endothelial cells is paramount to the 
development of atherosclerosis (as normal endothelium does not generally support 
leukocyte binding), in particular, the formation of the initial fatty streak, as the expression 
of VCAM-1, ICAM-1 and other adhesion molecules by endothelial cells is required to 
initiate leukocyte rolling and the migration of monocytes into the vessel wall. (Libby et al., 
2002, Laxton et al., 2009).  
Here, data is presented which confirms that diet can indeed have an effect on individual 
cellular functions, and that a fish oil supplemented diet alters the migration speed of 
primary macrophages, and can possibly influence the regulation of MMPs and TIMPs. The 
mechanism behind this remains unclear, but one can speculate that diet can have 
epigenetic effects, thus altering the behaviour of primary macrophages in response to 
certain stimuli. For example, epigenetic changes such as histone deacetylation (HDAC), 
DNA methylation and miRNA expression can lead to shifts in MMP expression. Culley et al, 
2013 showed that by inhibiting HDAC, then there was a repression of cytokine induced 
MMP expression in cartilage (Culley et al., 2013). In addition miRNA-29b has been shown 
to be upregulated by OxLDL, thus leading to MMP-2 and MMP-9 upregulation in 
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atherosclerosis (Chen et al., 2011), and in the context of cancer, a number of miRNAs have 
been shown to regulate cell migration and proliferation (Abba et al., 2014). 
5.4.3. The Effect of ApoE subtype on macrophage migration and MMP expression.  
The final objective of this chapter was to explore the differences that would arise from the 
different ApoE subtypes. In WT mice, ApoE is encoded by just a single variant, which is 
more homogenous to the human ApoE4 gene. However, in these mice, a humanised 
variant of ApoE3 or ApoE4 has been knocked in, in place of the natural, WT variant of the 
gene.  
The first difference in ApoE subtype is seen in Figure 5.1, although the difference is not 
obvious, in HFD+FO derived macrophages, there is a slight but significant increase in 
average migration speed in MCP-1 conditions in ApoE4 cells. 
In unstimulated cells there appear to be no major differences in MMP expression between 
the ApoE variants, although these changes may be subtle and overshadowed by the large 
effects of the differing diets. Regardless of this, in figure 5.8.C, we can observe that there 
is a trend towards a decrease in the levels of TIMP-2 in HFD derived E4 cells when 
compared to E3 cells. This decrease of TIMP-2 in ApoE4 cells could be linked to plaque 
instability, and thus be partially responsible for the detrimental prognosis of the ApoE4 
allele in atherosclerosis.  
Previous studies generally observe the difference between ApoE3 and ApoE4 in the 
context of Alzheimer’s disease, whereas studies focussing on atherosclerosis usually focus 
upon ApoE knockout models. Previous studies into the differences between the ApoE3/3 
genotype, and the ApoE4/4 genotype have shown that ApoE4 expressing macrophages 
and microglia have a stronger innate immune response including an increased NO 
production in response to IFNγ and LPS, along with an increased proinflammatory cytokine 
production (Colton et al., 2004, Vitek et al., 2009) 
It has been found previously that the possession of the ApoE4 allele, either hetero- or 
homozygously is associated with an increased activation of microglia, and a pro-
inflammatory state in vitro. 
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17β-estradiol is an anti-inflammatory agent capable of modulating the immune response 
of macrophages, and it is known that treatment of either macrophages or microglia with 
17β-estradiol results in the reduction of pro-inflammatory factors. Brown et al, 2008 
demonstrated that ApoE4 microglia and peritoneal macrophages responded differently to 
17β-etradiol than ApoE3 microglia and macrophages – leading to an increase in the 
amount of nitrite, TNFα and IL-6 produced in ApoE4 microglia, and a reduced response to 
17β-estradiol (Brown et al., 2008).  
Brown suggests that this decreased response to 17β estradiol is related to the differing 
levels of oestrogen receptor β levels, and that this may account partly for the pro-
inflammatory phenotype of ApoE4 microglia and macrophages. This suggests that the 
ApoE subtype favours a more pro-inflammatory response and is less responsive to anti-
inflammatory agents than the ApoE subtype (Brown et al., 2008). This may explain why 
ApoE3 HFD macrophages show a decreased production of MMP-13 and MMP-15 in 
response to treatment with IL-10, whereas ApoE4 macrophages do not. 
To conclude, the evidence that presented in Chapter 5 to some extent supports the idea 
that the ApoE4 results in altered macrophage responses when compared to cells derived 
from mice with the ApoE3 genotype. No major differences in random macrophage 
migration speed between those macrophages from ApoE3 mice and those from ApoE4 
mice, but unexpectedly in both genotypes the FO diet markedly enhance migration. 
 There is some evidence, however, that does support the case that ApoE4 may affect the 
modulation of anti-inflammatory agents – in ApoE3 cells derived from mice in fed on a high 
fat diet, IL-10 causes a reduction of MMP-13 and MMP-15 (supporting less migration which 
would be considered anti-inflammatory), but the ApoE4 counterparts fail to deliver this 
response to the anti-inflammatory agent. The situation is complex however since in mice 
fed with the FO diet, ApoE4 macrophages were more sensitive to these stimuli than ApoE3 
cells. 
Overall key findings in this Chapter relate to migration of primary macrophages and reveal 
that unexpectedly a fish oil diet leads to increased speed of migration in vitro. 
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Chapter 6: General Discussion 
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ATP is widely recognised now as an extracellular signalling molecule, capable of altering 
the behaviour of cells, and inducing migration of macrophages and microglia. In this thesis, 
the role of ATP and the downstream effects were explored, including the effects of BDNF, 
along with ATP induced MMP and TIMP expression.  
6.1. BDNF abrogates ATP-induced invasion.  
In Chapter 3, after first confirming that ATP did indeed induce invasion in the model used, 
the effect of adding BDNF to the inverted invasion assay was explored,  Trang et al, (2009), 
demonstrated that BDNF was released from microglia after stimulation of the P2X4 
receptor with ATP via a p38-MAPK pathway (Trang et al., 2009). In a novel finding BDNF 
alone had no significant effects on invasion when compared to the control level, however, 
when added in combination with ATP, BDNF was able to abrogate ATP-induced invasion 
significantly in both BMMs and Raw 264.7 cells. Here, it is speculated that this may be a 
feedback mechanism to prevent further recruitment of macrophages and microglia to the 
site of injury.  
BDNF is expressed by macrophages along with its receptor, TrkB (Artico et al., 2008). BDNF 
is known to be involved in the development of neuropathic pain and has shown to be a 
neuromodulator, able alter neurotransmitter release (including glutamate and aspartate) 
and thus modulate synaptic efficiency. (Thompson et al., 1999, Pezet, 2002). BDNF in spinal 
cord neurons is found dense core vesicles, which suggests that BDNF is likely to be released 
along with the activators of nociceptors. BDNF is also found to be increased in peripheral 
nerve injury and sciatic axotomy (Thompson et al., 1999).  
BDNF has also been implicated in the development of central sensitization. Nociceptive 
pain is a transient signal which requires a high threshold to activate.  Inflammatory and 
neuropathic pain, however, both have persisting symptoms, and central sensitization is a 
key step in the progression of neuropathic pain (Ji et al., 2003). Central sensitization is the 
consequence of the signalling of several factors, including BDNF, Substance P, and ephrin-
B. Both neuronal and non-neuronal BDNF is thought to play a role in central sensitization 
– BDNF-TrkB signalling enhances NMDAR-mediated C-fibre evoked responses and 
activates ERK, PKC and PKA signalling pathways (Kerr et al., 1999, Latremoliere and Woolf, 
2009, Boudes and Menigoz, 2009).  Coull et al, 2005 suggests that BDNF is responsible for 
Page | 162  
 
causing a depolarizing shift in lamina I neurons, leading to ectopic nerve activity and the 
onset of neuropathic pain (Coull et al., 2005). 
Nonetheless, many articles have provided evidence that BDNF may in fact be 
neuroprotective. In 2002, Eaton et al, demonstrated that the overexpression of BDNF (by 
adenovirus) could ameliorate chronic pain behaviour in CCI of the sciatic nerve (Eaton et 
al., 2002). Furthermore, the delivery of neurotrophins into the site of injury in several 
models in adult rats has been shown to rescue injured neurons, promote regeneration and 
restore function in injured nerves. After nerve injury, injured neurons will atrophy and die 
in the process of retrograde degeneration. However, it has been found that the 
transplantation of genetically modified fibroblasts with the ability to secrete BDNF and NT-
3 promote the rescuing of injured neurons and axon growth – restoring partial function 
after SCI and the reversal of chronic pain conditions (Shumsky et al., 2003, Tobias et al., 
2003). 
More evidence on the neuroprotective effects of BDNF comes from several studies which 
cite BDNF as being neuroprotective in models of hypoxia-induced brain damage, to such 
an extent that Zhao et al (2014) suggests that BDNF should be used as a treatment to 
promote neurological recovery after hypoxic ischemia (Zhao et al., 2014, Chen et al., 2013).  
Additionally, BDNF has been shown to be essential in neural stem cell survival. Imipramine 
is a tricyclic antidepressant that has been found to increase the neuronal survival rate. 
Peng et al observed that after treatment with imipramine, there was an increased survival 
rate of neural stem cells connected with an increase in the mRNA and protein levels of 
BDNF. It was also shown that imipramine was able to prevent LPS-induced apoptosis via 
activation of the MAPK pathway, and that siRNA inhibition of BDNF lead to the attenuation 
of neuroprotective effects seen - suggesting that BDNF is a mediator in the 
neuroprotective effects of imipramine (Peng et al., 2008).  
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In summary, BDNF has been shown to be able to regulate neuronal cell survival, synaptic 
plasticity and cell differentiation. Although BDNF has controversial roles in the onset of 
chronic pain, numerous papers have outlined its importance in neuronal cell survival. The 
data presented in this thesis suggests that BDNF can act to reduce macrophage 
recruitment to the site of injury. Here, we speculate that this may be a neuroprotective 
effect of BDNF in order to reduce the further infiltration of macrophages and microglia to 
the site of injury – and to counter the role of pro-inflammatory cytokines which are 
present. 
 
In Figure 6.1 the macrophage response after stimulation of ATP is summarised.  ATP is 
rapidly broken down in the extracellular milieu by ATPases such as CD46 to ADP. ATP 
activates P2X4 and P2X7, whereas ADP activates P2Y12 and can activate P2Y6. Meanwhile, 
the activation of surrounding astrocytes produces fibronectin, which cause an increase in 
the level of P2X4 receptors, through as yet unknown mechanisms (Tsuda et al., 2005). In 
turn, the activation of purinergic receptors leads an increase in the intracellular calcium 
levels, and activation of the MAPK pathway through ERK1/2 and p38 and PKA, which act 
Figure 6.1. What happens in macrophages after nerve injury? This figure displays a graphical representation of 
the effects of ATP stimulation upon macrophages in the context of nerve injury. 
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to promote chemotaxis and cell migration. MAPK activation also leads to the activation of 
transcription factors and the synthesis and release of MMPs. MAPK activation has also 
been shown to lead to the release of BDNF, which acts via TrkB to activate a variety of 
pathways including PLCγ, MAPK, PI3K and PKC – leading to wider effects such as those 
explored previously. 
 
6.2. Role of Sigma-1 receptor in macrophage migration. 
In an attempt to elucidate the mechanisms behind the BDNF abrogation of ATP-induced 
invasion in both Raw 264.7 cells and BMMs, the effects of agonism, antagonism and 
eventually siRNA knockdown of Sigma-1 receptor were explored. 
Results shown in Chapter 3 of this thesis demonstrates that the agonism of Sigma-1 
receptor leads in a decrease in macrophage migration in all conditions, whereas the 
antagonism and knockdown of sigma-1 receptor results in  an increase in migration, and a 
rescue of the BDNF attenuation of invasion. The role of Sigma-1 receptor has not 
apparently been previously explored in primary macrophages and Raw 264.7 cells. 
Previously, it has been shown that the agonism of sigma-1 receptor with DTG led to the 
attenuation of various cellular functions in primary microglia, including the migration of 
microglia towards ATP and MCP-1 (Hall et al., 2009). In addition, the sigma-1 receptor 
agonist 4-IBP was shown to reduce migration in human cancer cells – including the 
prostate cancer cell like PC3, the C32 melanoma cell line and U373-MG – a glioblastoma 
cell line in a scratch wound assay (Megalizzi et al., 2007). A non-selective sigma agonist, 
afobazole, is an anxiolytic drug currently in use in Russia, was explored by Cuevas et al on 
microglial migration. In a microchemotaxis chamber assay, afobazole was found to block 
the migration of microglia towards ATP and UTP. In addition, afobazole was found to block 
the Ca2+ increase associated with ATP stimulation in microglia, suggesting that sigma-1 
receptors can modulate purinergic receptor function, it was also found that afobazole and 
thus sigma receptor agonism could reduce microglial cell death after ischemic injury 
(Cuevas et al., 2011). 
Sigma-1 receptor has many links to pain, and has previously been found to be involved in 
the analgesic effects which are mediated by µ-, δ-, and κ- opioid receptors. The antagonism 
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of sigma-1 with haloperidol results in the potentiation of opioid induced analgesia (Mei 
and Pasternak, 2002, Maurice and Su, 2009).  Sigma-1 receptor has also been shown to act 
as a chaperone in the production and maturation of BDNF. 
The involvement of Sigma-1 receptor in neuropathic pain has been briefly explored 
previously in this thesis. However, Kibaly et al, 2008 demonstrated that the Sigma-1 
agonist, the neurosteroid DHEA, induced a pro-nociceptive effect in rats with chronic pain, 
and thus implicated cytochrome P450c17 (which is crucial in synthesizing DHEA) in 
neuropathic pain (Kibaly et al., 2008). Yoon et al (2009) also implicated DHEA and DHEAS 
as pro-nociceptive, and demonstrated that intrathecal injection of DHEAS induced 
mechanical allodynia in mice (Yoon et al., 2009). This pro-nociceptive effect was blocked 
with BD1047, a sigma-1 receptor antagonist. However, recently, Francardo and colleagues, 
found that the agonism of Sigma-1 receptor with PRE-084 led to neurorestoration in the 
context of Parkinson’s disease (Francardo et al., 2014). It was also found that in the context 
of amyotrophic lateral sclerosis, sigma-1 antagonism by PRE-084 was neuroprotective 
(Peviani et al., 2014). 
Yao, in 2010 and 2011, has implicated Sigma-1 receptor in increase monocyte adhesion 
and migration into the CNS in response to cocaine abuse in HIV. HIV-1 associated 
neurodegenerative disorders are a common complication of HIV, and are often 
exacerbated in response to the abuse of illicit drugs such as cocaine, in these conditions, 
monocytes can migrate through the blood brain barrier and cause disruption of the BBB, 
and neuroinflammation, along with activation of glial cells. Yao demonstrates that in 
microglia, cocaine can induce the translocation of Sigma-1 receptor from the 
mitochondrion associated membrane  to lipid rafts, thus inducing MCP-1 production via 
Src, MAPK, PI3K and NFκB signalling pathways, and in turn inducing monocyte migration 
into the CNS. Thus, this demonstrates that sigma-1 receptors could be responsible for the 
recruitment of further macrophages and monocytes towards the site of injury in chronic 
pain conditions (Yao et al., 2010, Yao et al., 2011).  
Although Sigma-1 receptors were discovered over 30 years ago, the mechanisms behind 
their actions have proven difficult to find due to the fact that the sequence of Sigma-1 is 
unlike that of any other mammalian proteins (Maurice and Su, 2009). However, the most 
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explored molecular mechanism behind the action of Sigma-1 receptor is the interaction 
with ion channels.  It has been found that Sigma-1 receptor antagonist BD-1047 was found 
to cause an increase in [Ca2+], and activate PLCγ along with elevating IP3 levels. It has also 
been found that the role of sigma receptors in the regulation of calcium stores concerns 
Ca2+ channels on the plasma membrane, but not intracellular Ca2+ stores, and ligands of 
sigma receptor appear to block all subtypes of Ca2+ ion channel (Maurice and Su, 2009). 
This block of all calcium channels may go some way to explain the data obtained when 
cells were exposed to DTG (a sigma agonist), and IPAG, (a sigma receptor antagonist). Data 
in this thesis shows that when exposed to DTG, macrophage invasion is suppressed and 
Hall et al. (2009) have shown that calcium channels are then blocked in microglia. Since 
calcium influx is required for macrophage cell migration, the DTG effect observed is likely 
mediated through eventual blockade of Calcium channels. However, when cells are 
treated with IPAG, the base level of invasion in all conditions was increased – for example, 
in the control conditions and BDNF alone conditions, where previously no invasion was 
observed. Although Hall et al. did not explore effects of antagonising Sigma 1 receptors it 
is interesting to note that DTG was able to suppress migration in response to both ATP and 
MCP-1, which suggests a broad effect, likely due to blockade of calcium channels, as the 
authors surmise (Hall et al., 2009).  
One could speculate that the treatment of cells with IPAG opens calcium channels, leading 
to an influx of calcium and a subsequent increase in macrophage invasion. RNA silencing 
of Sigma 1 receptor expression also led to enhanced invasion irrespective of the cell 
stimulus. Thus antagonism of Sigma 1 receptors appears to release macrophages from a 
stationary phenotype. Another possible explanation may lie in Sigma 1 receptor 
interaction with cholesterol in lipid rafts. Gene silencing of Sigma 1 receptor has been 
shown to block mammary tumour cell adhesion to several different ECM components 
including laminin (a major component of Matrigel used in invasion assays in this thesis) 
and fibronectin (with which Matrigel was supplemented in invasion assays) as well as type 
I collagen (Palmer et al., 2007). The mechanism for reduced adhesion was shown to be due 
to displacement of β1 integrins from lipid rafts. It is interesting to note that although 
reduced cell adhesion can be correlated with enhanced migration, although some 
adhesion to the ECM is necessary for traction. 
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In conclusion, the Sigma-1 receptor has been shown to be involved in macrophage invasion 
to towards ATP as well as in a general suppression of invasion but the precise mechanisms 
involved remain to be elucidated. 
6.3. ATP can induce MMP and TIMP expression. 
Seeking to explore whether pain-related stimuli modulate MMP expression a survey of 
MMP and TIMP expression in Raw 264.7 macrophages was performed. In the preliminary 
data obtained. MMP induction after stimulation with ATP was most highly upregulated at 
earlier time points (4 and 8 hours) – during which MMP-8, MMP-10, MMP-12 and MMP-
13, along with TIMP-2 were found to be upregulated after stimulation with 10µM and 
1mM ATP. To my knowledge, this is the first time that direct stimulation of macrophages 
with ATP has been demonstrated to induce MMP expression. 
Although ATP has not been investigated in the induction of MMPs from macrophages 
previously, ATP has been shown to be able to induce MMP and TIMP expression in other 
cell types. For example, in primary microglia and BV-2 microglial cells, it was found that 
ATP lead to an increase in the secretion and activation of MMP-9, through PI3K activation 
(Choi et al., 2010). Chang et al, demonstrated in human endometrial stromal cells, that 
10µM ATP lead to the induction of MMP-2, MMP-3, MMP-10 and MMP-24 expression after 
24hrs stimulation (Chang et al., 2007). ATP was also found to induce MMP-9 expression in 
peripheral blood mononuclear cells via activation of P2X7 receptor, it was also found that 
TIMP-1 expression was decreased – although it has also been shown that TIMP-1 can be 
degraded by cathepsin B after P2X7 activation (Gu and Wiley, 2006, Murphy and Lynch, 
2012). It should be noted that the effects of ATP on MMP expression may be cell or context 
dependent. Thus in human gingival fibroblasts ATP suppresses IL-1-induced MMP-1 
expression (Nemoto et al., 2013). 
MMPs have been implicated in Neuropathic Pain conditions previously – in 2008, Kawasaki 
et al implicated both MMP-2 and MMP-9 expression in the early and late phase 
developments of neuropathic pain, suggesting that MMP-9 was involved in the early phase 
response of nerve injury, whereas MMP-2 was expressed in a late phase response. It was 
also found that the intrathecal administration of MMPs -2 and -9 was capable of producing 
chronic pain behaviours, and that these MMPs are at least, in part, responsible for chronic 
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pain conditions by activating pro-inflammatory cytokine IL-1β by cleavage of its precursor 
(Schönbeck et al., 1998, Kawasaki et al., 2008).  MMP-9 has further been implicated in 
chronic pain conditions, due to the upregulation after SCI, along with MCP-1 and TIMP-1 
(Platt et al., 2003, Yong and Guoping, 2008, Sandhir et al., 2011), in particular, the 
emergence of a MMP-9/TIMP-1 activation axis has suggested that MMP-9 and TIMP-1 co-
localised within myelinating Schwann cells. Kim et al, demonstrated that MMP-9 knockout 
lead to an induction of immature myelinating Schwann cells into the injured nerve, 
suggesting that MMP-9 is required for the differentiation of Schwann cells and important 
in the regeneration of injured nerves (Kim et al., 2012). MMP-9 upregulation may also play 
a role in the release of BDNF from injured neurons, microglia and macrophages, as MMP-
9 has been implicated in the processing of proBDNF to mature BDNF (Yamamori et al., 
2013). 
Similarly MMP-3 and TIMP-3 have been shown to have important roles in nerve injury by 
ischemia. Walker and Rosenberg investigated MMP-3 and TIMP-3 due to their respective 
roles in the increase of inflammatory conditions and the promotion of apoptosis. It was 
found that knockout of TIMP-3 levels lead to a correlated reduction in microglial activity 
and neuronal cell death, and the knockout of MMP-3 lead to a reduction of microglial cells, 
and neuronal cell death. It was observed that the pharmacological inhibition of MMPs, 
along with the knockout of TIMP-3 lead to an additive addition and significantly less 
neuronal cell death in ischemic conditions (Walker and Rosenberg, 2009). 
As explored previously, MMPs have been shown to play a role in the remodelling of the 
extracellular matrix components. In the context of peripheral nerve injury, ECM 
components have been shown to play a role in creating a nerve regeneration positive 
environment – for example, it has been shown that laminin is essential for the sustained 
ability of axonal regeneration. (Gonzalez-Perez et al., 2013). It is thought that using 
collagen and laminin matrices is beneficial for the regeneration of axons and the 
restoration of function, and the presence of a collagen matrix is highly beneficial, and that 
fibronectin matrix presence is capable of improving neurite outgrowth and migration of 
Schwann cells – it is perhaps unsurprising that after nerve injury astrocytes produce 
fibronectin (Tsuda et al., 2008, Gonzalez-Perez et al., 2013). However, Koopmans et al, 
argue that after peripheral nerve injury, collagen production is overdriven and thus hinders 
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the growth of axons (Koopmans et al., 2009). ATP induced MMP expression then could 
play either a beneficial or detrimental role to nerve regeneration.  
As MMP-8 and MMP-13 are Collagenase -2 and -3, respectively, they are able to hydrolyse 
a number of collagens and other substrates – for example MMP-13 is also capable of 
cleaving Fibronectin and Laminin. ATP was found (in preliminary data shown in this thesis) 
to upregulate these MMPs, along with MMP-10 and MMP-12 – which can also degrade 
type IV collagen and fibronectin as well as chemokines (Dean et al., 2008). In vivo, this may 
be linked to the degradation of excess collagen and thus promote nerve regeneration, or 
degrade collagen essential to nerve regeneration, thus giving a detrimental effect. The 
upregulation of TIMP-2 observed could then be a feedback mechanism to inhibit MMP 
degradation of essential collagen required for nerve regeneration. In vitro, in this thesis, 
ATP was shown to induce invasion in Raw 264.7 cells through a Matrigel™/Fibronectin 
matrix, as Matrigel™ contains type IV collagen and laminin, one could speculate that the 
upregulation of these MMPs could offer an explanation for the increased invasion 
observed, although more data would be required. 
6.3.1. BDNF may attenuate MMP expression.  
This thesis presents data to demonstrate that when treated with a combination of ATP and 
BDNF, after 8 hours, there is a trend towards a decrease in the expression of MMP-8, 
MMP-12, MMP-13 and TIMP-2 observed. To our knowledge, BDNF has only previously 
been shown to induce levels of MMP-9 (Kuzniewska et al., 2013). Although these decreases 
in MMP expression were not shown to be significant, it could suggest that BDNF plays a 
role in reducing MMP degradation of essential extracellular matrix components, or that 
BDNF acts to reduce the cleavage (and subsequent activation) of pro-inflammatory 
cytokines by these MMPs – and thus has a neuroprotective effect. However, the cleavage 
of ECM components may be essential for nerve regeneration (Koopmans et al., 2009), and  
BDNF could, in contrast, support neurodegeneration. 
6.4. A Fish Oil supplemented diet leads to increased macrophage migration and a 
reduction in TIMP-2 expression. 
Data in this thesis demonstrates that when macrophages are derived from mice fed on fish 
oil supplemented high fat diet, perhaps unexpectedly; these cells migrate significantly 
faster than macrophages derived from mice fed on a high fat diet. Also, the data shown in 
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chapter 5 demonstrates that macrophages from HFD+FO fed mice also show a significant 
reduction in the expression TIMP-2 in conditions when stimulated with ATP, IL-10, MCP-1 
and a combination of IL-10 and MCP-1. The difference in ApoE subtype was found to have 
little effect on the migration and MMP expression of macrophages.  
Previously, the supplementation of fish oils has been shown to affect monocyte and 
macrophage infiltration into the atherosclerotic plaque. For example, Kanai et al 
demonstrated that the supplementation of diet with EPA was able to reduce arterial 
medial calcification, along with macrophage infiltration into the plaque in rats possibly due 
to a reduction in the expression of MCP-1 and MMP-2 and MMP-9 – however, an increased 
migration of macrophages was seen around the calcified area (Kanai et al., 2011). It has 
also been demonstrated that EPA and DHA supplementation led to decreased macrophage 
infiltration into gastric cancer tumours, which is due to the blocking of MMP-10 expression 
via a down-regulation of ERK activation (Wu et al., 2012). Luu et al (2007) also observed 
an EPA induced reduction of monocyte infiltration in atherosclerosis, but suggests that 
although an EPA supplemented diet leads to the modulation of the ability of monocytes to 
induce an inflammatory response, the reduction in infiltration of macrophages into the 
intima may be due to differences seen on the surface of endothelial cells. However, in 
1998, Sanderson and Calder found that lymphocytes from rats derived from fish oil 
supplemented diet fed rats were had a decreased level of CD2, CD11a, CD18 and CD44, 
which reduced adhesion to TNFα stimulated endothelial cells (Sanderson and Calder, 1998, 
Luu et al., 2007), hinting that reduced infiltration and thus migration of macrophages is 
reduced as they lack the necessary adhesion molecules.  
In addition to the examples mentioned above, the supplementation of diet with fish oils 
has been shown to alter MMP expression on numerous occasions and in different 
conditions. Velten et al, demonstrated that in a new-born mouse model of peritoneal 
inflammation DHA supplementation lead to a decrease in pulmonary fibrosis, perhaps a 
result of a  decrease in the expression of MMP-2, MMP-3 and MMP-8 in macrophages and 
monocytes (Velten et al., 2014). It was also found that in amnion explants, EPA and DHA 
lead to a decrease in the level of MMP-9 expression, possibly through a mechanism 
involving PPARγ and thus decreasing inflammation (Frew et al., 2013). N-3 PUFA 
supplemented diet also lead to the decrease in inflammation of adipose tissue in a model 
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of chronic kidney disease in humans, as a decrease in MMP-9 was found, again suggesting 
an anti-inflammatory role for dietary fish oil supplementation (Guebre-Egziabher et al., 
2013).  
In atherosclerosis in humans, fish oil dietary supplements were given to patients awaiting 
carotid endarterectomy, allowing the contents of the atherosclerotic plaque to be 
examined. It was found that EPA supplementation led to a decrease in foam cell content 
of the atherosclerotic plaque, along with a decrease in MMP-7, MMP-9 and MMP-12. 
Although this lead to no significant change in overall plaque stability, it was found that 
supplementation with EPA lead to more stable plaques (Cawood et al., 2010). Derosa et al, 
also found that fish oil supplements lead to a decrease in MMP-2 and MMP-9 levels in 
circulating blood plasma (Derosa et al., 2012). 
Johnson and colleagues (2006) reported that the overexpression of TIMP-2 by adenovirus 
in ApoE knockout mice with atherosclerosis resulted in the reduction of atherosclerotic 
lesion size, along with the reduction of many markers of plaque instability – such as the 
presence of buried fibrous caps and the presence of macrophages in the intima. In vitro, 
overexpression of TIMP-2 was found to inhibit macrophage migration and apoptosis 
(Johnson et al., 2006). 
In this thesis, data presented shows that macrophages derived from HFD+FO fed mice 
migrate faster, as the majority of evidence suggests that the supplementation of diet with 
fish oils is anti-inflammatory, one would be inclined to suggest that the increased 
migration speed is beneficial. This may be due to the formation of a macrophage 
phenotype that  circulates and surveys the environment, but does not migrate into the 
intima – for example Kanai et al reported that FO supplementation led to an increased 
number of macrophages surrounding the calcified area, but less macrophages infiltrating 
the calcified area (Kanai et al., 2011).  
The observation that mice fed with fish oil supplements produce macrophages with 
significantly reduced TIMP-2 levels which could be associated with enhanced macrophage 
migration (although this was not explored directly). In an in vivo atherosclerosis context 
this could support the notion that fish oil could lead to a reduction in TIMP2 expression 
would likely be associated with plaque instability but further investigation would be 
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required to confirm or refute this possibility. In conclusion, one would suggest that the 
increased macrophage migration speed and reduction of TIMP-2 expression in HFD+FO fed 
mice derived macrophages leads to the speculation that this is indicative of a pro- rather 
than an anti-inflammatory phenotype. 
 
6.5. Future Work. 
6.5.1. BDNF abrogates ATP-induced invasion.  
To further explore the effect of BDNF on ATP-induced invasion, in future studies, it is 
crucial to study the signalling mechanism behind both ATP stimulation – from which 
purinergic receptor conveys migration to the effect of individual signalling pathways, 
including PLCγ, MAPK and PI3K – to determine how ATP induces migration in macrophages. 
It is paramount to explore the activity of signalling pathways, and how the stimulation of 
each subtype of purinergic receptor influences the activity of these signalling pathways. 
Likewise, to investigate BDNF stimulation in macrophages in detail and exploring the effect 
of BDNF signalling not only through TrkB, but also through p75 is of importance for similar 
reasons – if one is to explore the BDNF abrogation of ATP invasion, it is imperative to 
explore the crosstalk in these mechanisms and identify the pathways which lead to the 
BDNF abrogation of ATP-induced invasion. If one were to have the chance to repeat the 
experience of researching and writing this thesis, it would be a priority to explore signalling 
mechanisms behind the observed effects of ATP and BDNF. 
6.5.2. Sigma receptor studies. 
It has been suggested that Sigma-1 receptor can translocate from the mitochondrion-
associated-membrane to the cell surface, where it can interfere with calcium, sodium and 
potassium channels, and other cell surface receptors including displacement of integrins 
from lipid rafts to modulate the effects of signalling, and thus alter the behaviour of the 
cell. Future work should aim to explore the mechanism behind this action, and also the 
mechanism behind which Sigma-1 is able to modulate the signalling of many different 
receptors. In the context of this thesis, it would be of interest to examine if Sigma-1 can 
alter the activation of TrkB signalling and that of purinergic signalling by FRET analysis and 
immunoprecipitation methods. It would also be important to examine the action by which 
Sigma-1 receptor controls macrophage migration by exploring the effect of the activation 
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of sigma-1 receptor on β1 integrin displacement, the activation of various signalling 
pathways and calcium signalling. 
6.5.3. ATP-induced MMP expression. 
To understand potential links between ATP regulation of MMPs and migration of Raw 
264.7 cells, an approach based on previous studies in invading tumour cells could be 
exploited. Zhang et al observed that ATP up-regulated activation of Rac1 and Cdc42 as well 
as migration in three different prostate cancer cell lines – in connection with the up-
regulation of MMP-3 and MMP-13 (Zhang et al., 2010). To further explore the role of the 
up-regulation of MMPs induced by ATP stimulation, it would be important to examine the 
functional role of MMP expression in macrophages. This could be achieved by measuring 
macrophage migration on different substrates and by zymography (for MMPs 2 and 9). 
The importance of these MMPs in migration could be explored using hydroxamate 
inhibitors and TIMPs and eventually siRNA knockdown experiments to determine if ATP 
induced macrophage migration is MMP-dependent. 
6.5.4. Dietary Fish Oils in Atherosclerosis. 
To further explore the effect of the dietary supplementation with fish oils on 
atherosclerosis, it would be important to first explore the effects of chemotaxis towards 
MCP-1 on macrophages derived from fish oil fed mice, and it would be interesting to 
explore the effects of anti-inflammatory cytokines on this chemotaxis. It would be 
important to explore the inflammatory response of macrophages derived from these mice 
– and the production of pro- and anti-inflammatory cytokines and nitric oxide – as these 
are measures of how macrophages can influence the surrounding environment and the 
stability of the plaque, as well as a way of assessing if the response of macrophages to 
dietary fish oil supplementation is pro- or anti-inflammatory. Furthermore, it would be 
crucial to explore plaque stability in response to a fish oil supplemented diet, by 
investigating the composition of the plaques induced by the high fat diet. It would also be 
of interest to explore chemokine production by macrophages, and also to examine the 
surrounding environment of the atherosclerotic plaque – for example, the chemokine 
production from the endothelial cells within the intima, to see if the action of fish oil 
supplemented diet is more generalised. To determine if fish oil supplemented diet is 
enough to prevent or promote the development of atherosclerosis would be of interest, 
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and also to determine factors that would promote the regression of the atherosclerotic 
plaque. 
6.6. Overall Conclusions 
Macrophage migration has been shown to play an important role in many normal 
biological functions, and also in pathologies. In this thesis, it is reported that ATP is capable 
of inducing macrophage migration, and BDNF can lead to an abrogation of ATP-induced 
invasion, although the mechanisms behind this effect have yet to be determined. Data is 
also presented which suggests that sigma-1 receptor is a regulator of macrophage 
migration, although the actions which allow sigma-1 receptor to do this are yet to be 
elucidated, previous studies suggest that the blockade of calcium channels and the 
reduction of adhesion due to β1 integrin displacement play a role. 
This thesis also presents data to show that ATP can induce the expression of MMPs and 
TIMPs, which may play a role in macrophage migration, although further investigation is 
required to determine if this conclusion is correct in this model.  
Fish oil supplementation of a high fat diet and its effect on macrophage migration and 
MMP expression was also explored. It was found that a HFD+FO diet led to significant 
changes in migration speed and TIMP-2 expression. This data hints that the 
supplementation of diet with EPA and DHA could be pro-inflammatory, rather than anti-
inflammatory, however. Further investigation is of importance. Figure 6.2 summarises 
these findings.  
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Figure 6.2. A diagram to summarise the speculations and findings of this thesis. This figure demonstrates a graphical representation of a macrophage, and the factors explored 
in this thesis which lead to increased macrophage migration. Red arrow fish oil diet leads to activation of PPARγ, but this has not been shown in our particular study. The blue 
arrows are indicative of a late-phase response as LPS leads to a later phase MMP response of Raw 264.7 than ATP in chapter 4, possibly mediated through ERK1/2 or NFκB. 
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